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ABSTRACT 
 
NATIVE FUNCTIONS OF THE ANDROGEN RECEPTOR ARE ESSENTIAL TO 
PATHOGENESIS IN A DROSOPHILA MODEL OF SPINOBULBAR 
MUSCULAR ATROPHY 
Natalia B. Nedelsky 
Supervisor: J. Paul Taylor 
 
Spinobulbar muscular atrophy (SBMA) is a progressive, late-onset disease characterized 
by degeneration of motor neurons in the brainstem and spinal cord. The disease is caused 
by expansion of a polyglutamine tract in the androgen receptor (AR) and is dependent on 
exposure to AR ligand. The expanded polyglutamine tract confers toxic function to the 
protein through unknown mechanisms, although the ligand-dependent nature of SBMA 
suggests that the mechanism of pathogenesis may be tied to ligand-dependent alterations 
in AR function. However, whether toxicity is mediated by native AR function or a novel 
AR function is unknown. We systematically investigated ligand-dependent modifications 
of AR in a Drosophila model of SBMA. We demonstrate in vivo that nuclear 
translocation of mutant AR is necessary but not sufficient for toxicity and that DNA 
binding by AR is necessary for toxicity. Mutagenesis studies demonstrated that a 
functional AF-2 domain is essential for toxicity, a finding corroborated by a genetic 
screen that identified AF-2 interactors as dominant modifiers of degeneration. As proof 
of this principle, we perform epistasis experiments using the AR coregulator limpet, 
which we find modifies polyglutamine-expanded AR toxicity in an AF-2-dependent 
manner. In addition, we use expression profiling to examine the molecular phenotype of 
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polyglutamine-expanded AR degeneration, revealing that expression of wild-type AR 
results in a molecular phenotype that is very similar to that caused by polyglutamine-
expanded AR. These findings suggest that expanded-polyglutamine AR toxicity may be 
mediated by amplification of normal function, a mechanism that may be broadly 
applicable to other polyglutamine diseases. 
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Chapter 1: Introduction 
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Introduction 
Polyglutamine expansion diseases together form the most common group of inherited 
neurodegenerative disease (Riley and Orr, 2006). The diseases are caused by expansion 
of trinucleotide (CAG) repeats in coding regions of DNA, yielding proteins with 
expanded polyglutamine tracts. These proteins cause adult-onset neurodegeneration 
through unknown mechanisms. Despite being caused by a common mutation, each of the 
polyglutamine diseases affects specific populations of neurons, resulting in diverse 
patterns of pathology and clinical presentations. Attempts to define and resolve this 
paradox have been at the heart of the most significant advances in understanding the 
pathogenesis of these diseases.  
 
This chapter takes a historical approach to the field of polyglutamine disease research, 
aiming to demonstrate how our understanding has evolved to produce the work contained 
in this thesis. Starting with patient observation and guided by computational, in vitro, and 
in vivo models, the field has seen a range of theories that seek to unite the various 
members of the polyglutamine disease family with a common mechanism of 
pathogenesis. This work, based largely on the inherent toxicity of expanded 
polyglutamine peptides, suggested that toxic aggregation of polyglutamine proteins could 
lead to disturbances in biological activities as diverse as axonal trafficking, synaptic 
transmission, and the ubiquitin proteasome system (UPS). Recently, however, an 
alternative approach has begun to uncover a more subtle picture of toxicity. Inspired by 
the diversity of the diseases within the polyglutamine disease family, this approach 
focuses on features that are unique to each disease protein rather than their shared 
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polyglutamine expansion. These investigations have advanced the idea that toxicity arises 
from alterations in native protein function rather than novel function imparted by the 
expanded polyglutamine tract. This perspective, still largely unexplored in the 
polyglutamine disease field, serves as the foundation of this thesis.  
 
Polyglutamine Disease: Discovery and Clinical Characterization 
The story of the polyglutamine diseases begins, experimentally speaking, with spinal and 
bulbar muscular atrophy (SBMA). SBMA was first identified in 1968 as an adult-onset 
X-linked disease characterized by progressive muscle weakness and atrophy due to lower 
motor neuron degeneration (Kennedy et al., 1968). Subsequent studies expanded the 
clinical picture to include signs of androgen insensitivity including gynecomastia and 
reduced fertility (Arbizu et al., 1983), providing an important clue to mapping the 
mutation responsible for the disease. More than 20 years later, the causative mutation was 
finally defined by linkage analysis and positional cloning (La Spada et al., 1991). The 
mutation was found to reside in the androgen receptor (AR) gene, a result that was 
perhaps unsurprising given the endocrine-related clinical features of the disease. The 
great surprise lay in the nature of the mutation, which was defined as a novel expansion 
of a polymorphic trinucleotide (CAG) repeat within the coding region of the gene. While 
the general population had CAG repeat lengths of 9-36, patients with SBMA had repeat 
lengths of 38 or greater, leading to expression of AR protein with an expanded 
polyglutamine tract. The mutation was presumed to cause disease via a gain of function, 
4 
because loss of AR function was known to cause androgen insensitivity syndrome (AIS), 
a condition not characterized by degeneration or weakness (Quigley et al., 1992). 
 
Within the same year, a number of groups identified similar mutations in other diseases, 
including trinucleotide repeat expansions that caused fragile X syndrome (Verkerk et al., 
1991) and myotonic dystrophy (Fu et al., 1992; Mahadevan et al., 1992). However, these 
mutations were found in untranslated regions of genes, and the relationship between these 
new “trinucleotide repeat expansion diseases” remained unclear. Finally, two years later 
(and after 20+ years of mapping work), a collaborative research project trying to identify 
the genetic basis for Huntington’s disease (HD) found that HD was caused by the same 
mutation as SBMA – expansion of a CAG repeat in a coding region of DNA, this time 
within a novel gene dubbed huntingtin (1993). By the time the HD mutation was 
confirmed to result in a protein product with an expanded polyglutamine tract (Sharp et 
al., 1995), an entire collection of polyglutamine diseases had been uncovered: 
spinocerebellar ataxia type 1 (SCA1, caused by expansion in ataxin-1) (Orr et al., 1993), 
dentato-rubro pallidoluysian atrophy (DRPLA, atrophin-1) (Koide et al., 1994; Nagafuchi 
et al., 1994), and SCA3 (ataxin-3) (Kawaguchi et al., 1994) were all found to be caused 
by CAG expansions in exonic regions of DNA. Over the last fifteen years, four more 
polyglutamine diseases have been identified: SCA2 (ataxin-2) (Pulst et al., 1996), SCA6 
(CACNA1A) (Riess et al., 1997; Zhuchenko et al., 1997), SCA7 (ataxin-7) (David et al., 
1997), and SCA17 (TATA-binding protein, TBP) (Nakamura et al., 2001) (Table 1.1). 
This family now sits within a broader class of hereditary diseases, the repeat expansion 
diseases (Table 1.2). 
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The polyglutamine disease family members have important fundamental similarities that 
reflect their shared mutation. Although most of the polyglutamine-expanded proteins are 
broadly expressed, each disease manifests as a progressive degeneration of a small subset 
of neurons (Table 1.1). With the exception of SBMA, all polyglutamine diseases are 
inherited in an autosomal dominant manner. These diseases also show robust correlations 
between phenotype and polyglutamine length: with longer polyglutamine lengths, disease 
onset occurs earlier, and disease severity increases (Orr and Zoghbi, 2007). 
Polyglutamine tracts are often progressively lengthened as they are transmitted from one 
generation to the next, a phenomenon that explains the genetic anticipation observed in 
these diseases, in which symptom severity increases with successive generations. 
 
The clinical differences between the polyglutamine diseases, however, are perhaps more 
striking than their similarities. Despite being caused by the same mutation, the symptoms 
of several of the diseases have virtually no phenotypic overlap: while HD manifests as a 
triad of involuntary movements, dementia, and psychiatric disturbance that culminates in 
death, the same mutation in SBMA causes proximal muscle weakness with sparing of 
cognitive capacity and no significant change in longevity. These clinical differences are 
directly related to the subset of neurons that are affected in each disease: striatum and 
cortex in HD (Vonsattel et al., 1985), lower motor neurons in SBMA (Sobue et al., 1989). 
This selective vulnerability occurs despite overlapping patterns of huntingtin and AR 
expression, providing one of the first clues that polyglutamine expansion could not be 
solely responsible for toxicity. In addition, none of the disease proteins have any apparent 
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structural or functional similarities beyond their polyglutamine tracts, although a 
common theme of transcription regulation may be emerging and will be discussed below 
(Shao and Diamond, 2007). 
 
Polyglutamine Disease: Lessons from the First Generation of Models 
With the recognition of this new family of diseases, researchers first focused their 
attention on what these disease genes had in common; namely, a polyglutamine 
expansion that appeared to have a universal toxic threshold of 36-41 repeats. (As more 
patients’ DNA was sequenced, this threshold widened; see Table 1.1. SCA6 also stands 
as a notable exception, since repeat lengths as short as 20 can cause disease.) Thus, the 
biochemical and biophysical properties of expanded polyglutamine became an area of 
intense interest. One of the seminal papers influencing this view came from Nobel 
laureate Max Perutz, who suggested that expanded polyglutamine peptides can self-
associate to form “polar zippers” (Perutz et al., 1994; Perutz, 1996). In these structures, 
polyglutamine tracts form paired antiparallel β-strands linked together by hydrogen 
bonds between the main-chain and side-chain amides, excluding water molecules and 
thereby rendering the protein insoluble. In modeling these structures, Perutz found that he 
could replicate several fundamental properties of polyglutamine disease. First, his models 
suggested that the thermodynamic threshold for polar zipper formation coincided with the 
polyglutamine length threshold for disease. Second, his data suggested that longer 
polyglutamine stretches would lead to tighter polar zippers that formed with faster 
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kinetics, an observation that provided a biophysical basis for increasing severity of 
disease and earlier age of onset with longer polyglutamine lengths.  
 
At the time of Perutz’s molecular models, none of the polyglutamine diseases were 
known to have neuropathologic changes that supported a model of aggregation. However, 
when the first generation of HD mouse models appeared, Perutz’s hypothesis was 
deemed prescient. The most influential model was a transgenic strain that expressed exon 
1 of the huntingtin gene, the region of the protein that contains the polyglutamine tract. 
The authors reported that these mice showed HD-like movement disorder phenotypes 
(Mangiarini et al., 1996), although decreased body weight, hind limb clasping, and poor 
rotarod performance have proven to be the most robust phenotypes of this model (Hockly 
et al., 2003). These phenotypes were accompanied by pronounced widespread neuronal 
intranuclear inclusions that contained huntingtin protein (Davies et al., 1997) and were 
also immunopositive for ubiquitin, suggesting that the inclusions were made up of 
misfolded and aggregated proteins that had been marked for proteasomal degradation. 
Within the next year, ubiquitinated neuronal intranuclear inclusions were found in patient 
tissue in SCA3 (Paulson et al., 1997), HD (DiFiglia et al., 1997; Becher et al., 1998), 
DRPLA (Becher et al., 1998), SCA1 (Skinner et al., 1997), and SBMA (Li et al., 1998). 
 
In follow-up studies, it soon became clear that expanded polyglutamine tracts not only 
aggregated and formed ubiquitinated inclusions – they were also very toxic. Expression 
of expanded polyglutamine tracts – whether flanked by a minimal amount of disease 
protein context, inserted into non-disease-related genes, fused to GFP tags, or even 
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expressed with no flanking sequence whatsoever – resulted in strong toxicity in cells 
(Ikeda et al., 1996; Moulder et al., 1999; Yang et al., 2002), flies (Jackson et al., 1998; 
Warrick et al., 1998; Kazemi-Esfarjani and Benzer, 2000; Marsh et al., 2000), and mice 
(Ikeda et al., 1996; Ordway et al., 1997; Adachi et al., 2001), nearly always accompanied 
by ubiquitin-positive inclusion formation. This toxicity suggested to many researchers 
that aggregation and inclusion formation reflected a common pathway of cellular 
dysfunction and polyglutamine-mediated toxicity (Ross, 1997). Indeed, the presence of 
aggregates was proposed to block axonal vesicle trafficking (Gunawardena and 
Goldstein, 2005) and cause defects in synaptic transmission (Mattson and Sherman, 
2003) in a manner that applied broadly to all diseases marked by protein aggregation. 
However, a significant question remained: if the diseases shared a common toxic 
mechanism, what could account for the differential neuronal vulnerability in the different 
diseases? Different levels of disease protein expression in different cell types might 
contribute, but were clearly not the dominant factor in determining cell-type specificity 
(Zoghbi and Orr, 2000; Sieradzan and Mann, 2001). 
 
Some groups chose to call into question the causative link between inclusions and 
toxicity. One of the first and most direct challenges came from a transgenic model of 
SCA1, in which mice expressed full-length polyglutamine-expanded ataxin-1 with a 
point mutation to its self-association domain (Klement et al., 1998). These mice 
developed ataxia and pathology similar the original SCA1 model mice, although the self-
association mutants did not show any signs of inclusions to accompany their phenotype. 
Other groups examining the temporal course of disease also found that measurable 
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phenotypic changes can occur before inclusions are detectable (Reddy et al., 1998; 
Hodgson et al., 1999). Elegant studies using huntingtin exon 1, ataxin-3, ataxin-7, and 
AR subsequently revealed inverse correlations between inclusion formation and toxicity, 
suggesting that inclusions may actually reflect a neuroprotective effort to relocate toxic, 
soluble protein into inert, insoluble protein deposits (Cummings et al., 1999; Yoshizawa 
et al., 2001; Taylor et al., 2003b; Arrasate et al., 2004; Bowman et al., 2005; Evert et al., 
2006; Rub et al., 2006; Truant et al., 2008). Indeed, compounds that promote inclusion 
formation have recently shown therapeutic potential in in vitro models of HD (Bodner et 
al., 2006) and in vitro and in vivo models of SBMA (Appendix I). 
 
While addressing the controversy regarding the nature of inclusions, however, it became 
clear that polyglutamine proteins did not exist in one of only two states; that is, as either 
soluble monomers or insoluble inclusions. Rather, researchers recognized that a 
continuum existed along which soluble monomers can self-associate to form oligomers, 
which may proceed to form larger structures, which in turn may coalesce into 
microscopically visible inclusions. Unfortunately, there is considerable confusion in 
terminology regarding these different biophysical states. In this thesis, we generally 
distinguish protein aggregates, which are defined primarily biochemically and include 
submicroscopic oligomers, from inclusions, which are defined histologically (Taylor et 
al., 2003b). Inclusions are likely inert and neuroprotective, as described above. In the 
search for the toxic polyglutamine conformer, attention has now shifted to oligomers, 
which have been correlated with toxicity in an animal model of SBMA (Li et al., 2007). 
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In the same paper that dissociated SCA1 toxicity from inclusions, Klement et al. used a 
second transgenic model of SCA1 with a different point mutation to full-length, 
polyglutamine-expanded ataxin-1 (Klement et al., 1998). This mutation disrupted the 
nuclear localization signal (NLS), restricting ataxin-1 to the cytoplasm. These mice did 
not develop disease, demonstrating that polyglutamine expansion in itself was not 
sufficient to cause toxicity – at least when restricted to the cytosol. Thus, the ataxin-1 
NLS mutant provided critical insight into the importance of the nucleus as a site of 
toxicity. Some groups had already noted that several of the polyglutamine disease 
proteins (e.g. huntingtin, ataxin-3, and atrophin-1) are normally cytoplasmic, yet are 
found in inclusions in the nucleus in the context of disease (Zoghbi and Orr, 2000). These 
observations prompted the suggestion that although intranuclear inclusions may not be 
necessary for disease, nuclear translocation may be the more critical pathogenic event 
(Kim and Tanzi, 1998). Supporting this idea, toxicity was also mitigated by cytoplasmic 
retention of polyglutamine-expanded huntingtin (Saudou et al., 1998), AR (Takeyama et 
al., 2002), ataxin-3 (Bichelmeier et al., 2007), atrophin-1 (Nucifora et al., 2003), and even 
pure polyglutamine (Yang et al., 2002). Of note, the polyglutamine diseases SCA2 and 
SCA6 are marked by cytoplasmic inclusions, indicating that the nuclear localization is 
not a universal prerequisite for polyglutamine protein toxicity (Ishikawa et al., 1999; 
Huynh et al., 2000). 
 
As alluded to above, the presence of certain polyglutamine disease proteins in the nucleus 
was a mystery in itself. HD provides the best example: given that the protein has no 
known NLS and that the upper size limit for passive nuclear entry of 60-70 kDa (Wei et 
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al., 2003), it is not clear how the large >350 kDa huntingtin protein could enter the 
nucleus (Truant et al., 2007). Instead, it appears that full-length huntingtin is cleaved to 
generate a small polyglutamine-containing N-terminal fragment that diffuses into the 
nucleus. This fragment has been proposed to be at the heart of toxicity, since inhibiting 
caspase cleavage of huntingtin can eliminate toxicity in vivo (Graham et al., 2006). N-
terminal fragments of huntingtin have also been identified in HD patient tissue and are 
correlated with toxicity (DiFiglia et al., 1997). Such evidence has prompted theories that 
protein cleavage may be a common theme in polyglutamine disease, even providing a 
possible explanation for selective neuronal vulnerability. According to this theory, the 
subset of neurons that are affected in each disease could be defined by the presence of 
relevant proteases that generate toxic polyglutamine-containing fragments. However, in 
vivo evidence for cleavage of most polyglutamine-containing proteins is inconsistent 
across different diseases and models, and the contradictory evidence for the production 
and role of proteotoxic fragments suggests that protein cleavage is not a unifying 
mechanism of polyglutamine disease toxicity (Walsh et al., 2005). 
 
Shortly after the first generation of mouse models appeared, Drosophila models of 
polyglutamine disease were introduced, providing their own mechanistic insights. 
Dominant modifier screens proved to be especially productive. The first paper to use this 
technique revealed two chaperone molecules as suppressors of toxicity, confirming that 
modification of protein folding pathways could dramatically modify polyglutamine  
toxicity (Warrick et al., 1999; Kazemi-Esfarjani and Benzer, 2000). Indeed, this result 
has been now reproduced numerous times in models of several polyglutamine diseases 
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(Opal and Zoghbi, 2002), establishing that chaperones can mitigate polyglutamine 
toxicity by either promoting refolding or enhancing degradation of polyglutamine-
containing proteins. 
 
The importance of protein quality control was further highlighted by the identification of 
modifiers of a fly SCA1 model, which included critical players in the ubiquitin-
proteasome system (UPS) (Fernandez-Funez et al., 2000). The importance of this 
degradation pathway was confirmed by reports that proteasomes were found in the 
ubiquitinated inclusions in SCA1 patient tissue and HD models (Cummings et al., 1998; 
Waelter et al., 2001), supporting the idea that polyglutamine disease proteins accumulate 
in inclusions due to insufficient degradation by the UPS. Indeed, it appears that 
polyglutamine sequences cannot be degraded by eukaryotic proteasomes, which prefer to 
cleave after hydrophobic, basic, or acidic residues (Venkatraman et al., 2004). A number 
of groups have demonstrated that the UPS actually becomes impaired in models of 
polyglutamine disease (Bence et al., 2001; Bennett et al., 2005; Pandey et al., 2007b), 
possibly due to long polyglutamine tracts entering the proteasome and failing to exit 
properly (Venkatraman et al., 2004). Indeed, a recent report showed that expression of an 
expanded huntingtin fragment impairs UPS function (albeit transiently) in vivo (Ortega et 
al., 2010), although the relative contribution of UPS impairment to pathogenesis remains 
controversial. A second degradation pathway, the autophagy-lysosomal system, has 
recently gained attention as a compensatory pathway for protein degradation when the 
UPS is impaired. The relationship between the UPS and autophagy, as well as the 
relevance of these systems to neurodegenerative disease, is explored in Appendices II-IV. 
13 
 
Unexpected modifiers were also uncovered in Drosophila models. One particularly 
intriguing family of modifiers included proteins that function as coregulators in 
transcriptional regulation (Boutell et al., 1999; Fernandez-Funez et al., 2000). Indeed, 
transcriptional coregulators such as CREB-binding protein (CBP) have been found in 
inclusions in multiple polyglutamine diseases, and overexpression of CBP rescues 
polyglutamine-induced toxicity in cells (McCampbell et al., 2000; Nucifora et al., 2001) 
and flies (Taylor et al., 2003a). However, the nature of the interactions between 
polyglutamine disease proteins and transcriptional regulators is uncertain. The 
interactions could be due to relatively non-specific effects, as short polyglutamine tracts 
are found in many transcription factors (including CBP) and could potentially be 
incorporated into the polar zippers formed by the expanded disease proteins, resulting in 
functional sequestration (Schaffar et al., 2004). On the other hand, most polyglutamine 
disease proteins have now been shown to play some role in transcriptional regulation as 
part of their native function, suggesting that the modifier effects of transcriptional 
coregulators might reflect normal interactions that have gone awry due to polyglutamine 
expansion. Specifically, besides the obvious transcription regulatory role of AR and TBP, 
huntingtin interacts with general DNA-binding proteins such as Sp1, TFIID, and TFIIF, 
ataxin-7 plays a role in chromatin structure, and huntingtin, ataxin-1, and atrophin-1 
interact with transcriptional coregulators (Riley and Orr, 2006). Such a common function 
suggests that transcriptional regulation may be a pathway that has particularly great 
impact on pathogenesis, and has led some to propose the polyglutamine diseases may in 
fact be “transcriptionopathies” (La Spada and Taylor, 2003). 
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Polyglutamine Disease: the Next Generation 
With the notable exception of the SCA1 models from the Zoghbi and Orr labs, the vast 
majority of “first generation” polyglutamine disease models employed only truncated 
versions of polyglutamine disease proteins. Of particular note are the HD models that 
express only exon 1 of the huntingtin gene. Huntingtin is very large, with exon 1 
accounting for only 3% of the total protein. And while evidence exists that 
polyglutamine-containing fragments of huntingtin are produced in HD, there remains a 
conceptual problem in modeling the disease using truncated proteins: these fragments 
produce toxicity in nearly every cellular context tested, yet pathology in HD occurs 
almost exclusively in striatal neurons. Indeed, as researchers began to compare the 
models expressing truncated proteins to those expressing full-length proteins, it soon 
became clear that truncated proteins were much more toxic than their full-length 
versions, and did not recapitulate the cell-type-specific neurodegeneration characteristic 
of each disease. Mouse models of SBMA provide an ideal example of this phenomenon: 
truncated, polyglutamine-expanded AR that is widely expressed in the CNS causes 
widespread neuronal dysfunction (Abel et al., 2001), and pure polyglutamine that is 
expressed specifically under the AR promoter also causes widespread neuronal 
dysfunction (Adachi et al., 2001). However, when full-length expanded AR is expressed 
under the AR promoter, the symptoms are more limited, showing specific vulnerability in 
lower motor neurons (Sopher et al., 2004). 
 
15 
Based on these and other studies, the Zoghbi and Orr labs were the first to openly 
speculate that the activities of polyglutamine peptides (and by implication, the pathology 
that arose from their expression) were distinct from those of the full-length 
polyglutamine-expanded proteins (Lin et al., 1999; Orr, 2001). They raised the possibility 
that the toxicity observed using polyglutamine peptides was a generalized toxicity that 
may overlap with some features of polyglutamine disease, but may not faithfully reflect 
pathogenesis of the human disease. Instead, taking cues from their ataxin-1 NLS mutant, 
these labs suggested that regions outside the polyglutamine tract could be determinants of 
toxicity, with the context of the polyglutamine tract defining the specificity of the 
disease. 
 
Setting out to test these ideas, the Zoghbi and Orr labs developed a new experimental 
perspective on polyglutamine disease, one that focused on the protein context in which 
the polyglutamine tract was located. In a series of papers using both fly and mouse 
models of SCA1, these groups demonstrated that the phosphorylation status of ataxin-1 
could dramatically alter toxicity: animals expressing polyglutamine-expanded ataxin-1 
with a single point mutation (S776A, rendering a phosphoserine non-phosphorylatable) 
showed no pathogenic phenotype (Chen et al., 2003; Emamian et al., 2003). 
Phosphorylation of the S776 residue, located far from the polyglutamine tract, was 
further shown to regulate the protein complexes in which ataxin-1 could participate (Lam 
et al., 2006). Polyglutamine expansion enhanced interactions that were normally 
regulated by phosphorylation at this site, resulting in alterations in the interaction of 
ataxin-1 with its native partners (Lim et al., 2008). These enhanced interactions occurred 
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at the expense of other ataxin-1 interactions, suggesting the possibility that polyglutamine 
expansion contributes to disease by both gain-of-function and partial loss-of-function 
mechanisms. Furthermore, these imbalances in ataxin-1 complexes could contribute to 
the differential vulnerability of particular neuronal populations, since the levels of these 
interacting partners could be in particularly short (or large) supply in vulnerable neurons 
(Zoghbi and Orr, 2009). 
 
Native protein function and SBMA 
Although Zoghbi and Orr’s studies were the first to formally test the importance of 
protein context in polyglutamine disease, the idea that regions outside the polyglutamine 
tract might play a role in toxicity was not a new one. For several years, SBMA had been 
used as a prime example of the importance of protein context, since polyglutamine-
expanded AR is toxic only in the presence of AR ligand (testosterone, or its more potent 
derivative dihydrotestosterone, DHT). In experimental models, flies expressing 
polyglutamine-expanded AR develop pathology only if they are administered AR ligand 
(Takeyama et al., 2002; Pandey et al., 2007b), male SBMA mice do not develop disease 
if they are castrated, and female SBMA mice develop pathology only if they are injected 
with AR ligand (Katsuno et al., 2002). It is for this reason that SBMA affects only men; 
females who carry the mutation (even rare homozygotes (Schmidt et al., 2002)) are 
protected by their low levels of circulating androgen. However, the specific pathogenic 
events that occur in the presence of AR ligand remain largely unexplored. 
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The ligand dependence of SBMA leads to a model in which testosterone or DHT converts 
an innocuous protein into a toxic one, and suggests that experimental approaches that 
dissect ligand-dependent events may shed light on pathogenesis. In this regard, SBMA 
researchers have a distinct advantage over those who study other polyglutamine diseases, 
since the majority of polyglutamine disease proteins have unknown functions and ill-
defined interactomes. In contrast, AR is a widely studied protein with a well-
characterized function as a ligand-dependent transcription factor. Ligand binding to AR is 
known to result in a dramatic change in AR localization and function: although normally 
sequestered in the cytoplasm bound to heat-shock proteins (Hsps), ligand-bound AR 
dissociates from Hsps and translocates to the nucleus. Conformational changes occur to 
reveal two “activation function” domains, AF-1 and AF-2, which serve as binding sites 
for transcriptional coregulators. AR also undergoes ligand-dependent post-translational 
modifications including phosphorylation, SUMOylation, and acetylation. The protein 
dimerizes, binds to DNA, recruits transcriptional coregulators, and finally activates or 
represses its target genes. How these ligand-dependent events relate to the pathogenesis 
of SBMA will be addressed in Chapter 2. 
 
Whether this experimental approach will give insight into pathogenesis, however, 
depends on the validity of an underlying hypothesis – specifically, that the normal 
behavior of wild-type AR is somehow related to the toxic behavior of polyglutamine-
expanded AR. While the results of the SCA1 models argue that pathology is caused by an 
imbalance of native interactors of ataxin-1, this idea has remained largely untested in 
other polyglutamine disease models and is still far from widely accepted in the field. The 
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“toxic aggregate” hypothesis, for example, does not require that the toxic interactions of 
polyglutamine-expanded AR have any relationship to the native interactions of its wild-
type counterpart; instead, this hypothesis only requires that the expanded polyglutamine 
adopt an aggregated conformation in a susceptible region of the cell (e.g. the nucleus). 
Any interactions this aggregate may initiate may be with native or non-native interactors 
that associate via the expanded polyglutamine tract.  
 
A surprising phenomenon in SCA1 and SBMA models has yielded unexpected insight 
into this issue, lending support to the importance of native interactions in toxicity: in 
several fly and mouse models, degeneration can result from very high expression levels 
of wild-type, non-expanded protein. Animals expressing high levels of wild-type ataxin-1 
develop the same degenerative phenotype caused by polyglutamine-expanded ataxin-1 
(Fernandez-Funez et al., 2000), while expression of wild-type AR at high levels in mouse 
muscle leads to an SBMA-like phenotype (Monks et al., 2007). These observations 
suggest the possibility that amplification of native AR function may contribute to the 
toxicity of polyglutamine-expanded AR. Pursuing this hypothesis, Chapter 2 of this thesis 
illustrates how native AR function is required for toxicity in a Drosophila model of 
SBMA. 
 
Concluding remarks 
Following the discovery of the first polyglutamine mutation in 1991, it took only three 
years for a bona fide family of diseases to be identified. Given that these disorders were 
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all caused by the same mutation, it was only logical to predict that they would share a 
common pathogenic mechanism, and the undeniable toxicity of expanded polyglutamine 
peptides supported this idea. However, many years of research have led us down a much 
more complex path. Having started with the search for a unifying model, it is now 
becoming clear that the diseases’ differences may be more important than their 
similarities. Using the precedent of SCA1 and the present findings on SBMA, we hope 
that these experimental perspectives will meet: perhaps our insights into aspects of 
pathogenesis that are unique to each disease will help uncover a common pattern of 
dysfunction that applies to all members of this disease family. We propose that this 
common pattern of dysfunction is centered on polyglutamine-induced modification of 
native protein function. 
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Table 1.1. The polyglutamine disease family 
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Table 1.1. The polyglutamine disease family. Nine diseases are currently known to be 
caused by trinucleotide (CAG) repeat expansions in exonic regions of DNA. The identity 
of each expanded disease protein is given, along with the normal and pathogenic 
polyglutamine repeat lengths and the known normal functions of these proteins (in many 
cases ill defined). Notably, many of the proteins are widely expressed in the nervous 
system, yet only particular tissues are affected in the disease. The major clinical 
symptoms of each disease are also listed. 
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Table 1.2 
 
 
Table 1.2. Repeat expansion diseases. The repeat expansion diseases can be generally 
classified into three categories based on their pathogenic mechanism. Type 1 diseases 
include the polyglutamine diseases as well as oculopharyngeal muscular dystrophy, a 
polyalanine disease; all are caused by a toxic gain of function at the protein level. Type 2 
diseases are caused by toxic gain of function mediated at the RNA level; in these 
diseases, repeats occur in the 5’ or 3’ untranslated regions (UTR) of genes and affect 
cellular function, including alternative splicing of various genes. Type 3 diseases caused 
by loss of function; these diseases are caused by mutations located in introns or 5’ UTRs. 
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Summary 
Spinobulbar muscular atrophy (SBMA) is a neurodegenerative disease caused by 
expansion of a polyglutamine tract in the androgen receptor (AR). This mutation confers 
toxic function to AR through unknown mechanisms. Mutant AR toxicity requires binding 
of its hormone ligand, suggesting that pathogenesis involves ligand-induced changes in 
AR. However, whether toxicity is mediated by native AR function or a novel AR 
function is unknown. We systematically investigated events downstream of ligand-
dependent AR activation in a Drosophila model of SBMA. We show that nuclear 
translocation of AR is necessary but not sufficient for toxicity and that DNA binding by 
AR is necessary for toxicity. Mutagenesis studies demonstrated that a functional AF-2 
domain is essential for toxicity, a finding corroborated by a genetic screen that identified 
AF-2 interactors as dominant modifiers of degeneration. These findings indicate that 
SBMA pathogenesis is mediated by misappropriation of native protein function, a 
mechanism that may apply broadly to polyglutamine diseases. 
 
Running Title 
Native functions of AR mediate SBMA pathogenesis 
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Introduction 
Spinobulbar muscular atrophy (SBMA, also known as Kennedy’s disease) is a 
progressive late-onset degenerative disorder of the motor neurons in the brainstem and 
spinal cord that affects only men (Kennedy et al., 1968). SBMA is a member of the 
polyglutamine repeat disease family, which includes at least eight other disorders, 
including Huntington’s disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), 
and six forms of spinocerebellar ataxia (SCA). All of these diseases are caused by gain-
of-function mutations characterized by expanded trinucleotide (CAG) repeats in exonic 
regions of DNA, and all result in late-onset, progressive neurodegeneration (Zoghbi and 
Orr, 2000). In SBMA, the CAG repeat site is located in the androgen receptor (AR) gene 
and causes disease when the number of repeats is 40 or greater (La Spada et al., 1991). 
Patients often display signs of mild feminization, likely due to partial loss of AR 
function. Although loss of AR function may contribute to disease (Thomas et al., 2006), 
it is not sufficient for degeneration, as loss-of-function mutations to AR result in 
androgen insensitivity syndrome without signs of neuronal degeneration (Quigley et al., 
1992). 
 
A central mystery in the field of polyglutamine disease research arises from the 
observation that the same mutation in nine different proteins results in nine different 
diseases; yet in each disease, different subsets of neurons are affected. This pattern occurs 
despite widespread and overlapping expression of the disease proteins, suggesting that 
the inherent toxicity of the expanded polyglutamine is not the sole basis of toxicity. 
Indeed, in SBMA mouse models, expression of polyglutamine-expanded fragments of 
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AR results in widespread neuronal degeneration, a phenotype that is not dissimilar from 
that observed in transgenic animal models expressing fragments of other polyglutamine-
expanded proteins (Abel et al., 2001). In contrast, models employing full-length 
polyglutamine-expanded AR protein more accurately reflect the human disease, 
displaying restricted symptoms, lower motor neuron specificity in degeneration, and 
gender specificity (Chevalier-Larsen et al., 2004; Sopher et al., 2004).  
 
These findings highlight the importance of protein context in polyglutamine disease, and 
raise the question of the role of protein domains other than the polyglutamine tract in 
toxicity. It is not clear whether the mutation results in the formation of novel, toxic 
interactions, or whether the mutation alters the normal, native interactions of the 
polyglutamine-containing protein in such a way as to result in neurotoxicity. While these 
possibilities are not mutually exclusive, recent studies in SCA1, SCA7, and SCA17 have 
provided evidence in favor of a model in which the normal function of the disease protein 
is tied to the mechanism of pathogenesis (Emamian et al., 2003; Friedman et al., 2007; 
Helmlinger et al., 2006; Lim et al., 2008; McMahon et al., 2005; Palhan et al., 2005; 
Tsuda et al., 2005). More direct evidence that native interactions may mediate toxicity 
comes from animal models in which overexpression of non-expanded ataxin-1 or AR 
result in pathology resembling SCA1 and SBMA, respectively (Fernandez-Funez et al., 
2000; Monks et al., 2007). 
 
In the majority of polyglutamine diseases, neither the primary function nor the native 
interactors of the disease proteins are well known. SBMA is an exception in that the 
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disease protein has a well-characterized role as a ligand-dependent transcription factor. 
AR is a member of the nuclear hormone receptor (NHR) superfamily and resides in the 
cytoplasm when inactive. A number of events occur upon ligand binding, the final result 
of which is AR-mediated activation or repression of target genes. These ligand-induced 
events include several post-translational modifications, nuclear translocation, and DNA 
binding. These changes occur in concert with conformational changes that result in the 
exposure of two coregulator interaction surfaces, termed activation function-1 (AF-1) and 
activation function-2 (AF-2). Ligand binding to polyglutamine-expanded AR is a 
requisite step in disease pathogenesis. Indeed, there is now incontrovertible evidence 
from animal model studies as well as human studies that gender specificity in SBMA is 
due to higher levels of circulating androgens in males (Katsuno et al., 2002; Takeyama et 
al., 2002). 
 
Although the basis of the toxic gain of function imparted by the polyglutamine expansion 
remains unknown, the ligand dependence of SBMA implies that ligand-induced 
alterations of AR play important roles in toxicity. In this study, we used a Drosophila 
model to test the hypothesis that SBMA is mediated by ligand-induced alterations in 
native AR interactions. First, we present evidence that nuclear translocation of AR is 
necessary but not sufficient for toxicity, demonstrating that ligand-induced modifications 
of AR (beyond nuclear translocation) are required for pathogenesis. Second, we showed 
that DNA binding of polyglutamine-expanded AR is required for toxicity, indicating that 
the native DNA-binding function of AR is critical to pathogenesis. Third, we used a 
genetic screen to identify modifiers of SBMA toxicity, which revealed a pattern of AF-2-
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based coregulators that genetically interact with polyglutamine-expanded AR. Pursuing 
this finding, we show rescue of polyglutamine-expanded AR toxicity through two 
independent point mutations designed to disrupt the AF-2 coregulator interaction surface. 
To more precisely define the degenerative phenotype associated with polyglutamine-
expanded AR toxicity we used expression profile analysis. This analysis confirmed that 
interruption of either the AF-2 or DNA binding domains robustly suppressed this 
molecular phenotype. In addition, analysis of the molecular phenotype of flies expressing 
wild-type AR revealed the same (albeit weaker) molecular phenotype as polyglutamine-
expanded AR, indicating that amplification of normal AR function may underlie the 
toxicity of polyglutamine-expanded AR. Finally, we investigated the AR coregulator 
ortholog limpet, a gene identified in our genetic screen, as proof of principle that 
polyglutamine-expanded AR toxicity is mediated via native function of the AF-2 binding 
surface following DNA binding. 
 
Results 
Expression of polyglutamine-expanded AR in Drosophila results in toxicity 
In order to investigate the contributions of AR interactions to polyglutamine-expanded 
AR toxicity, we used a Drosophila model of SBMA. Although human AR has no direct 
ortholog in flies, the NHR system is well conserved (King-Jones and Thummel, 2005). 
This conservation is reflected in the domain architecture of Drosophila nuclear receptors, 
including AF-1 and AF-2 coregulator interaction domains that bind to conserved motifs 
in nuclear receptor coregulators. It was previously demonstrated that human AR 
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expressed in Drosophila tissues translocates to the nucleus and activates transcription of 
an ARE-GFP reporter transgene in response to DHT (Takeyama et al., 2002). This cross-
species transactivational capacity reflects the fact that human AR interacts with 
endogenous Drosophila coactivators and corepressors; indeed, genetic modulation of 
Drosophila homologs of mammalian AR coregulators can modify the transactivational 
capacity of AR in vivo (Takeyama et al., 2004).  
 
When human AR of varying polyglutamine lengths is expressed using the GAL4-UAS 
system (Brand and Perrimon, 1993), flies develop polyglutamine length- and ligand-
dependent degenerative phenotypes, thus recapitulating two fundamental features of 
SBMA (Pandey et al., 2007b; Takeyama et al., 2002). To assess toxicity in an externally 
visible neuronal tissue, we expressed AR in the eye using the glass multimer reporter 
driver (GMR-GAL4), which leads to transgene expression in photoreceptor neurons and 
accessory pigment cells in developing eye discs (Moses and Rubin, 1991). While flies 
expressing AR show no eye phenotype when reared on normal food, flies reared on food 
containing DHT exhibit a degenerative phenotype that is limited to the posterior margin 
of the eye (Figure 2.1A). The severity of the phenotype is also polyglutamine-length 
dependent, with AR52Q-expressing flies showing severe ommatidial pitting, 
disorganization, and fusion, as well as abnormal and supernumerary interommatidial 
bristles. In contrast, AR12Q-expressing flies show only mild ommatidial and bristle 
phenotypes when the transgene is expressed at equivalent levels (Figure 2.1A-C). 
Confocal imaging of eye discs confirmed that AR undergoes DHT-dependent nuclear 
translocation in vivo. This analysis also revealed diffuse nuclear accumulation of AR and 
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the formation of small nuclear and cytoplasmic puncta that were particularly prominent 
with polyglutamine-expanded AR (Figure 2.1D). 
 
The polyglutamine length- and DHT-dependence of SBMA is recapitulated in several 
larval tissues. For example, using the larval salivary gland driver (fkh-GAL4) (Andrew et 
al., 2000), expression of polyglutamine-expanded AR results in a dramatic reduction of 
salivary gland cell size (Figure 2.1 E-F). Larvae expressing AR in motor neurons under 
the control of the D42-GAL4 driver (Yeh et al., 1995) also show polyglutamine length- 
and DHT-dependent defects in locomotor ability as measured by larval crawling assay, 
indicating a significant functional deficit (Figure 2.1G). In addition, the number of type 
1B boutons at the larval neuromuscular junction (NMJ) is significantly decreased in a 
DHT-dependent manner when polyglutamine-expanded AR is expressed using the motor 
neuron driver OK371-GAL4 (Mahr and Aberle, 2006) (Figure 2.1H-I).  
 
Importantly, we noticed that expression of wild-type polyglutamine-length AR at high 
levels results in a degenerative phenotype that is indistinguishable from that caused by 
polyglutamine-expanded AR (Figure 2.1J-K). This is reminiscent of the SBMA-like 
phenotype associated with high level expression of wild-type AR in mice (Monks et al., 
2007). The dose-dependent toxicity of wild-type AR suggests the possibility that 
amplification of native AR function may contribute to the toxicity of polyglutamine-
expanded AR.  
 
Nuclear translocation of polyglutamine-expanded AR is necessary for toxicity 
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The observation that ligand binding to AR is required for pathogenesis suggests a model 
in which non-toxic AR is converted to a proteotoxin through ligand-induced events. The 
first major event to occur upon ligand binding is translocation of AR to the nucleus. In 
most polyglutamine diseases, the primary site of cellular toxicity is thought to be the 
nucleus (Klement et al., 1998; Montie et al., 2009; Peters et al., 1999; Saudou et al., 
1998; Takeyama et al., 2002), although cytoplasmic toxicity may also contribute 
(Hodgson et al., 1999; Morfini et al., 2006; Szebenyi et al., 2003). In the case of SBMA, 
whether nuclear translocation of polyglutamine-expanded AR is both necessary and 
sufficient for toxicity has not been examined in vivo.  
 
AR has three major domains (Figure 2.2A): 1) an N-terminal transactivation domain 
(NTD) that contains activation function-1 (AF-1) and serves as a coregulator interaction 
surface, 2) a DNA-binding domain (DBD) that binds regulatory elements in AR-
regulated promoters, and 3) a C-terminal ligand-binding domain (LBD) that binds 
testosterone or dihydrotestosterone (DHT) and also harbors a second coregulator 
interaction surface (activation function-2, or AF-2). Bridging the DBD and LBD is a 
flexible hinge domain that harbors a bipartite nuclear localization sequence (NLS). To 
address the necessity of nuclear translocation, we generated two AR constructs designed 
to remain in the cytoplasm even in the presence of DHT (Figure 2.2A). In the first 
construct, we used phosphomimetic substitutions of serines 210 and 790 (AR65Q 
SS/DD) that prevent DHT binding to AR (Palazzolo et al., 2007). In the second construct, 
we mutated residues K632 and K633 (AR73Q KK/AA) in the NLS of AR; these 
substitutions markedly alter DHT-induced nuclear translocation (Thomas et al., 2004). 
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COS-1 cells transfected with these constructs showed that the SS/DD and KK/AA 
mutations each caused AR to remain in the cytoplasm even in the presence of DHT 
(Supplemental Figure 2.1A-B). 
 
In order to investigate whether these cytoplasmic AR mutants cause toxicity in vivo, we 
generated transgenic Drosophila lines that express these proteins under the control of the 
GAL4-UAS system. We first confirmed that these modified AR proteins resist DHT-
induced nuclear translocation in vivo in Drosophila by expressing the AR transgenes with 
the larval salivary gland driver fkh-GAL4. Salivary glands provide an ideal model to 
assess subcellular localization of proteins in Drosophila due to their highly ordered 
histoarchitecture and high ratio of cytoplasm to nucleus. Using fkh-GAL4, we found that 
while AR52Q showed nuclear localization, AR65Q SS/DD and AR73Q KK/AA 
remained in the cytoplasm despite the presence of DHT in the larval medium (Figure 
2.2C).  
 
In order to test the toxicity of these constructs in a neuronal tissue, we next expressed the 
AR transgenes using GMR-GAL4. As previously shown, expression of AR52Q in the eye 
resulted in a degenerative phenotype in a DHT-dependent manner (Figure 2.2B,D). In 
contrast, eyes expressing AR65Q SS/DD or AR73Q KK/AA showed no degenerative 
phenotype even in the presence of DHT despite high expression of AR (Figure 2.2B,D 
and Supplemental Figure 2.2A). Consistent with prior reports (Montie et al., 2009; 
Takeyama et al., 2002), these results indicate that nuclear translocation of polyglutamine-
expanded AR is necessary for toxicity.  
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Nuclear translocation of polyglutamine-expanded AR is not sufficient for toxicity 
In order to address whether nuclear translocation of polyglutamine-expanded AR is 
sufficient for toxicity, we designed AR constructs that translocate to the nucleus in a 
DHT-independent manner, thereby dissociating nuclear translocation from ligand 
binding. To this end, we fused the SV40 NLS to either the C- or N-terminus of AR 
(Figure 2.2A). As an additional control, we fused an NLS to the AR65Q SS/DD protein 
that is unable to bind DHT. COS-1 cells transfected with AR65Q-NLS or NLS-AR65Q 
SS/DD show AR localized to the nucleus even in the absence of DHT (Supplemental 
Figure 2.1C-D). In addition, AR65Q-NLS retained its transactivation ability in response 
to DHT as measured by an ARE-luciferase reporter, though only at about 50% of AR65Q 
(Supplemental Figure 2.1E). As expected, NLS-AR65Q SS/DD did not activate 
transcription, due to its inability to bind DHT. 
 
We next made transgenic Drosophila carrying UAS-AR65Q-NLS and UAS-NLS-
AR65Q SS/DD. After confirming that AR65Q-NLS and NLS-AR65Q SS/DD translocate 
to the nucleus in the absence of DHT in vivo using fkh-GAL4 (Figure 2.2E), we 
expressed these transgenes in the eye using GMR-GAL4 (Figure 2.2F and Supplemental 
Figure 2.2B). Expression of AR65Q-NLS or NLS-AR65Q SS/DD did not cause toxicity 
in the absence of DHT, indicating that nuclear translocation of polyglutamine-expanded 
AR is not sufficient for toxicity. However, once the AR65Q-NLS animals were exposed 
to DHT, they developed the characteristic SBMA eye phenotype, demonstrating that 
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DHT binding to AR provides the critical step in the conversion of polyglutamine-
expanded AR from a non-toxic to a toxic molecule (Figure 2.2B, F).  
 
An intact DNA-binding domain is required for polyglutamine-expanded AR toxicity 
Having determined that the role of DHT in SBMA is not simply to effect translocation of 
AR to the nuclear compartment, but also to modify nuclear AR, we hypothesized AR’s 
function as a DNA-binding transcription factor might play a role in pathogenesis. To 
investigate this hypothesis, we introduced a mutation to the AR DBD (A574D) that 
blocks the ability of AR to bind DNA without disrupting its ligand-binding ability 
(Bruggenwirth et al., 1998). 
 
AR65Q A574D showed normal DHT-induced nuclear translocation in vitro 
(Supplemental Figure 2.3), although transactivation capacity was severely disrupted, as 
predicted due to the inability of the mutated AR to bind DNA (Figure 2.3A). Strikingly, 
transgenic flies expressing AR52Q A574D using GMR-GAL4 showed no degenerative 
phenotype even in the presence of DHT, indicating that the A574D mutation abolished 
the toxicity of polyglutamine-expanded AR despite nuclear localization of AR and high 
transgene expression (Figure 2.3B-D and Supplemental Figure 2.2C-D). Supporting this 
result, flies expressing polyglutamine-expanded AR with the A574D mutation showed no 
larval crawling defect when AR was expressed in motor neurons (Figure 2.3E). 
Additionally, introduction of the A574D mutation resulted in salivary gland cell size that 
was indistinguishable from AR52Q without DHT (Figure 2.3F-G). These results indicate 
that the native DNA-binding function of AR is critical for pathogenesis. 
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AF-2-interacting coregulators modify the toxicity of polyglutamine-expanded AR 
In the normal life cycle of AR, DNA binding is followed by the recruitment of 
coregulators (either corepressors or coactivators) that associate with AR at target 
promoters (Heinlein and Chang, 2002). We hypothesized that coregulator binding, an 
event immediately downstream of DNA binding, might play a role in pathogenesis.  
 
In order to investigate the role of AR coregulators in SBMA, we performed a candidate-
based genetic screen for modifiers of polyglutamine-expanded AR toxicity. We began 
with 73 human coregulators that are known to interact with AR. We identified 61 
putative Drosophila orthologs of these coregulators, including 23 coactivators, 34 
corepressors, and 4 coregulators with dual function. RNAi-mediated knockdown of 19/61 
(31%) of these Drosophila coregulators dominantly modified the SBMA fly phenotype 
(Table 2.1, Supplemental Figure 2.4A-B). These modifiers included some coregulators 
with obvious mechanisms of enhancement, including Pat1 and Pten, which normally 
function to inhibit AR nuclear translocation. The mechanism for other modifiers was less 
clear, although there was an interesting pattern among the hits because seven of them 
relate to the function of the AF-2 domain of AR. Specifically, CycD, gskt, jbug, Lmpt, 
Rad9, Smr, and wts (putative Drosophila orthologs of CCND1, GSK3B, FLNA, FHL2, 
RAD9, NCOR1/2, and LATS2, respectively) each plays a role in AF-2 interactions, 
either by binding AF-2 directly or by modifying the AF-2-based interaction with the 
NTD (Table 2.1). To confirm the specificity of these hits and to rule out off-target effects 
due to RNAi, we confirmed the effects of these AF-2-related hits in three additional 
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contexts. First, we confirmed that classical alleles and aneuploid aberrations of these 
same genes would similarly enhance the AR52Q eye phenotype (Supplemental Figure 
2.4C). Second, after verifying that RNAi knockdown had no effect on larval crawling 
ability when expressed in motor neurons in the absence of AR52Q, we showed that these 
RNAi lines enhanced the AR52Q larval crawling defect in 6/7 cases (Table 2.1, 
Supplemental Figure 2.4 D-E). Third, we showed that the RNAi lines did not enhance the 
AR52Q eye phenotype nonspecifically, by crossing RNAi-expressing lines to an 
unrelated disease model of inclusion body myopathy associated with Paget's disease of 
bone and frontotemporal dementia (IBMPFD) that shows a modifiable degenerative eye 
phenotype (Ritson et al., 2010) (data not shown). 
 
A functional AF-2 binding site is required for toxicity 
AF-2 is a ligand-dependent hydrophobic surface flanked by opposing charged residues, 
K720 and E897 (Figure 2.4A). This surface is highly conserved across steroid hormone 
receptors and across species, and in most cases serves as a binding pocket for the LxxLL 
motifs of steroid receptor coactivator (SRC) family members (He et al., 1999). Unlike 
other steroid hormone receptors, however, the AF-2 of AR binds an additional motif, 
defined as FxxLF, with higher affinity (Dubbink et al., 2004; He et al., 2001; He et al., 
2004). The FxxLF motif is found in a small number of coregulators, as well as in the N 
terminus of AR, which allows for an intra- or intermolecular interaction between the 
NTD and AF-2 domains of AR. Current models propose that AF-2 binds the NTD FxxLF 
motif while AR is mobile, and that the NTD/AF-2 interaction is lost upon AR binding to 
DNA, rendering AF-2 optimally accessible to coregulators (van Royen et al., 2007). 
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Since our targeted RNAi screen highlighted the importance of coregulator interactions 
with AF-2, we next investigated the role of AF-2 function in polyglutamine-expanded 
AR toxicity by taking advantage of three well-characterized mutations that disrupt AF-2-
based interactions without influencing protein stability. The first, E897K, reverses the 
charge of one of the two charge clamp residues in AF-2, thereby abolishing both LxxLL- 
and FxxLF-mediated interactions (He et al., 1999) (Figure 2.4A). The second, K720A, 
which neutralizes the charge of the other charge clamp residue in AF-2, partially impairs 
AF-2 function by severely disrupting LxxLL-mediated interactions and decreasing 
FxxLF-based interactions by approximately 50% (Dubbink et al., 2004; He et al., 1999). 
The third, G21E, located two amino acids from the FxxLF sequence in the NTD, blocks 
the NTD/AF-2 interaction without affecting AF-2 structure (Callewaert et al., 2003). 
Neither E897K nor K720A alters the equilibrium binding affinity for ligand (He et al., 
1999). 
 
In COS-1 cells, AR E897K, K720A, and G21E showed DHT-induced nuclear 
translocation similar to wt AR (Supplemental Figure 2.5A-B). Luciferase-based 
transactivation assays indicated that while K720A and G21E mutants showed unaltered 
transactivation capacity, the activity of AR E897K was modestly decreased (Figure 
2.4C). When expressed in vivo using fkh-GAL4, we found that all three mutant proteins 
translocated to the nucleus in response to DHT (Figure 2.4B). Importantly, the AF-2 
mutations E897K and K720A strongly suppressed the phenotype caused by expression of 
polyglutamine-expanded AR in salivary glands cells (Figure 2.4B and Supplemental 
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Figure 2.5C-D). In contrast, the G21E mutation had no impact on salivary gland 
phenotype (Figure 2.4B). 
 
We next tested the toxicity of these mutant proteins using GMR-GAL4. We found that 
introduction of the E897K mutation abolished the degenerative eye phenotype, indicating 
that complete disruption of AF-2 binding eliminates the toxicity of polyglutamine-
expanded AR despite high levels of AR expression (Figure 2.4E, Supplemental Figure 
2.2C-D, and Supplemental Figure 2.5E). The K720A mutation also suppressed 
degeneration, confirming that LxxLL- and FxxLF-based binding to AF-2 are critical 
mediators of toxicity. In contrast, the G21E mutation had no discernable impact on the 
eye phenotype. This latter result argues that impaired coregulator interactions with AF-2, 
rather than impaired NTD binding to AF-2, underlie the suppressive effect of E897K and 
K720A mutations. 
 
To corroborate the suppression seen by the K720A and E897K mutations, we next used 
the driver elav-GAL4, which drives transgene expression in all neurons. While 
expressing AR52Q with elav-GAL4 resulted in early larval lethality, introducing the AF-
2 mutations E897K or K720A resulted in increased viability, as evidenced by more flies 
surviving to the pupal stage (Figure 2.4D and Supplemental Figure 2.5F). When 
expressed in motor neurons with D42-GAL4, the E897K and K720A mutations also 
significantly suppressed the larval crawling defect seen in AR52Q flies (Figure 2.4F). In 
addition, AF-2 mutations suppressed the NMJ bouton phenotype, resulting in a 
significantly increased number of synaptic boutons, while the G21E mutation had no 
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effect on this phenotype (Figure 2.4G-H). These results confirm the suppression observed 
in the eye while extending the findings to the cell type most affected in the human 
disease. 
 
Expression profile analysis of AR mutants reveals the molecular phenotype of eye 
degeneration 
While the rescue of eye degeneration we observe with mutations to the DNA-binding 
domain or AF-2 domain are robust, and we have corroborated the findings in other 
tissues, we felt it would be valuable to generate a molecular phenotype to serve as an 
objective, quantifiable assay of degeneration. Using GMR-GAL4 to drive transgene 
expression in the eye, we used Affymetrix arrays to profile gene expression changes in 
flies expressing wild-type AR, polyglutamine-expanded AR, or polyglutamine-expanded 
AR with mutations affecting the DBD or AF-2. 149 genes were identified whose 
expression significantly changed in concert with ligand-induced degeneration in AR52Q-
expressing flies, representing a molecular signature of degeneration (Figure 2.5A, 
Supplemental Figure 2.6, and Supplemental Table 2.1). Hierarchical cluster analysis 
revealed strong correlation between this molecular read-out and visual inspection of eye 
morphology (Figure 2.5A-B). Principal components analysis showed that introduction of 
the E897K and A574D mutations reverted the molecular phenotype back to a pattern that 
is indistinguishable from AR12Q or AR52Q without ligand (Figure 2.5C). The K720A 
mutation partially reversed the molecular phenotype observed in the AR52Q flies +DHT, 
reflecting the milder suppression observed in these eyes when scored according to the 
severity of their external degenerative phenotype.  
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For the purpose of our study, we used expression profiles as a means of quantifying eye 
degeneration in our model. We caution against making too much of the identity of the 
individual genes whose expression is changed because the molecular phenotype that 
accompanies eye degeneration is likely dominated by secondary gene expression changes 
that are a consequence rather than a cause of degeneration. Nevertheless, we recognized 
the possibility that embedded within these expression profiles are some gene expression 
changes that are primary due to AR binding. To address this possibility, we performed 
promoter analysis which found no evidence of enrichment of genes containing AR 
binding sites among the DHT-responsive gene set (data not shown). Similarly, promoter 
analysis showed no enrichment for genes that are responsive to endogenous nuclear 
hormone receptors such as the ecdysone receptor (data not shown). These results suggest 
that although the molecular phenotype captured by our expression profiling can be used 
to quantify neurodegeneration in the adult eye, secondary gene changes are likely to 
obscure primary gene changes that occurred in the first steps of pathogenesis. 
 
In addition to corroborating our visual inspection with respect to E897K, A574D, and 
K720A mutations and toxicity, the expression profile analysis also revealed that AR12Q 
+DHT caused nearly the same molecular signature as AR52Q +DHT, although the degree 
of expression level changes was generally weaker in AR12Q compared to AR52Q 
(Figure 2.5A and Supplemental Figure 2.6). This observation is consistent with a model 
in which amplification of normal AR function may underlie the toxicity of 
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polyglutamine-expanded AR. Indeed, as described above, expression of AR12Q in fly 
eyes can also result in degeneration when expressed at very high levels. 
 
Modification of the SBMA phenotype by the FxxLF-containing coregulator limpet is 
dependent on AF-2 
The strong suppression observed in the E897K mutants (which eliminates FxxLF-based 
interactions), along with the milder suppression observed in the K720A mutants (which 
merely decreases FxxLF-based interactions), implicated FxxLF-based coregulator 
interactions as playing a significant role in toxicity. Based on our genetic screen (Table 
2.1), we further examined the identity of our genetic modifiers in the context of FxxLF-
based AF-2 interactions. Although some of these modifiers are not known to interact with 
AF-2 directly and not all contain FxxLF motifs, the AR coregulator four-and-a-half LIM 
domains 2 (FHL2, the human ortholog of Drosophila limpet) interacts with AF-2 directly 
via an FxxLF motif (Hsu et al., 2003). FHL2/limpet is well-conserved between fly and 
human (56.4% similarity, 74.4% identity), including the FxxLF motif (Supplemental 
Figure 2.7A), and is one of a family of LIM domain-containing proteins, several of which 
are known to play a role in motor neuron development (Bhati et al., 2008). The exact 
mechanism whereby FHL2 modifies AR transactivation is unknown, although LIM 
domain-containing proteins have been found to act as bridging molecules between 
transcription factors, suggesting that they may act as scaffolds in the assembly of 
transcriptional complexes (Wadman et al., 1997). Thus, limpet provided a good candidate 
for further investigation, given that it may act to positively or negatively regulate the 
assembly of AF-2 complexes.  
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We therefore performed epistasis experiments to examine the ability of limpet to modify 
the toxicity of polyglutamine-expanded AR. While RNAi knockdown of limpet in the 
Drosophila eye using GMR-GAL4 results in no externally visible phenotype in flies 
without the mutant AR transgene, limpet knockdown in flies expressing AR52Q 
enhanced the AR52Q degenerative eye phenotype (Figure 2.6A,C,M and Supplemental 
Figure 2.7B-C). Similarly, a classical P-element allele (LmptGE27535) of limpet enhanced 
the AR52Q phenotype (Figure 2.6B,C,M and Supplemental Figure 2.7B). A 
chromosomal duplication that produces two copies of the limpet gene (Dp(3;3)st+g18) 
(Tearle et al., 1989) suppressed the AR52Q phenotype, suggesting that depletion of 
limpet by AR contributes to toxicity (Figure 2.6C,D,M and Supplemental Figure 2.7B). 
This suppression was confirmed through expression profile analysis in which we 
determined that 46% of the gene expression changes that accompanied ligand-dependent 
degeneration in AR52Q flies were completely reversed by limpet duplication (Figure 
2.6N). 
 
Interestingly, although genetic manipulation of limpet did not modify the mild phenotype 
of flies expressing AR12Q at moderate levels (data not shown), limpet alleles did modify 
the more severe phenotype of flies expressing AR12Q at very high levels (Figure 2.6E-
H,M), suggesting that the molecular pathophysiology of high-expressing AR12Q flies is 
related to that of AR52Q flies. Importantly, limpet knockdown did not modify the 
phenotype of AR66Q E897K, indicating that the enhancement by limpet RNAi requires a 
functional AF-2 binding surface (Figure 2.6I-J). In addition, limpet duplication did not 
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suppress the degenerative phenotype caused by pure polyglutamine protein (127Q) 
(Kazemi-Esfarjani and Benzer, 2000), demonstrating that increased levels of limpet are 
not globally protective, but instead show a specific genetic interaction with AR (Figure 
2.6K-L). These results are consistent with a model in which polyglutamine-expanded AR 
causes toxicity through AF-2-based interactions with coregulators. 
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Discussion 
In this study, we investigated the basis for the toxicity of polyglutamine-expanded AR by 
systematically interrogating ligand-dependent modifications of this nuclear hormone 
receptor. We showed that nuclear translocation of polyglutamine-expanded AR is 
necessary but not sufficient for toxicity and that DNA binding is required for toxicity. 
Insight from a genetic screen indicated that native interactions, those mediated by the AF-
2 domain in particular, play a key role in toxicity. This suspicion was confirmed by our 
results indicating that toxicity is dependent upon a functional AF-2 binding surface. 
Specifically, we demonstrated that K720A and E897K mutations to the AF-2 coregulator 
interaction surface attenuated polyglutamine-expanded AR toxicity, while interruption of 
the NTD/AF-2 interaction had no effect. In the majority of assays, the E897K mutation 
resulted in a stronger suppression than K720A (Figure 2.4D-E, G-H), an observation that 
is consistent with the stronger AF-2 disruption due the reversal of charge (E/K) compared 
to the neutralization of charge (K/A). These results indicate that AF-2 function is 
essential for polyglutamine-expanded AR toxicity. Importantly, the morphological 
(Figure 2.1J) and molecular (Figure 2.5) phenotypes of AR12Q recapitulate those of 
AR52Q, only less strongly, suggesting that polyglutamine-expanded AR toxicity may be 
mediated by amplification of wild-type AR function. We conclude that SBMA 
pathogenesis is mediated by amplification of native AR interactions, and that functions of 
the AF-2 domain are essential to toxicity. 
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Although we have demonstrated that polyglutamine-expanded AR toxicity requires DNA 
binding followed by association with AF-2 coregulators, we do not yet know how this 
results in toxicity. We favor a model in which the AF-2 domain of AR competes with 
other transcription factors for a finite supply of coregulators. According to this model, 
amplification of AR activity could result in reduced availability of coregulators for 
important functions. This model is consistent with our observation that RNAi-mediated 
knockdown of AF-2 interactors consistently enhances toxicity. A key outstanding 
question not answered in this study is how AR activity in the nucleus is amplified. One 
possibility is that aggregation-prone polyglutamine-expanded AR adopts a toxic 
conformation that amplifies AF-2-based interactions. However, the fact that we did not 
detect polyglutamine length-dependent changes in co-immunoprecipitation of AR and 
FHL2 argues against this possibility (Supplemental Figure 2.8). An alternative possibility 
is that polyglutamine expansion amplifies AR activity (and AF-2 function in particular) 
independent of any change in the intrinsic ability of AR to interact with coregulators. For 
example, by reducing the inactivation rate of DNA-bound AR or by reducing the rate of 
AR nuclear efflux similar to what has been observed for ataxin-7 (Taylor et al., 2006). 
The mechanism by which polyglutamine expansion amplifies AR nuclear activity will be 
an important focus for future studies. In previous analysis we observed the presence of 
high molecular weight species of presumed aggregated polyglutamine-expanded AR in 
our Drosophila model of SBMA (Pandey et al., 2007b). These species are also present in 
the mutant forms of AR included in the current study. Quantitative analysis shows no 
correlation between the amount of high molecular weight species and neurodegeneration 
in this Drosophila model (Supplemental Figure 2.2 E-F). While this observation is 
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intriguing, thorough assessment of the relative contributions of aggregation and altered 
native function will require follow up studies in mammals. 
 
While our results indicate that AF-2 function is essential to toxicity (Figure 2.7), it is 
likely that multiple native interactions influence the toxicity of polyglutamine-expanded 
AR, and this is substantiated by the results of our genetic screen. For example, AF-1-
interacting coregulators Hey and Rbf were found to modify toxicity, indicating that 
coregulator interactions at AF-1 likely participate in pathogenesis. One of these proteins, 
Rbf, (the Drosophila ortholog of Rb, or Retinoblastoma protein) was also recently shown 
to modulate the toxicity of polyglutamine-expanded AR in another Drosophila model of 
SBMA. In this study, Rb was shown to have increased association with polyglutamine-
expanded AR, leading to reduced Rb activity and subsequent loss of regulation of Rb-
associated genes (Suzuki et al., 2009). Such a model may also apply to AF-2-based 
interactions. 
 
These observations may easily be aligned with recent reports relating to three other 
polyglutamine diseases in which the data point away from the intrinsic toxicity of 
expanded polyglutamine and toward the toxic consequences of amplified native 
interactions. A series of publications from the Orr and Zoghbi labs has illuminated the 
role of native interactions of ataxin-1 in the pathogenesis of SCA1 (Emamian et al., 2003; 
Lim et al., 2008; Tsuda et al., 2005). Specifically, polyglutamine expansion favors 
interaction with the RNA-binding protein RBM17, contributing to SCA1 neuropathology 
through a gain-of-function mechanism. Concomitantly, polyglutamine expansion 
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attenuates interaction with Capicua, contributing to SCA1 through a partial loss-of-
function mechanism (Lim et al., 2008). Analogous mechanisms have been implicated in 
the pathogenesis of SCA7 and SCA17, although less is known about the identity of the 
native interactions that are key to pathogenesis (Friedman et al., 2007; Helmlinger et al., 
2006; McMahon et al., 2005; Palhan et al., 2005).  
 
While the AF-2 result is interesting insofar as it highlights a model in which 
polyglutamine expansion drives toxicity through native function, the greatest significance 
is that these results reveal an opportunity for therapeutic intervention. An entire 
therapeutic enterprise has developed around targeting of AF-2/coregulator interactions 
with small molecules in efforts to combat prostate cancer, hyperandrogenic syndromes 
and male-pattern baldness among others (Chang and McDonnell, 2005; Schapira, 2002). 
Indeed, the drug ASC-J9 was found to ameliorate neurodegeneration in a mouse model of 
SBMA and this was attributed to increased degradation of polyglutamine-expanded AR 
(Yang et al., 2007). However, in light of our findings it is worth noting that ASC-J9 
disrupts the interaction between AF-2 and FxxLF-containing coregulators, suggesting 
that the beneficial effect of ASC-J9 may represent targeted interruption of AF-2-based 
interactions that are essential mediators of toxicity (Ohtsu et al., 2002). Although further 
studies are required to replicate these results in a mammalian model, our current findings 
allow for the possibility that SBMA patients will not have to rely on drugs that result in 
global androgen deprivation, but instead hope for therapeutic agents that will act in motor 
neurons to specifically target toxic AR interactions. 
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Experimental Procedures 
Antibodies 
Primary antibodies used: AR (N20, Santa Cruz Biotechnology), actin (I-19-R, Santa Cruz 
Biotechnology), α-tubulin (T5168, Sigma), FLAG (M2 F1804, Sigma), Anti-HRP-Cy3 
conjugate (Jackson Immunoresearch), Discs-Large (DSHB 4F3). Secondary antibodies 
used for biochemistry: IRDye 800CW Goat Anti-Mouse IgG, IRDye 680 Goat Anti-
Mouse IgG, IRDye 680 Goat Anti-Rabbit IgG, IRDye 800CW Goat Anti-Rabbit IgG (Li-
Cor Biosciences). For in vivo staining: Goat anti-mouse Alexa Fluor 488 (Invitrogen), 
Goat anti-rabbit Alexa Fluor 488 (Invitrogen), FITC anti-rabbit (Jackson 
ImmunoResearch). The mouse anti-Discs-Large hybridoma antibody developed by Corey 
Goodman was obtained from the Developmental Studies Hybridoma Bank developed 
under the auspices of the NICHD and maintained by the University of Iowa, Department 
of Biology, Iowa City, IA 52242. 
 
Cloning 
Mutagenesis (G21E, S210D, A574D, K720A, S790D, and E879K) was performed using 
Quikchange II XL Mutagenesis Kit (Stratagene). NLS sequences were added to AR using 
a PCR-based method. 
 
Eye disc staining 
UAS-AR flies were crossed to GMR-GAL4 flies on food with or without 1 mM DHT 
(Steraloids). Pupal eye discs were dissected and fixed with 4% PFA for 30 minutes at 
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room temperature. Discs were stained with primary antibody for 16 hours at 4°C and 
secondary antibody for 1 hour at room temperature. Phalloidin staining (Alexa Fluor568 
Phalloidin, Invitrogen) was performed for 2 hours at room temperature. Discs were 
washed and embedded using Glycergel (Dako), mounted, and examined by laser 
scanning confocal microscopy. 
 
Eye phenotypes 
UAS-AR flies were crossed to GMR-GAL4 flies at 25°C or 29°C on food containing 
either 1 mM DHT (Steraloids) or 1% ethanol. Eye phenotypes of anesthetized female 
flies were evaluated with a Leica MZ APO or M205C stereomicroscope and 
photographed with a Leica DFC320 digital camera. Blinded scoring of the AR phenotype 
was performed as previously described (Pandey et al., 2007b). 
 
Fly stocks 
Mutant AR flies were generated by cloning human AR constructs into pUAST. DNA was 
injected into w1118 embryos by BestGene Inc (Chino Hills, CA). At least 4 independently 
generated transgenic lines were evaluated for all AR-expressing flies. Classical alleles 
and deficiency lines (Df(1)sd72b, Df(3R)tll-e, Df(2R)Exel6079, Df(3L)Cat, Df(1)N105, 
wts[3-17], LmptGE27535, and Dp(3;3)st+g18) were obtained from Bloomington Stock 
Center (Bloomington, IN). RNAi transgenic lines were obtained from the Vienna 
Drosophila RNAi Center (Vienna, Austria). 
 
Larval crawling 
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UAS-AR flies were crossed to D42-GAL4 flies at 25°C on food containing either 1 mM 
DHT (Steraloids) or 1% ethanol. Larval crawling was performed on a 1% agarose gel in a 
245 mm2 dish with gridlines spaced by 2.5 mm. Wandering third instar larvae were 
allowed to acclimate for 5 minutes, and the number of gridlines passed by the posterior 
end of the larvae in 30 seconds was counted. Each larva was tested 3 times. 
 
Luciferase assays 
Luciferase assays were performed in HEK293T cells as previously described (Palazzolo 
et al., 2007). Briefly, cells were transfected with indicated AR constructs together with 
both the luciferase pARE-E1b-Luc and the β-galactosidase pCMVβ reporter constructs. 
AR transactivation was measured in the presence and absence of DHT by luciferase assay 
and normalized to β-galactosidase activity. 
 
Microarray gene expression profiling analysis 
UAS-AR flies were crossed to GMR-GAL4 flies at 29°C on food containing either 1 mM 
DHT (Steraloids) or 1% ethanol. Heads of 15 female offspring were collected, frozen, 
and RNA was extracted using TRIzol (Invitrogen). Details of processing and analysis 
may be found in Supplemental Information. 
 
Neuromuscular bouton counting 
UAS-AR flies were crossed to OK371-GAL4 flies at 25°C on food containing either 1 
mM DHT (Steraloids) or 1% ethanol. Third instar larvae were heat killed, dissected in 
PBS, and fixed with 4% PFA for 20 minutes. Primary antibody staining was performed at 
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4°C overnight and secondary antibody staining was performed at room temperature for 4 
hours. After staining, pelts were mounted in Fluoromount-G (SouthernBiotech).  Boutons 
at muscle 4 segments A2-A5 on the right and left side were quantified in the mounted 
muscle preparations.  
 
RNAi screen 
The list of 73 AR-interacting coregulators was generated through literature review. 
Orthology prediction for Drosophila orthologs of these coregulators was performed using 
the HUGO Gene Nomenclature Committee Comparison of Orthology Prediction tool 
along with PSI-BLAST. RNAi lines were obtained from the Vienna Drosophila RNAi 
Center. Flies expressing UAS-RNAi were crossed to flies expressing GMR-GAL4; UAS-
AR52Q at 29°C on food containing either 1 mM DHT (Steraloids) or 1% ethanol. Eye 
phenotypes of anesthetized female flies were evaluated with a Leica MZ APO or M205C 
stereomicroscope and photographed with a Leica DFC320 digital camera.  
 
Salivary gland staining 
UAS-AR flies were crossed to fkh-GAL4 flies at 25°C on food containing either 1 mM 
DHT (Steraloids) or 1% ethanol. For antibody staining, wandering third instar larvae 
were collected and salivary glands were dissected into 4% PFA in PBS. Glands were 
stained with primary antibody for 16 hours at 4°C and secondary antibody for 2 hours at 
room temperature. For details of fixation and washing, see Supplemental Information. 
For phalloidin staining, wandering third instar larvae were collected and salivary glands 
were dissected and stained as previously described (Martin and Baehrecke, 2004) using 
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Texas Red-Phalloidin (Invitrogen). Slides were examined using a Leica DMIRE2 
microscope and cell size was determined using phalloidin staining and Slidebook 
software (Intelligent Imaging Innovations). 
 
Statistics 
Statistical comparisons were performed by ANOVA and Tukey HSD Test or Student’s t-
test as appropriate. 
 
Viability 
UAS-AR flies were crossed to elav-GAL4 flies at 25°C on food containing either 1 mM 
DHT (Steraloids) or 1% ethanol. Crosses were set up using 1 female and 1 male. The 
number of pupae on the sides of the vial and the surface of the food were counted 16 days 
after parents were added. 
 
Western blotting 
UAS-AR flies were crossed to GMR-GAL4 flies at 29°C. Heads of 3 female offspring 
were collected, frozen, and lysed in RIPA buffer (150 mM NaCl, 6 mM Na2HPO4, 4 mM 
NaH2PO4, 2 mM EDTA, 1% NaDOC, 1% Triton X-100, 0.1% SDS) with protease 
inhibitors (Roche). The lysate was sonicated, boiled, and run on 7.5% Tris-HCl SDS-
PAGE gels (Bio-Rad). Proteins were transferred to nitrocellulose membranes (GE 
Healthcare) and immunoblotted. Blots were developed using the Odyssey Imaging 
System (Li-Cor Biosciences).  
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Supplemental Experimental Procedures 
Antibodies 
Additional primary antibodies used: α-tubulin (T5168, Sigma), FLAG (M2 F1804, 
Sigma). Secondary antibody used for in vitro immunofluoresence: Alexa Fluor 488-Goat 
Anti-Rabbit IgG antibody (Molecular Probes).  
 
Immunofluorescence 
Immunofluorescence was performed in COS-1 cells as previously described (Palazzolo et 
al., 2007). Images were acquired digitally with a DeltaVision microscope and 
deconvolved with the softWoRx algorithm (Applied Precision). For quantification of 
nuclear translocation, the percentage of transfected cells with a greater concentration of 
AR in the nucleus than the cytoplasm was determined for each AR construct. 
 
Real-time quantitative PCR 
 
Total RNA was isolated from 5-10 animals of the appropriate genotype with TRIzol 
reagent (Invitrogen) and cDNA was generated using the iScript cDNA Syntheses kit 
(BioRad #170-8890) following the manufacturer’s protocol. Concentrations for each 
primer probe set were individually optimized. Quantitative real-time PCR reactions were 
carried out in a total reaction volume of 25µl of iQ Supermix (BioRad #170-8860) 
using an BioRad iCycler iQ5 machine for 40 cycles. Quantitation of each transcript was 
determined using the ∆∆CT method. The primer/probe set for Drosophila GAPDH2 
(product number Dm01843776_S1) and for Limpet (product number Dm01836996_gH) 
were purchased from Applied Biosystems. 
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Nuclear extraction and co-immunoprecipitation 
 
HEK293T cells were co-transfected with pcDNA3 FLAG-FHL2 and pEF AR12Q or pEF 
AR52Q using Fugene (Roche). 48 hours post-transfection, cells were treated with 100 
nM DHT (Steraloids) for 1 hour. Cells were collected and allowed to swell for 10 
minutes in Buffer A (10 mM HEPES-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
DTT) plus protease inhibitor cocktail (PIC, Roche). Cells were vortexed 10 seconds and 
centrifuged at max speed for 30 seconds; supernatant was discarded. The pellet was 
resuspended in Buffer C (20 mM HEPES-KOH pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT) plus PIC. Cells were extracted in Buffer C for 
20 minutes on ice, then centrifuged at max speed for 2 minutes. The resulting supernatant 
(comprising nuclear extract) was diluted in bead incubation buffer to yield a final 
concentration of 10 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.5% NP-40, 0.1ug/ul BSA 
plus PIC. Extracts were pre-cleared with Protein-G agarose beads for 1 hour, washed 3 
times, then incubated with M2 agarose beads (F2426, Sigma) for 2.5 hours. Beads were 
washed 5 times with bead incubation buffer. After final wash, 25ul of 1x SDS sample 
buffer was added to beads and boiled for 5 minutes. Samples were loaded onto 8-16% 
Novex gels (Invitrogen) and transferred onto nitrocellulose membranes (GE Healthcare) 
using the iBlot transfer system (Invitrogen). All buffers were supplemented with 100 nM 
DHT or ethanol as appropriate. All steps performed at 4° except as indicated. 
 
Microarray gene expression profiling analysis 
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RNA quality was confirmed by analysis on the Agilient 2100 Bioanalyzer. Total RNA 
(100 ng) was processed in the Hartwell Center microarray core according to the 
Affymetrix 3’ IVT Express target labeling protocol 
(https://www.affymetrix.com/support/downloads/manuals/3_ivt_express_kit_manual.pdf)
. Biotin-labeled cRNA (10 ug) was hybridized overnight at 45°C to the Drosophila 
Genome 2.0 GeneChip array which interrogates more than 18,500 transcripts. After 
staining and washing, arrays were scanned and expression values summarized using the 
MAS5 algorithm as implemented in the GCOS v1.4 software (Affymetrix, Santa Clara, 
CA). Detection calls (Present, Absent and Marginal) were determined using the default 
parameters of the software. Signals were normalized for each array by scaling to a 2% 
trimmed mean of 500. Prior to statistical analysis the MAS5 signals were variance 
stabilized by the started logarithm transformation (Rocke & Durbin, 2003). Principal 
component analysis (PCA) and statistical analyses were performed using Partek 
Genomics Suite v6.4 (Partek Inc., St. Louis, MO). Analysis of differential expression was 
determined using a two-factor ANOVA model where genotype and treatment were the 
factors. Three or four independent replicates were analyzed for each condition. The false 
discovery rate was estimated as described (Benjamini and Hochberg, 1995) and was 
controlled at a level of 0.05 or as otherwise stated. An additional filter was applied to 
select transcripts with robust expression by including those with at least one Present call 
across the dataset. Hierarchical clustering was performed using Spotfire DecsionSite 9.1 
(TIBCO, Palo Alto, CA). Probeset annotations were obtained from the Affymetrix 
website (http://www.affymetrix.com/analysis/index.affx). 
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Transcription factor binding motif analysis 
 
The upstream sequences of the 52Q-responsive genes were analyzed for potential 
transcription factor binding sites using the following method. Sequences 5kb upstream 
from the transcription start site of all known Drosophila genes were downloaded using 
the UCSC Genome Browser (http://www.genome.ucsc.edu/; Drosophila melanogaster 
genome build BDGP R5/dms, Apr 2006). The sequences were searched for homology 
(minimum identity 80%) to the consensus human androgen receptor binding site 
(AGAACANNNTGTTCT) and the endogenous ecdysone receptor binding sequence 
([A/C])GGTCANTGACCT using CLC Genomics Workbench v3.7.1 (CLC bio, 
Cambridge MA). The frequency of binding motifs identified in the 52Q-responsive gene 
set (136 total) was compared to the frequency identified in all genes (21,243 total).   
There was no difference in the proportion of 52Q-responsive genes predicted to have 
androgen receptor binding sites (125/136 vs. 19,831/21,243; Chi Square p = 0.614), or 
ecdysone receptor binding sites (22/136 vs. 4,010/21,243; Chi Square p = 0.486). Further, 
there was no signficant enrichment of the distribution of predicted binding sites within 
the 52Q-responsive genes as compared to all genes (Wilcoxon rank sum test: Androgen 
receptor p = 0.385, Ecdysone receptor p = 0.491). Statistical analyses were performed 
using R 2.11.0. 
 
Cell culture and transfections 
COS-1 (ATCC, CRL-1650) and HEK293T (ATCC, CRL-1573) cells were cultured as 
previously described (Palazzolo et al, 2007). All experiments were carried out in 
complete medium containing 10% charcoal dextran stripped-fetal bovine serum (CDS) 
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(HyClone), when not indicated otherwise. COS-1 cells were transiently transfected using 
the Cell Line Nucleofector kit V (Amaxa Biosystem) with 5 µg of DNA. HEK293T were 
transfected with 2 µg of DNA using Lipofectamine/Plus reagent (Invitrogen). Cells were 
treated for 48 hours with DHT (10 nM, Sigma). 
 
Salivary gland staining details 
For antibody staining, wandering third instar larvae were collected and salivary glands 
were dissected into 4% PFA in phosphate buffered saline (PBS). Glands were fixed in 
4% PFA/heptane for 20 minutes at room temperature, rinsed 3x in methanol, rinsed 3x in 
PBS + 0.1% Tween-20 (PBST), rinsed 4x in PBST + 1% BSA (PBSBT), blocked in 
PBSBT for 2 hours at room temperature, and incubated with primary antibody for 16 
hours at 4°C. Salivary glands were then washed for 2 hours in PBSBT, incubated with 
secondary antibody for 2 hours at room temperature, washed for 30 minutes in PBSBT at 
room temperature, and mounted using Prolong Gold Antifade Reagent with DAPI 
(Invitrogen). 
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 Figures and Legends 
Figure 2.1. Expression of polyglutamine-expanded AR in Drosophila results in 
toxicity.   
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Figure 2.1 Expression of polyglutamine-expanded AR in Drosophila results in 
toxicity.  (A) Drosophila females expressing AR in eyes using GMR-GAL4 were raised 
in medium containing vehicle or DHT and adult eye phenotypes were assessed by light 
microscopy. (B) Blinded scoring of the external eye phenotypes in (A) using a 
quantitative scoring system (Pandey et al., 2007b). (C) Western blot showing levels of 
AR expression for AR12Q- and AR52Q-expressing flies shown in (A). (D) Pupae 
expressing AR in eyes using GMR-GAL4 were raised in medium with or without DHT 
and whole mount preparations of eye discs were immunostained for lamin (blue) and AR 
(green). Phalloidin (red) was used to stain F-actin. Samples were examined by confocal 
microscopy. (E-F) Third instar larvae expressing AR using the salivary gland fkh-GAL4 
were dissected and stained with DAPI (blue) and phalloidin (red). Overall gland size 
shown in (E), cell size shown in (F). Phalloidin staining was used to delineate cell 
boundaries and determine cell size. Scale bar, 50 µm. (G) Third instar larvae expressing 
AR12Q or AR52Q using D42-GAL4 were assessed for their ability to travel distances 
along the surface of an agar plate. (H-I) Larvae expressing AR52Q using OK371-GAL4 
were raised in medium containing vehicle or DHT, dissected as third instar wandering 
larvae, and stained using the post-synaptic marker discs large (DLG, green) and the pre-
synaptic marker HRP (red). Type 1B boutons were counted at muscle 4. Scale bar, 10 
µm. (J) Female flies expressing AR12Q using GMR-GAL4 were raised on medium 
containing DHT. Each line shown represents an independent transformant line. (K) 
Western blot analysis of heads shown in (J). In (A) and (J), left side of each diptych 
shows light micrograph imaged at 63x, while right side shows increased magnification 
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(~140x) of the posterior region of the eye in which degeneration is concentrated. ** 
p<0.01 in all panels. Bars, mean + SEM in all panels. 
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Figure 2.2. Nuclear localization of polyglutamine-expanded AR is necessary but not 
sufficient for toxicity in vivo.  
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Figure 2.2. Nuclear localization of polyglutamine-expanded AR is necessary but not 
sufficient for toxicity in vivo. (A) Schematic of AR constructs used. NTD, N-terminal 
transactivation domain; DBD, DNA-binding domain; H, hinge; LBD, ligand-binding 
domain; NLS, nuclear localization sequence. (B) Blinded scoring of the external eye 
phenotypes in (D) and (F) using a quantitative scoring system. Bars, mean + SEM. (C) 
Salivary glands of Drosophila larvae expressing AR using fkh-GAL4. Larvae were raised 
in medium containing DHT and processed for immunocytochemistry. AR was detected 
with anti-AR antibody (green) and nuclei were stained with DAPI (blue). Scale bar, 50 
µm. (D) Drosophila females expressing AR in eyes using GMR-GAL4 were raised in 
medium containing vehicle or DHT and adult eye phenotypes were assessed by light 
microscopy. (E) Salivary glands of Drosophila larvae expressing AR using fkh-GAL4. 
Larvae were raised in medium containing ethanol and processed for 
immunocytochemistry as in (C). Scale bar, 50 µm. (F) Drosophila females expressing AR 
in eyes using GMR-GAL4 were raised in medium containing vehicle or DHT and adult 
eye phenotypes were assessed by light microscopy. See also Supplemental Figure 2.1 and 
S2. 
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Figure 2.3. DNA binding by polyglutamine-expanded AR is required for toxicity. 
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Figure 2.3. DNA binding by polyglutamine-expanded AR is required for toxicity. 
(A) HEK293T cells were transfected with indicated AR constructs together with both the 
luciferase pARE-E1b-Luc and the ß-galactosidase pCMVß reporter constructs. AR 
transactivation was measured in the presence and absence of DHT by luciferase assay 
and normalized to ß-galactosidase activity. (B) Salivary glands of Drosophila larvae 
expressing AR using fkh-GAL4. Larvae were raised were raised in medium containing 
DHT and processed for immunocytochemistry. AR was detected with anti-AR antibody 
(green) and nuclei were stained with DAPI (blue). Scale bar, 50 µm. (C) Drosophila 
females expressing AR in eyes using GMR-GAL4 were raised in medium containing 
DHT and adult eye phenotypes were assessed by light microscopy. (D) Blinded scoring 
of the external eye phenotypes in (C) using a quantitative scoring system. (E) Third instar 
larvae expressing AR using the motor neuron driver D42-GAL4 were assessed for their 
ability to travel distances along the surface of an agar plate. (F-G) Third instar larvae 
expressing AR using the salivary gland fkh-GAL4 were dissected and stained with DAPI 
(blue) and phalloidin (red). Overall gland size shown in (F), cell size shown in (G). 
Phalloidin staining was used to delineate cell boundaries and determine cell size. Scale 
bar, 50 µm. ** p<0.01 in all panels. n.s., not significant. Bars, mean + SEM in all panels. 
See also Supplemental Figure 2.2 and S3. 
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Figure 2.4. Disruption of AF-2 blocks polyglutamine-expanded AR toxicity. 
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Figure 2.4. Disruption of AF-2 blocks polyglutamine-expanded AR toxicity.  
(A) Crystal structure of the AR LBD (PDB ID: 2AMA) showing the AF-2 binding 
surface (gold) and the two charge clamp residues in AF-2, K720 (blue) and E897 (red). 
Green, FxxLF peptide co-crystallized with AF-2 (PDB ID: 1T7R). Pink, LxxLL peptide 
co-crystallized with AF-2 (PDB ID: 1T7F). (B) Salivary glands of Drosophila larvae 
expressing AR using fkh-GAL4. Larvae were raised in medium containing DHT and 
processed for immunocytochemistry. AR was detected with anti-AR antibody (green) and 
nuclei were stained with DAPI (blue). Scale bar, 50 µm. (C) HEK293T cells were 
transfected with indicated AR constructs together with both the luciferase pARE-E1b-
Luc and the β-galactosidase pCMVβ reporter constructs. AR transactivation was 
measured in the presence and absence of DHT by luciferase assay and normalized to β-
galactosidase activity. (D) Viability assay of Drosophila expressing indicated AR 
transgenes using elav-GAL4. Crosses were performed in medium containing DHT. The 
number of pupae from each 1x1 cross was counted and normalized to lacZ. Expression of 
AR52Q resulted in larval lethality, while E897K or K720A mutations increased 
survivability to the pupal stage. (E) Drosophila females expressing AR in eyes using 
GMR-GAL4 were raised in medium containing DHT and adult eye phenotypes were 
assessed by light microscopy. Left, AR constructs with 12Q. Right, AR constructs with 
expandedQ (AR52Q wt, AR66Q E897K, AR72Q K720A, AR65Q G21E). See 
Supplemental Figure 2.5E for phenotype severity scores. (F) Third instar larvae 
expressing AR using the motor neuron driver D42-GAL4 were assessed for their ability 
to travel distances along the surface of an agar plate. (G-H) Larvae expressing AR using 
the motor neuron driver OK371-GAL4 were raised in medium containing vehicle or 
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DHT, dissected as third instar wandering larvae, and stained using the post-synaptic 
marker discs large (DLG, green) and the pre-synaptic marker HRP (red). Type 1B 
boutons were counted at muscle 4. Scale bar, 10 µm. ** p<0.01 in all panels. Bars, mean 
+ SEM in all panels. See also Supplemental Figure 2.2 and S5. 
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Figure 2.5. Molecular phenotype of AR mutants. 
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Figure 2.5. Molecular phenotype of AR mutants. (A) RNA from fly heads expressing 
AR using GMR-GAL4 was extracted and analyzed using Affymetrix arrays. Using a 
false discovery rate of 0.1, 149 genes were identified as showing significant changes in 
AR52Q flies due to DHT treatment and were thereby selected for further analysis. (B) 
Scoring of the external eye phenotype shows a correlation between the severity of the 
observable external phenotype and the clustering results. (C) PCA analysis using the 149 
genes shown in (A). See also Supplemental Figure 2.6 and Supplemental Table 2.1. 
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Figure 2.6. Manipulation of limpet levels modifies polyglutamine-expanded AR 
toxicity in an AF-2-dependent manner.  
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Figure 2.6. Manipulation of limpet levels modifies polyglutamine-expanded AR 
toxicity in an AF-2-dependent manner. (A-D) RNAi knockdown of limpet (A) and a P-
element allele of limpet (limpetGE27535) (B) enhance the phenotype of AR52Q alone (C). 
Flies with a chromosomal duplication of a region containing limpet (Dp(3;3)st+g18) (D) 
show suppression of the AR52Q degenerative phenotype. (E-H) Limpet alleles similarly 
modify the phenotype of AR12Q flies with a strong phenotype. (I-J) Expression of limpet 
RNAi fails to enhance the phenotype in flies expressing AR66Q E897K. (K-L) 
Chromosomal duplication of limpet fails to suppress the phenotype in flies expressing 
pure polyglutamine (127Q). (M) Blinded scoring of the external eye phenotypes in (A-H) 
using a quantitative scoring system. All crosses performed on medium containing DHT. 
Bars, mean + SEM. ** p<0.01, * p<0.05. (N) Of 81 genes that changed in a DHT-
dependent manner by expression profile analysis, 37 genes showed an opposite change in 
the presence of limpet duplication. Expression changes of these 37 genes are shown and 
plotted as relative expression (std dev) to the mean. See also Supplemental Figure 2.7. 
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Figure 2.7 
 
 
Figure 2.7. Schematic representation of the minimal ligand-dependent events that 
precede initiation of pathogenesis. (1) Ligand binding induces a conformational change 
in the LBD to create the AF-2 binding surface. Ligand also induces post-translational 
modifications that are not depicted. (2) Ligand-activated AR translocates to the nucleus. 
(3) Prior to DNA binding, the AF-2 domain is occupied by the N-terminal FxxLF in an 
intra- or inter-molecular interaction. (4) Following DNA binding, AF-1 and AF-2 interact 
with coregulators. In order to initiate pathogenesis, polyglutamine-expanded AR must 
bind DHT, translocate to the nucleus, bind DNA, and interact with coregulators at AF-2. 
While interactions at AF-1 modify toxicity, AF-2 function is essential for toxicity. 
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Table  2.1 
 
 
Table 2.1. Results from RNAi-based targeted genetic screen. 73 previously described 
AR coregulator genes were investigated for the existence of Drosophila orthologs. We 
identified 61 putative orthologs and obtained RNAi lines for these genes from the Vienna 
Drosophila RNAi Center. RNAi lines were tested for their ability to modify the SBMA 
fly phenotype. Shown are 19 hits from the screen which dominantly modified the AR52Q 
eye phenotype. Mammalian orthologs and mechanisms of AR interaction are shown. As 
indicated, seven of these hits were found to have AF-2-based interactions. These seven 
hits were validated in motor neurons by larval crawling assay, as well as with alternate 
alleles (classical alleles or aneuploid aberrations) in the eye. See also Supplemental 
Figure 2.4.  
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Supplemental Figure 2.1. AR mutants SS/DD and KK/AA do not show DHT-
induced nuclear localization, while AR-NLS fusions show DHT-independent nuclear 
localization and decreased transactivation.  
 
 
77 
Supplemental Figure 2.1, related to Figure 2.2. AR mutants SS/DD and KK/AA do 
not show DHT-induced nuclear localization, while AR-NLS fusions show DHT-
independent nuclear localization and decreased transactivation. (A) COS-1 cells 
transfected with AR were treated with vehicle or DHT and processed for 
immunocytochemistry. AR was detected with anti-AR antibody (green) and nuclei were 
stained with DAPI (blue). (B) Quantification of nuclear translocation shown in (A). The 
percentage of transfected cells with a greater concentration of AR in the nucleus than the 
cytoplasm was determined for each AR construct. (C) COS-1 cells transfected and 
processed as in (A). (D) Quantification of nuclear translocation shown in (C). (E) 
HEK293T cells were transfected with indicated AR65Q constructs together with both the 
luciferase pARE-E1b-Luc and the β-galactosidase pCMVβ reporter constructs. AR 
transactivation was measured in the presence and absence of DHT by luciferase assay 
and normalized to β-galactosidase activity. All bars indicate mean + SEM. 
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Supplemental Figure 2.2.  
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Supplemental Figure 2.2, related to Figures 2.2-2.5. Western blots of AR-expressing 
fly lysates. (A-D) Fly heads expressing AR driven by GMR-GAL4 were lysed and 
subjected to Western blotting to verify AR expression. α-tubulin is shown as loading 
control. (E-F) Western blots showing high molecular weight species of AR in protein 
extract from Drosophila eyes. Flies were crossed to GMR-GAL4 and reared on food 
containing DHT. Female heads were collected, lysed, and subjected to Western blotting 
to verify AR expression (short exposure) and look for biochemical aggregation (long 
exposure). No correlation was observed between the amount of high molecular weight 
species and degeneration. Quantitation of 5 independent experiments was performed 
using Image J. 
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Supplemental Figure 2.3. 
 
 
 
Supplemental Figure 2.3, related to Figure 2.3. A574D mutant AR undergoes DHT-
induced nuclear localization.  (A) COS-1 cells transfected with AR were treated with 
vehicle or DHT and processed for immunocytochemistry. AR was detected with anti-AR 
antibody (green) and nuclei were stained with DAPI (blue). (B) Quantification of nuclear 
translocation shown in (A). The percentage of transfected cells with a greater 
concentration of AR in the nucleus than the cytoplasm was determined for each AR 
construct. Bars, mean + SEM. 
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Supplemental Figure 2.4. Results from candidate-based genetic screen.  
 
 
 
82 
Supplemental Figure 2.4, related to Table 2.1. Results from candidate-based genetic 
screen. Flies expressing AR were crossed to either UAS-LacZ flies (A) or UAS-RNAi 
flies (B). Effects of RNAi were validated using classical alleles or aneuploid aberrations 
that disrupt or delete the relevant genes (C). For columns labeled “RNAi” and “Allele,” 
flies were crossed to GMR-GAL4 to test for baseline eye phenotypes. Shown are seven 
genetic modifiers that play a role in AF-2 based interactions (see Table 2.1 for full list). 
All crosses performed at 29°C except gkst RNAi, Smr RNAi, and wts RNAi performed at 
25°C. 
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Supplemental Figure 2.5, related to Figure 2.4. AR AF-2 mutants undergo DHT-
induced nuclear localization, rescue the salivary gland and eye phentoypes caused 
by polyglutamine-expanded AR, and do not affect viability -DHT. 
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Supplemental Figure 2.5, related to Figure 2.4. AR AF-2 mutants undergo DHT-
induced nuclear localization, rescue the salivary gland and eye phentoypes caused 
by polyglutamine-expanded AR, and do not affect viability -DHT. (A) COS-1 cells 
transfected with AR were treated with DHT and processed for immunocytochemistry. AR 
was detected with anti-AR antibody (green) and nuclei were stained with DAPI (blue). 
(B) Quantification of nuclear translocation shown in (A). The percentage of transfected 
cells with a greater concentration of AR in the nucleus than the cytoplasm was 
determined for each AR construct. (C-D) Salivary glands expressing AR with AF-2 
mutations show rescued cell size. AR was expressed using fkh-GAL4 and dissected 
tissues were stained with phalloidin (red) and DAPI (blue). Salivary gland cell size was 
determined using  phalloidin staining. Scale bar, 50 µm. ** p<0.01. (E) Blinded scoring 
of the external eye phenotypes in Figure 2.4E. (F) Viability assay performed on -DHT 
food. Elav-GAL4 flies were crossed to UAS-AR or UAS-LacZ flies. The number of 
pupae from each 1x1 cross was counted and normalized to LacZ. No significant 
differences were found between groups. Bars, mean + SEM in all panels. 
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Supplemental Figure 2.6, related to Figure 2.5. Molecular phenotype of AR-
expressing flies. 
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Supplemental Figure 2.6, related to Figure 2.5. Molecular phenotype of AR-
expressing flies. UAS-AR flies were crossed to GMR-GAL4 flies on food containing 
either DHT or vehicle. Total RNA was extracted and subjected to analysis on Affymetrix 
chips. Using a false discovery rate of 0.05, 108 genes were identified that significantly 
differ in a DHT-dependent manner in AR52Q-expressing flies. Cluster analysis of these 
108 genes demonstrates that A574D and E897K mutations suppress the molecular 
phenotype of AR52Q +DHT, while K720A mutation results in a mild suppression. 
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Supplemental Figure 2.7, related to Figure 2.6. Supporting information for limpet 
allele crosses. 
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Supplemental Figure 2.7, related to Figure 2.6. Supporting information for limpet 
allele crosses. (A) Alignment of Drosophila limpet (top) and human FHL2 (bottom). 
Protein sequences were aligned using ClustalW. FHL2 contains two FxxLF-like 
sequences that interact directly with AF-2 in AR. One of these sequences is conserved as 
FGELF in Drosophila limpet (box). (B) Eye phenotype of limpet alleles expressed alone. 
Flies expressing GMR-GAL4 alone, UAS-limpet RNAi, or a P-element allele of limpet 
(limpet GE27535) exhibit no phenotype. Flies with a chromosomal duplication of a 
region containing limpet (Dp(3;3)st+g18) show a very mild phenotype of slight 
ommatidial disorganization. (C) Quantitation of RNAi knockdown. To determine the 
degree of knockdown of limpet, UAS-Lmpt RNAi was crossed to GMR-GAL4 and total 
RNA was isolated from 5-10 heads in triplicate. Real-time quantitative PCR was 
performed as described in Supplemental Methods. Graph shows mean transcript levels 
relative to GAPDH2. 
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Supplemental Figure 2.8 
 
Supplemental Figure 2.8. Co-IP of AR and FLAG-FHL2. HEK293T cells were co-
transfected with FLAG-FHL2 and AR followed by treatment with DHT or vehicle. 
Nuclear extracts were collected as described in Supplemental Methods and 
immunoprecipated for FLAG. No difference in FHL2-AR interaction was observed based 
on polyglutamine length. 
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Supplemental Table 2.1 
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Supplemental Table 2.1, related to Figure 2.5 and Supplemental Figure 2.6. 
Identities of 149 genes that change in response to DHT in AR52Q-expressing flies. 
Identifiers given are Probeset IDs from Affymetrix, Gene Title, and FlyBase ID. For each 
gene, the relative change (DHT vs. vehicle) is shown as an increase or decrease. Of the 
149 genes DHT-responsive genes identified for AR52Q flies, 111 genes (indicated in 
bold) show a similar DHT-responsive trend in AR12Q flies. * indicates that the gene 
achieved significance at false discovery rate of 0.1. 
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Chapter 3: Conclusions 
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General Conclusions 
The work described in the previous chapter extends our understanding of SBMA 
pathogenesis in several important ways. First, it strengthens the concept that native 
protein functions are key to polyglutamine pathogenesis, an idea that was still largely 
untested outside SCA1. More specifically, it defines the precise molecular events that are 
required for pathogenesis of SBMA, elucidating the molecular basis for the ligand 
dependence of the disease and identifying targets for therapeutic intervention.  
 
It is important to note the scientific climate in which these results are being published. 
The dominant hypothesis within the polyglutamine disease field holds that degeneration 
results from the generation of polyglutamine-containing cleavage fragments that are 
prone to oligomerization and acquisition of neurotoxic properties due to the intrinsic 
toxicity of expanded polyglutamine. In contrast, the idea that native protein function 
might play a role in pathogenesis has remained largely unexplored. To a certain extent, 
the lack of investigation in this research vein is due to practical limitations; in many 
cases, the native function of polyglutamine disease proteins is ill defined, and in those 
proteins with known functions, the domains required for such functions have not been 
mapped. Certainly, the richness of the basic scientific knowledge of AR allowed us to 
pursue our hypothesis farther than would be possible with another protein in the same 
disease family. 
 
Although prior studies have suggested that polyglutamine toxicity may be influenced by 
protein context (reviewed in (La Spada and Taylor, 2003, 2010)), these investigations 
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have had limited impact on the debate about the relative pathogenic contribution of 
intrinsic polyglutamine toxicity vs. altered native function. Indeed, two prior publications 
that are relevant to our study demonstrate the prism through which most polyglutamine 
disease research in viewed. The first showed that nuclear localization of AR is necessary 
for toxicity in vivo (Takeyama et al., 2002), and the second showed that nuclear 
localization of AR is not sufficient for toxicity in vitro (Montie et al., 2009). These 
manuscripts concluded that the nucleus presented an environment in which AR 
undergoes ligand-dependent cleavage (Montie et al., 2009) and subsequent 
polyglutamine-mediated aggregation (Takeyama et al., 2002; Montie et al., 2009). 
Indeed, Takeyama et al. state that “[the neurotoxic] events are thought to be mediated 
through factors associated with the expanded polyQ stretches in the aggregates and not 
through any innate function of the disease proteins” (Takeyama et al., 2002). On the basis 
of our current study, we advance the alternative hypothesis that the pathogenesis of 
SBMA is mediated by native coregulator interactions of AR in its full-length, DNA-
bound form. These findings are consistent with a mechanism wherein polyglutamine 
expansion results in toxicity that is mediated by the normally-folded protein that is trying 
to carry out its native function, but is altered in a minor way such that its ratio of native 
interactions is subtly altered. It is important to note that AR might not have a single 
“normal” conformation, but instead has multiple subtly different native conformations, 
the ratio of which may be altered by polyglutamine expansion. 
 
More specific to SBMA, our work provides a promising list of therapeutic targets to 
combat pathogenesis. Previous work that determined that androgen binding to AR was 
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necessary for toxicity led to clinical trials of anti-androgen drugs that target the 
hypothalamic-pituitary-gonadal axis (Banno et al., 2009); however promising, these 
drugs decrease levels of androgen globally and cause a wide range of undesired side 
effects. In the present work, we have identified a number of detailed molecular events 
that underlie this requirement for ligand binding: in order to cause toxicity, ligand-bound 
mutant AR must translocate to the nucleus, bind DNA, and interact with coregulators at 
AF-2. Although myriad AR antagonists could be used to restrict the mutant protein to the 
cytoplasm, to outcompete endogenous ligand at the AR LBD, or to prevent AR binding to 
DNA, each of these approaches suffers from the same global drawbacks as anti-androgen 
therapy. Instead, it is the last identified requirement – AF-2-based interactions – that 
presents an unprecedented opportunity for therapeutic intervention.  
 
Inspired by the clinical success of SERMs (selective estrogen receptor modulators) in 
treating breast cancer, an entire pharmaceutical enterprise has developed to produce 
SARMs (selective androgen receptor modulators), defined as compounds that act as AR 
agonists or antagonists in a tissue-specific manner (Chang and McDonnell, 2005). 
Although initially designed to combat AR-related conditions such as hirsutism, benign 
prostatic hypertrophy, prostate cancer, and others, SARMs provide a tantalizing 
therapeutic approach to promote tissue-selective (in)activation of AR in SBMA. The 
tissue specificity of these drugs is thought to be tied to the distinct AF-2 conformations 
that are induced by DHT vs various SARMs, with the result being preferential binding of 
particular AF-2-based coregulators over others (Baek et al., 2006; Estebanez-Perpina et 
al., 2007). Given our findings, it is not unreasonable to predict that SBMA patients might 
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be able to take particular SARM(s) that alter the complement of transcriptional 
coregulators in such a way as to restore the balance of AR complexes in motor neurons 
while leaving AR activity in other tissues unaltered. 
 
Future directions 
Obviously, the results presented in the previous chapter must be replicated in a 
mammalian system before thoughts of SARM-based therapeutics can be reasonably 
entertained. We have already begun to pursue this avenue of research, generating 
transgenic mouse models of SBMA that express each of the key mutations described in 
this work. These mice were designed using a Cre-Lox system that will allow mutant AR 
to be expressed either ubiquitously or in a tissue-specific manner, with motor neurons 
being of primary interest. If we can replicate the rescue of mutant AR toxicity using the 
mutants A574D and E897K, these mice can be further used to answer important 
mechanistic questions. 
 
For example: in the present work, we show that native protein function is essential to 
initiate degeneration. However, we do not rule out a role for polyglutamine length-
dependent aggregation in toxicity, largely because our Drosophila model of SBMA does 
not show appreciable ligand- or polyglutamine length-dependent biochemical 
aggregation. Instead, using a mouse model of SBMA (where biochemical aggregation has 
traditionally been more prominent), we can address the respective roles of aggregation 
and altered native function in pathogenesis. Although our model predicts that the 
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suppressive mutations A574D, K720A, and E897K will have no effect on polyglutamine 
length-dependent aggregation, it is important to examine this question in order to 
reconcile our results with the aggregation-centric history of the field. 
 
Mammalian systems will also provide a key source of material with which to investigate 
the proteomic consequences of the AF-2 mutations. As described in the previous chapter, 
we favor a model in which the AF-2 domain of AR competes with other transcription 
factors for a limited supply of coregulators, and that polyglutamine expansion alters the 
balance of AR-coregulator interactions in such as way as to deplete coregulators away 
from their normal functions. Proteomic work in mammalian systems, likely beginning in 
immortalized cell culture and leading to work in mouse, may provide insight into these 
altered complexes – not only those complexes that change with polyglutamine expansion, 
but also those that occur in the context of K720A and E897K mutations. In an ideal 
experiment, these proteomic data could be aligned with proteomic profiles of AR bound 
to a collection of candidate SARMs. 
 
According to our proposed mechanism of pathogenesis, amplification of AR activity by 
polyglutamine expansion would be expected to result in reduced availability of 
coregulators for important coactivating or corepressing functions. As mentioned in the 
preceding chapter, however, a crucial outstanding question is how AR activity in the 
nucleus is amplified. One possibility involves aggregation-prone polyglutamine-
expanded AR adopting a conformation that amplifies AF-2-based interactions. However, 
arguing against this possibility is our failure of detect any polyglutamine length-
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dependent changes in co-immunoprecipitation of AR and the AF-2-interacting 
coregulator FHL2. Testing for polyglutamine length-dependent alterations in binding of 
additional AF-2-based interactors would be necessary to rule out this possibility, ideally 
using endogenous proteins rather than overexpressed epitope-tagged proteins as in our 
FHL2 co-IP. An alternative possibility is that polyglutamine expansion amplifies AR 
activity (and AF-2 function in particular) independent of any change in the intrinsic 
ability of AR to interact with coregulators. For example, this could occur by reducing the 
inactivation rate of DNA-bound AR or by reducing the rate of AR nuclear efflux similar 
to what has been observed for ataxin-7 (Taylor et al., 2006). In fact, reduced nuclear 
efflux might be a parsimonious explanation for the diffuse nuclear accumulation of AR 
that is found in SBMA patient tissue, a phenomenon that correlates with increasing 
polyglutamine length (Adachi et al., 2005). The mechanism by which polyglutamine 
expansion amplifies AR nuclear activity will be an important focus for future studies, and 
may in fact lead to additional therapeutic targets. 
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Abstract 
Expanded polyglutamine tracts cause neurodegeneration through a toxic gain-of-function 
mechanism. Generation of inclusions is a common feature of polyglutamine diseases and 
other protein misfolding disorders. Inclusion formation is likely to be a defensive 
response of the cell to the presence of unfolded protein. Recently, the compound B2 has 
been shown to increase inclusion formation and decrease toxicity of polyglutamine-
expanded huntingtin in cultured cells. We explored the effect of B2 on spinal and bulbar 
muscular atrophy (SBMA). SBMA is caused by expansion of polyglutamine in the 
androgen receptor (AR) and is characterized by the loss of motor neurons in the 
brainstem and spinal cord. We found that B2 increases the deposition of mutant AR into 
nuclear inclusions, without altering the ligand-induced aggregation, expression, or 
subcellular distribution of the mutant protein. The effect of B2 on inclusions was 
associated with a decrease in AR transactivation function. We show that B2 reduces 
mutant AR toxicity in cell and fly models of SBMA, further supporting the idea that 
accumulation of polyglutamine-expanded protein into inclusions is protective. Our 
findings suggest B2 as a novel approach to therapy for SBMA. 
 
Introduction 
Polyglutamine diseases are late-onset, inherited neurodegenerative diseases caused by 
expansion of CAG repeats encoding polyglutamine tracts in nine different genes (Orr and 
Zoghbi, 2007). Expansion of polyglutamine in the androgen receptor (AR), huntingtin, 
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atrophin 1, and ataxin-1, -2, -3, -6, -7, and -17 causes spinal and bulbar muscular atrophy 
(SBMA), Huntington's disease, dentatorubral-pallidoluysian atrophy, and six types of 
spinocerebellar ataxia, respectively. All the polyglutamine diseases are inherited in an 
autosomal dominant fashion, except for SBMA, which is X-linked (La Spada et al., 1991) 
and gender-specific (Katsuno et al., 2002; Schmidt et al., 2002; Yu et al., 2006). There is 
no available effective therapy for SBMA and the other polyglutamine diseases, although 
several therapeutic approaches have been proposed to date (for review see (Pennuto and 
Fischbeck, 2010). Polyglutamine diseases share several features, such as a positive 
correlation between repeat length and disease severity and the phenomenon of genetic 
anticipation, which causes the next generation to inherit a longer repeat than the previous 
one, and so to have an earlier age of onset or a more severe phenotype. Expansion of 
polyglutamine confers a toxic gain of function on the mutant protein. Evidence also 
indicates a contribution of loss of protein function to the disease pathogenesis (Zuccato et 
al., 2001; Thomas et al., 2006; Lim et al., 2008). Although disease-specific features imply 
the contribution of protein-specific features in polyglutamine disease pathogenesis, the 
observation that the same mutation in nine unrelated genes causes neurodegeneration 
suggests a common disease mechanism. 
 
Expansion of polyglutamine leads the protein to acquire a stable, non-native -sheet 
conformation (Perutz et al., 1994), which results in protein unfolding and deposition into 
microaggregates and inclusions (Ross and Poirier, 2004). Microaggregates are small 
oligomeric species detectable by biochemistry (Taylor et al., 2003b; Li et al., 2007; 
Palazzolo et al., 2009). Inclusions are large macromolecular species detectable primarily 
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by immunohistochemistry (Taylor et al., 2003b). Inclusions contain several cellular 
constituents, including molecular chaperones and components of the ubiquitin-
proteasome system and autophagic degradation (Garcia-Mata et al., 1999; Wigley et al., 
1999; Taylor et al., 2003b). The observation that polyglutamine-positive inclusions are 
present in the nuclei of the degenerating neurons from patients and animal models of 
polyglutamine diseases led to the idea that inclusions are toxic species (for review see 
(Taylor et al., 2002). Toxicity was attributed to sequestration of essential cellular 
constituents and aberrant protein-protein interactions, with consequent disruption of 
cellular homeostasis (Gidalevitz et al., 2006). However, a series of findings has not only 
dissociated inclusions from neurodegeneration (Saudou et al., 1998; Cummings et al., 
1999; Slow et al., 2005; Rub et al., 2006) but also highlighted a protective role for 
inclusions in neurodegenerative diseases (Taylor et al., 2003b; Arrasate et al., 2004). 
These findings suggest that enhancing inclusion formation may be a therapeutic target for 
polyglutamine diseases. The compound B2 (5-[4-(4-chlorobenzoyl)-1-piperazinyl]-8-
nitroquinoline) has been shown to increase inclusion formation and reduce the toxicity of 
mutant huntingtin in vitro (Bodner et al., 2006). 
 
Here we investigated the effect of B2 on SBMA. We show that B2 increases formation of 
mutant AR-positive nuclear inclusions, without altering mutant AR ligand-dependent 
aggregation, expression, or subcellular localization. The effect of B2 on inclusions 
correlates with a reduction of AR transactivation, which is not due to altered ligand 
binding. Finally, we show that B2 reduces the toxicity of mutant AR in both cell and fly 
models of SBMA. Our results provide evidence that B2 reduces the toxicity of mutant 
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AR by increasing the deposition of the protein into inclusions and highlight B2 as a 
potential therapy for SBMA. 
 
Materials and Methods 
Plasmids 
The pCMV-AR65Q-K632A,K633A and pARE-E1b-luc expression vectors were kindly 
provided by Drs. A. Lieberman (University of Michigan, Ann Arbor, MI) and C. Smith 
(Baylor College of Medicine, Huston, TX), respectively; pFHRE-luc reporter vector was 
purchased from Addgene. 
 
Cell Cultures and Transfections 
HEK293T (ATCC, CRL-1573) and PC12-TET ON cells stably expressing AR112Q 
(Walcott and Merry, 2002) were cultured as previously described (Walcott and Merry, 
2002; Palazzolo et al., 2007). HEK293T cells (6 x 105) were transiently transfected with 
1 g DNA using Lipofectamine Plus (Invitrogen, Carlsbad, CA). PC12-AR112Q cells (8 x 
105) were cultured on collagen-coated dishes for 24 hr in differentiation medium (1% 
heat-inactivated horse serum, 5% heat-inactivated charcoal-stripped fetal bovine serum, 4 
mM glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 132 g/ml G-418, 70 g/ml 
hygromycin B, and 100 ng/l nerve growth factor) in the presence of doxycycline (10 g/l; 
Calbiochem, La Jolla, CA) and treated with B2 (3448-6548; ChemDiv, San Diego, CA) 
and R1881 (Sigma, St. Louis, MO) at the indicated concentrations. Motor neuron-derived 
MN-1 cells stably expressing AR65Q were previously described (Brooks et al., 1997). 
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The cells were maintained in culture in the presence of G418 (350 g/ml), plated (1 x 106 
cells) in charcoal-dextran-stripped fetal bovine serum (HyClone, Logan, UT)-containing 
medium for 48 hr and processed for caspase 3 assay. Where indicated, the cells were 
treated with staurosporin (1 M) for 6 hr and z-VAD-FMK (30 M) for 48 hr. 
 
Immunocytochemistry and Microscopy 
PC12 cells were grown for 24 hr on collagen-coated dishes in differentiation medium, 
induced for 4 hr with doxycycline, pretreated for 20 hr with B2 (10 M), and then treated 
for 48 hr with R1881 (10 nM) and B2. Immunofluorescence was performed as previously 
described (Palazzolo et al., 2007). The person who analyzed the images was blind for the 
treatments. For the graph in Figure A1.1A, the cells treated with R1881 together with 
either vehicle or B2 were classified into cells with diffuse nuclear AR or cells with 
nuclear inclusions. The percentage of cells with nuclear inclusions was calculated for 
each treatment. Data in the graph represent the fold increase in the number of cells with 
nuclear inclusions in the B2/R1881-treated sample compared with the R1881-treated 
sample, which was set as 1. The graph represents the average of four independent 
experiments; in each experiment, three different fields (n = 150 cells) for each treatment 
were analyzed. 
 
Western Blotting and Nuclear/Cytoplasmic Fractionation 
For Western blotting, cells were washed in ice-cold 1x PBS and scraped in lysis buffer 
[150 mM NaCl, 6 mM Na2HPO4, 4 mM NaH2PO4, 5 mM ethylenediaminetetraacetic 
acid, 1% Na-deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS)] plus 
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protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). The lysate was 
sonicated and then centrifuged at 18,000g for 10 min at 4°C. Cell lysates were denatured 
at 95°C in 5x sample buffer (60 mM Tris, pH 6.8, 2% SDS, 25% glycerol, 0.1% 
bromophenol blue, 20% -mercaptoethanol) and processed for 7.5-10% SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred to a PVDF 
membrane (Millipore, Bedford, MA). Immunoblottting was done in 5% nonfat dry milk 
in Tris-buffered saline. Antibodies used were anti-AR (N20; sc-816; Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-tubulin (T6199; Sigma), anti-Hsp90 (SPA-830; 
Assay Design), anti-Hsp40 (SPA-400; Assay Design), anti-Hsp70 (Spa810; Assay 
Design), and anti-actin (sc-1616; Santa Cruz Biotechnology). Immunoreactivity was 
detected using peroxidase-conjugated AffiniPure goat anti-rabbit or anti-mouse IgG 
(Jackson Immunoresearch, West Grove, PA), and visualized using Lightning 
chemiluminescence reagent (Perkin Elmer, Norwalk, CT), following the manufacturer's 
instructions. Nuclear/cytosolic fractionation was performed per manufacturer's 
instructions (NE-PER; Pierce, Rockford, IL). 
 
XTT, Caspase 3, Ligand Binding, and Transcriptional Assays 
Caspase 3 activity, cell survival (XTT assay), and transcriptional activity were measured 
according to manufacturers' instructions using the ApoTarget fluorometric assay 
(Biosource International, Camarillo, CA), Cell Proliferation Kit II (Roche Diagnostics), 
and LucLite Luminescence Reporter Gene Assay System (Perkin Elmer), respectively. 
For the XTT assay, the cells were incubated in aphidicolin (0.4 g/ml; Calbiochem) to 
inhibit cell proliferation. For transcriptional assay to measure AR transactivation, cells 
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were transfected with pARE-E1b-luc reporter vector, pre-treated for 24 hr with B2 at the 
indicated concentrations, and incubated with the ligand together with either B2 or vehicle 
for other 24 hr. For FOXO-mediated transcriptional activity, cells were transfected with 
pFHRE-luc reporter vector, pre-treated with B2 for 24 hr, and incubated with IGF-1 or 
under serum-deprivation conditions for 24 hr prior to the assay. To normalize for 
transfection efficiency, luciferase activity was compared with β-galactosidase activity. 
For the ligand binding assay, 24 hr after transfection, HEK293T cells were incubated for 
2 hr in 0.5% bovine serum albumin and 10 M triamcinolone acetonide in Dulbecco's 
modified Eagle's medium (binding medium) with 10 nM [3H]R1881 (72.0 Ci/mmol; 
Perkin Elmer). Specific binding of [3H]R1881 was calculated as previously described 
(Palazzolo et al., 2007). 
 
SBMA Flies 
Generation of transgenic flies expressing AR52Q was previously described (Pandey et 
al., 2007b). Drosophila stocks were crossed on standard cornmeal agar media at 29°C. 
GMR-GAL4 virgin females were mated to UAS-AR52Q male flies on media containing 
either 1 mM dihydrotestosterone (DHT) + 0.5% DMSO or 1 mM DHT + 50 M B2 
diluted in DMSO. The phenotype of female flies was assessed blindly on day 1 post-
eclosion. The scoring method was modified from (Pandey et al., 2007b), as follows: 1 
point for presence of bristle phenotype (supernumerary interommatidial bristles or 
abnormal bristle orientation), 1 point for presence of ommatidial phenotype (fusion or 
disorganization), 1 point for ommatidial pitting, 3 points for retinal collapse, 3 points if 
the phenotype covered more than 20% of the eye, 6 points if the phenotype covered more 
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than 50% of the eye. The number of flies analyzed was n = 45 for DHT + vehicle and n = 
57 for DHT + B2. 
 
Statistical Analysis 
Each experiment was repeated a minimum of three times. One-way ANOVAs were used 
to evaluate the effect of B2 and ligand among treatment groups. Two-sample t-tests were 
used for post hoc comparisons. 
 
Results 
B2 Increases the Formation of AR-Positive Nuclear Inclusions in Cultured Cells 
B2 increases the deposition of mutant huntingtin into inclusions (Bodner et al., 2006). We 
asked whether B2 has similar effect on mutant AR. Mutant AR accumulates into nuclear 
inclusions in motor neurons in patients (Katsuno et al., 2006). Generation of mutant AR-
positive nuclear inclusions with features similar to those observed in patient tissues can 
be reproduced in an inducible PC12 cell line, which expresses human full-length AR with 
112 glutamine residues (PC12-AR112Q; (Walcott and Merry, 2002)). In these cells, 
transgene AR expression is induced by treatment of the cells with doxycycline, and 
inclusion formation is promoted by exposure of the cells to androgens (Walcott and 
Merry, 2002). To test whether B2 affects inclusion formation in SBMA, the PC12-
AR112Q cells were treated with doxycycline and the synthetic androgen analog R1881 
together with either vehicle or B2, and the AR-positive inclusions were detected by 
immunocytochemistry using the AR-specific antibody N20 (Figure A1.1A). In the 
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absence of ligand, mutant AR localizes in the cytosol. Treatment of the cells with ligand 
resulted in nuclear translocation and formation of AR-positive nuclear inclusions. 
Treatment of the cells with B2 did not induce AR inclusion formation in the absence of 
ligand. Instead, treatment of the cells with B2 in the presence of ligand significantly 
increased the number of cells with nuclear inclusions by 13% compared with the cells 
exposed to ligand alone. Expansion of polyglutamine leads the mutant protein to form not 
only inclusions but also microaggregates (Taylor et al., 2002; Ross and Poirier, 2004). 
Mutant AR-positive microaggregates can be detected by Western blotting as high-
molecular-weight species accumulating in the stacking portion of polyacrylamide gels 
(Palazzolo et al., 2009). Therefore, we asked whether B2 affects mutant AR aggregation 
in the PC12-AR112Q cells (Figure A1.1B). Treatment of the cells with ligand 
significantly increased AR aggregation. Treatment of the cells with B2 increased mutant 
AR aggregation in the absence of ligand but did not affect the biochemical aggregation of 
mutant AR induced by ligand.  
 
To investigate whether the effect of B2 on AR inclusions is due to an increase in the AR 
expression levels, we analyzed the levels of human AR mRNA (Supplemental Figure 
A1.1A) and protein (Figure A1.1B). By real-time PCR and Western blotting analyses, we 
found that neither the levels of transgene AR transcript nor the levels of monomeric 
mutant AR protein change upon B2 treatment. Then, we asked whether B2 increases 
nuclear inclusion formation because it increases the translocation of mutant AR into the 
nucleus. To test this, we performed nuclear/cytosolic fractionation in HEK293T cells 
transiently transfected with vector expressing mutant AR with 65 glutamine residues 
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(AR65Q) and treated with R1881 together with either vehicle or B2 (Figure A1.1C). B2 
did not change the amount of AR accumulating in the nucleus in the presence of ligand. 
Because AR interacts with the heat shock proteins (Hsps; (Poletti, 2004)), we asked 
whether the effect of B2 occurs through induction of Hsp90, Hsp70, and Hsp40 (Figure 
A1.1D). Expression of these proteins was analyzed by Western blotting in the PC12-
AR112Q cells. Treatment of the cells with B2 did not alter the levels of expression of 
Hsp90, Hsp70, and Hsp40 in either the absence or the presence of ligand, indicating that 
the B2 effect on AR inclusion is independent of the Hsps. Collectively, these results 
indicate that B2 increases the deposition of mutant AR into nuclear inclusions without 
affecting AR ligand-dependent aggregation, expression, or subcellular distribution in 
cultured cells. 
 
B2 Alters AR Function 
 
AR is a transcription factor activated by androgens (Poletti, 2004). We reasoned that B2 
by entrapping mutant AR into macromolecular complexes may alter the ability of AR to 
activate transcription. We tested this hypothesis in HEK293T cells transiently transfected 
with an expression vector encoding AR65Q together with a reporter vector in which 
luciferase expression is driven by a regulatory region containing three androgen-
responsive elements (ARE), as previously described (Palazzolo et al., 2007). The cells 
were treated with vehicle or B2 (10 M) and increasing amounts of R1881 (from 0.1 to 10 
nM), and AR transactivation was measured by luciferase assay (Figure A1.2A). 
Treatment of the cells with R1881 induced mutant AR transactivation in a dose-
dependent fashion. Treatment of the cells with B2 significantly reduced the AR 
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transactivation induced by ligand. As with the effect of B2 on AR inclusions observed in 
the PC12-AR112Q cells, the effect of B2 on mutant AR transcription observed in 
HEK293T cells was not due to a decrease in transgene mRNA transcript or protein levels 
(Supplemental Figure A1.1B). To investigate whether the effect of B2 also occurs on 
non-expanded AR and is dose-dependent, we treated cells transfected with either normal 
or mutant AR with a constant dose of R1881 (10 nM) and a range of concentrations of B2 
from 1 M to 10 M (Figure A1.2B). The effect of B2 on polyglutamine AR transactivation 
was dose-dependent. At 1 M, B2 slightly increased normal, but not mutant, AR 
transactivation, whereas, at 5 M, B2 had no significant effect on either normal or mutant 
AR transcription. At 10 M, B2 reduced both normal and mutant AR transactivation. 
Similar results were obtained with B21 (Supplemental Figure A1.2), which is a 
compound structurally similar to B2 and that has been shown to have the same effect as 
B2 on mutant huntingtin inclusion formation (Bodner et al., 2006). It is relevant to note 
that B21 had no effect on normal AR transactivation. 
 
One explanation for the effect of B2 on AR transactivation is the recruitment of AR into 
inclusions. However, we explored other possibilities. To rule out the possibility that 
treatment of the cells with B2 disrupts the cellular transcription machinery, we tested 
whether B2 alters the transcription mediated by FKHRL1, a member of the Forkhead 
family of transcription factors (Brunet et al., 1999). The Forkhead transcription factors 
are active in the absence of survival factors, a condition that we reproduced here by 
serum deprivation, and are inactivated by the insulin-like growth factor 1 (IGF-1) through 
Akt phosphorylation. HEK293T cells were transfected with a reporter vector in which the 
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luciferase gene is under the control of the forkhead-responsive element (pFHRE-luc; 
(Holtz-Heppelmann et al., 1998)). As expected, transcription of the reporter gene was 
observed upon serum starvation and was decreased by IGF-1 treatment (Figure A1.2C). 
Treatment of the cells with B2 did not have any effect on this reporter. These results 
indicate that B2 does not alter the cellular transcription machinery. Moreover, these data 
suggest that the effect of B2 on transcription is likely to be specific to mutant AR. 
 
B2 has recently been shown to have inhibitory activity against sirtuin 2 (SIRT2) 
microtubule deacetylase (Outeiro et al., 2007). Normal AR is acetylated at specific lysine 
residues lying in the acetylation consensus site KXKK at position 630-633 
(NM_000044), where K is lysine and X any amino acid (Fu et al., 2000). To test whether 
B2 reduces AR transactivation through acetylation at this site, we used an acetylation-
defective mutant AR in which the lysine residues were replaced by alanine (AR65Q-
K632A,K633A; (Thomas et al., 2004)). In HEK293T cells, the acetylation-defective 
mutant had enhanced transactivation compared with the non-substituted AR (Figure 
A1.2D). Similar results were obtained with the non-polyglutamine-expanded AR 
(Supplemental Figure A1.3). This is consistent with previous results obtained with non-
polyglutamine-expanded AR but different promoter regions (Haelens et al., 2007; Faus 
and Haendler, 2008). B2 treatment decreased the transactivation of the acetylation-
defective mutant, indicating that B2 effect on AR transactivation does not occur through 
regulation of acetylation at lysines 632 and 633. 
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Because AR transactivation is strikingly ligand dependent (Poletti, 2004), we wondered 
whether B2 works as a competitive antagonist. To test this, we incubated HEK293T cells 
transiently expressing AR65Q cells with nonmetabolizable radioactive ligand [3H]R1881 
and measured the displacement of radioactive bound R1881 by increasing amounts of B2 
(Figure A1.2E). If B2 competes with R1881 for binding to the same site, incubation of 
the cells with increasing concentrations of B2 is expected to result in a dose-dependent 
displacement of radioactive ligand from the AR. As positive control, we treated the cells 
with increasing amounts of cold R1881. B2 did not displace the bound [3H]R1881, 
whereas cold R1881 completely displaced [3H]R1881 at 100 nM and 1 M, as expected. 
These data indicate that B2 does not compete for binding to the same site on the mutant 
AR where androgens bind, thereby excluding the possibility that B2 acts as a competitive 
antagonist of AR. At high doses, B2 inhibits normal AR transactivation (Figure A1.2B). 
To rule out the possibility that B2 alters binding of normal AR to ligand, we measured 
ligand binding in HEK293T cells transfected with normal AR as previously described 
(Palazzolo et al., 2007). We found that B2 does not alter the binding of ligand to normal 
AR (Figure A1.2F). Altogether, these results show that B2 specifically decreases mutant 
AR transactivation in a manner that is independent of acetylation at the KXKK site and 
does not affect ligand binding. Rather, these results are consistent with the idea that the 
B2-induced formation of AR-positive inclusions results in a reduction of AR function. 
 
B2 Reduces the Toxicity of Mutant AR in Cultured Cells 
Because increased accumulation of polyglutamine-expanded proteins into inclusions has 
been correlated with reduced toxicity in both cell and animal models of polyglutamine 
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disease (Taylor et al., 2003b; Arrasate et al., 2004), we asked whether B2 attenuates the 
toxicity of mutant AR. We tested this in the PC12-AR112Q cells. The cells were treated 
with R1881 and either vehicle or B2, and cell viability was measured by XTT assay 
(Figure A1.3A). Treatment of the cells with increasing concentrations of R1881 resulted 
in a dose-dependent decrease in cell viability (Figure A1.3A, open bars). Treatment of the 
cells with B2 significantly increased cell viability by 29% compared with the cells treated 
with ligand alone (Figure A1.3A, solid bars). Similar results were obtained measuring 
cell death by propidium iodide incorporation (Supplemental Figure A1.4A). 
 
SBMA is characterized by the loss of lower motor neurons from spinal cord and 
brainstem (Adachi et al., 2007). Therefore, we asked whether B2 has any effect on 
mutant AR toxicity in motor neuron-derived MN-1 cells stably expressing 
polyglutamine-expanded AR with 65 glutamine residues (AR65Q; (Brooks et al., 1997)). 
Although these cells do not show ligand-dependent toxicity, they do show polyglutamine 
length-dependent toxicity. Indeed, we have previously shown that expression of 
polyglutamine-expanded AR in these cells results in increased caspase 3 activity and 
reduced cell viability compared with cells expressing non-polyglutamine-expanded AR 
(Palazzolo et al., 2007). Treatment of the mutant MN-1 cells with B2 reduced caspase 3 
activation by 31% (Figure A1.3B). The effect of B2 on toxicity was specific to 
polyglutamine-dependent caspase 3 activation, as B2 did not have any effect on caspase 3 
activation induced by staurosporin (Figure A1.3, inset). We also asked whether the B2 
analog compound B21 impacts the toxicity of mutant AR in the MN-1 cells. Similarly to 
B2, B21 reduced the caspase 3 activation induced by mutant AR (Supplemental. Figure 
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A1.4B). These results indicate that B2 attenuates the toxicity of mutant AR in cell 
cultures. 
 
B2 Protects Flies from the Toxicity Induced by Mutant AR 
Next, we sought to determine whether B2 counteracts mutant AR-induced 
neurodegeneration in vivo. With this aim, we used transgenic flies that express mutant 
AR with 52 glutamine residues (AR52Q; (Takeyama et al., 2002; Pandey et al., 2007b)). 
Flies expressing polyglutamine-expanded AR recapitulate the unique feature of SBMA, 
which is the ligand dependence of the disease (Pandey et al., 2007b). Transgenic flies 
expressing AR52Q in the eye do not show any sign of neurodegeneration in the absence 
of hormone (Pandey et al., 2007b). In contrast, the flies show alteration of the eye 
phenotype when fed with the AR natural ligand dihydrotestosterone (DHT; Figure A1.4). 
Exposure of the flies to B2 together with ligand attenuated the extent of damage. To 
quantify the effect of B2 on disease severity, we analyzed the phenotype of about 50 flies 
per group and scored the disease severity as described in Materials and Methods (Figure 
A1.4, middle panel). We found that B2 treatment significantly decreased the extent of 
alteration of the eye phenotype in this fly model of SBMA. The effect of B2 was not due 
to a decrease in the level of expression of the mutant AR (Figure A1.4, bottom panel). 
This is the first evidence that B2 protects against polyglutamine-expanded toxicity in 
vivo. These results are important, because they highlight B2 as a novel potential therapy 
for SBMA. 
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Discussion 
The current study tested the effect of B2 on SBMA. We found that B2 increases 
deposition of mutant AR into inclusions. This was associated with reduced 
transactivation of mutant AR. Furthermore, we show that B2 reduces the toxicity of 
mutant AR in cell models of the disease. We show for the first time that B2 attenuates 
polyglutamine-expanded toxicity in vivo. Our results provide further evidence that 
inclusions represent a protective response of the cell to cope with misfolded protein. 
Moreover, because we found that the increased accumulation of mutant AR into 
inclusions correlates with decreased AR function, we speculate that B2 attenuates 
polyglutamine-expanded toxicity through a mechanism that involves 
compartmentalization of the mutant protein and reduction of native protein function. 
Finally, we propose B2 as a potential therapy for SBMA. 
 
B2 Increases the Compartmentalization of Mutant AR Into Inclusions and Reduces 
Toxicity 
B2 was isolated from a drug screen to increase the formation of inclusions while reducing 
proteasome dysfunction in cell models of Huntington's disease (Bodner et al., 2006). B2 
has a similar effect on α-synuclein toxicity, suggesting a general protective role in 
protein misfolding diseases, such as Parkinson's disease. We report that B2 increases 
inclusion formation in cell models of SBMA. It is relevant to note that, unlike the case in 
Huntington's disease, B2 does not induce AR inclusion formation per se. In the absence 
of ligand, a condition in which there is no effect on inclusion formation, B2 increases the 
accumulation of mutant AR into microaggregates, further suggesting that inclusions and 
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microaggregates behave differently. In contrast, B2 increases the deposition of mutant 
AR into inclusions in the presence of ligand. This suggests that the effect of B2 occurs at 
a stage that follows ligand binding. A unique feature of SBMA among the polyglutamine 
diseases is gender specificity. In SBMA, only males show full disease symptoms, and this 
is a result of high levels of circulating androgens in the serum. In the absence of ligand, 
AR is in the cytosol in an inactive state bound to Hsps, such as Hsp90, Hsp70, and 
Hsp40. Ligand binding induces a conformational change, which results in dissociation 
from the Hsps, translocation to the nucleus, and generation of inclusions. AR-positive 
inclusions have been found in motor neurons from SBMA patients (Li et al., 1998) as 
well as in cultured cells (Walcott and Merry, 2002). We explored the mechanism through 
which B2 increases formation of mutant AR-positive inclusions. We tested whether the 
induction of inclusion formation in the nucleus is a consequence of increased expression 
of the mutant protein or increased nuclear translocation. However, we did not find any 
difference in mutant AR expression or in the ligand-induced nuclear translocation in the 
presence or absence of B2. We also tested whether the mechanism through which B2 
works involves the induction of the Hsps, such as Hsp90, Hsp70, and Hsp40. However, 
we could not detect any change in expression of these Hsps. From these results, we 
excluded the possibility that the effect of B2 on mutant AR toxicity and inclusion 
formation is due to an alteration of chaperone levels. These results are consistent with a 
previous report that B2 attenuates polyglutamine-expanded huntingtin toxicity through a 
mechanism that does not involve chaperone activity (Bodner et al., 2006). 
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Although inclusions had initially been considered toxic, the observations that 
accumulation of mutant huntingtin into inclusions in cultured striatal neurons inversely 
correlates with cell death (Arrasate et al., 2004) and that drugs that interfere with the 
ability of the cell to form inclusions cause cell death (Taylor et al., 2003b) suggest a 
protective role for inclusions. Consistent with this model, mutant AR has been shown to 
accumulate more frequently and extensively in a diffuse nuclear pattern rather than in 
nuclear inclusions, with the extent of diffuse nuclear accumulation correlating with 
polyglutamine repeat length (Adachi et al., 2005). We show here that B2 decreases the 
toxicity of mutant AR not only in cultured cells but also in a fly model of SBMA. B2 had 
no effect on the toxicity induced by agents, such as staurosporin, that cause apoptosis 
independently of inclusion formation (Tamaoki et al., 1986; Matsumoto and Sasaki, 
1989). However, we cannot exclude additional effects of B2 on cellular toxicity 
independent of polyglutamine inclusion formation. Our results provide the first evidence 
that B2 counteracts the toxicity of polyglutamine-expanded protein in vivo and suggest 
that agents that promote the deposition of unfolded proteins into inclusions may have 
therapeutic potential. 
 
B2 Alters Mutant AR Function in Cultured Cells 
Recent evidence suggests that altered protein function is an important component of 
polyglutamine disease pathogenesis (Lim et al., 2008). AR is a transcription factor 
activated by the male hormones testosterone and its derivative DHT (Poletti, 2004). Upon 
ligand binding, AR translocates to the nucleus to activate transcription of those genes 
whose regulatory regions contain specific androgen-responsive element sequences. 
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Polyglutamine-expanded AR has been shown to have altered transcriptional activity in 
motor neuron-derived cells, which may contribute to disease pathogenesis (Lieberman et 
al., 2002). We found that B2 reduces AR transactivation in cultured cells without 
disrupting the general cellular transcription machinery. Although this is unlikely, B2 
might have a repressive effect on the transactivation of other steroid receptors whose 
structure is similar to that of AR. Were this to occur, B21 might represent a valid 
alternative to B2. In fact, we found that B21 has no effect on normal AR transactivation, 
suggesting that it specifically targets the disease protein. 
 
B2 inhibits activity of SIRT2 deacetylase, catalyzing the NAD+-dependent reaction of 
acetyl group removal from lysine residues of protein substrates such as α-tubulin and 
histones (Outeiro et al., 2007). Acetylation of non-polyglutamine-expanded AR at the 
KXKK acetylation consensus site is important for AR transactivation (Fu et al., 2003) 
and is regulated by sirtuin activity (Fu et al., 2006). However, when we tested whether 
B2 affects transactivation of an acetylation-defective AR, we found that B2 is still active 
on this AR variant, indicating that B2 does not require this site to alter AR function. 
Rather, B2 may affect AR transcription by regulating acetylation of AR at different lysine 
residues or through a mechanism that is independent of AR acetylation. The observation 
that B2 increases the deposition of mutant AR into inclusions, while decreasing AR 
function and toxicity, leads us to speculate that, by increasing the compartmentalization 
of mutant AR into inclusions, B2 affects AR function and reduces mutant AR toxicity. 
 
Is B2 a Potential Therapy for SBMA? 
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There is no effective therapy available for SBMA. A unique feature of SBMA among the 
polyglutamine diseases is gender specificity. This feature of SBMA has been reproduced 
in animal models of the disease, including mice (Katsuno et al., 2002; Yu et al., 2006) 
and flies (Takeyama et al., 2002; Pandey et al., 2007b), and may be attributed to 
androgen-dependent toxicity of the mutant AR protein. The androgen dependence of the 
disease offers the opportunity to develop therapy based on the reduction of testosterone 
levels in the serum. Indeed, reduction of testosterone levels by leuprorelin has had 
promising results in mouse models of SBMA (Katsuno et al., 2003) and, more recently, 
in a phase 2 clinical trial (Banno et al., 2009). However, the use of anti-androgens can be 
accompanied by several undesired side effects. We show here that B2 reduces the toxicity 
of mutant AR in cell cultures and fly models of SBMA. Based on these results, we 
propose B2 as a novel therapeutic approach for SBMA. 
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Figures and Legends 
 
Figure A1.1. B2 increases the accumulation of mutant AR into nuclear inclusions. 
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Figure A1.1. B2 increases the accumulation of mutant AR into nuclear inclusions.  
A:  PC12 cells stably expressing mutant AR (AR112Q) were induced with doxycycline: 
treated with vehicle, B2 (72 hr), and R1881 (48 hr) as indicated: and processed for 
immunocytochemistry. AR was detected with N20 antibody (green) and nuclei with 
DAPI (blue). Quantification of the number of cells with AR-positive nuclear inclusions 
and of cells with nuclear diffused AR is shown at the bottom. Graph, mean ± sem, n = 4, 
*P  = 0.002 (post hoc t-test). B: Upper panel: Western blotting of PC12-AR112Q cells 
showing AR protein in cells treated with R1881 and B2 as indicated in A. Actin is shown 
as loading control. Shown is one experiment representative of three. MW, molecular 
weight. Bottom panel: Quantification of mutant AR aggregation reveals that B2 increases 
AR aggregation in the absence of ligand but has no effect on aggregation in the presence 
of ligand. HMW, high molecular weight. Graph, mean ± sem, n = 3, *P = 0.02; NS, non-
significant (post hoc t-test). C: Nuclear-cytoplasmic fractionation of HEK293T cells 
transiently transfected with vector expressing AR65Q and treated as indicated shows that 
B2 does not affect nuclear translocation induced by ligand. Shown is one experiment 
representative of three. N, nuclear fraction; C, cytosolic fraction. D: Western blotting 
analysis of PC12-AR112Q cells treated as described for A shows that B2 treatment does 
not change the expression levels of Hsp90, Hsp70, or Hsp40. Actin is shown as loading 
control. This is one experiment representative of three. Scale bar = 10 µm. 
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Figure A1.2. B2 alters AR transactivation. 
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Figure A1.2. B2 alters AR transactivation. A,B:  Transcriptional assay of HEK293T 
cells transfected with vectors expressing AR65Q (A) or as indicated (B) and the reporter 
vectors pARE-E1b-luc and pCMV for luciferase and β-galactosidase expression, 
respectively, and treated with B2 (48 hr) and R1881 (24 hr) shows that B2 reduces 
mutant AR transactivation. Data are represented relative to AR65Q-expressing cells 
treated with 10 nM R1881, which are set as 100%. Graphs, mean ± sem, n = 3 
independent experiments; A: *P = 0.05 and **P = 0.001; B: R1881 10 nM, *P = 0.004 
(post hoc t-test). C: Transcriptional assay of HEK293T cells transfected with the pFHRE-
luc and pCMV reporter vectors, treated with B2 (48 hr), and either serum starved or 
treated with IGF-1 for 24 hr revealed that B2 does not affect pFHRE reporter activity. 
Data were analyzed as described for A. Graph, mean ± sem, n = 3. D: Transcriptional 
assay of HEK293T cells transfected with the AR expression vectors indicated and the 
reporter vectors as for A shows that B2 is active on the acetylation-defective AR mutant. 
Data were analyzed as in A. Graph, mean ± sem, n = 3, *P = 0.02 (post hoc t-test). E: 
Ligand binding assay of HEK293T cells transfected with vector expressing AR65Q, 
treated with radioactive ligand for 2 hr, then treated with either B2 or cold ligand for 1 hr, 
shows that B2 does not compete with ligand for binding to mutant AR. Schatchard 
analysis shows that B2 does not compete for binding with radioactive ligand. Graph, 
mean ± sem, n = 3 independent experiments. F: Ligand binding assay of HEK293T cells 
transiently expressing normal AR and treated with either vehicle (AR24Q) or 10 M B2 
(AR24Q + B2) shows that B2 does not alter binding of normal AR to ligand. Graph, 
mean ± sem, n = 3 independent experiments. 
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Figure A1.3 
 
 
 
 
Figure A1.3. B2 reduces the toxicity of mutant AR in cultured cells. A: XTT assay of 
PC12-AR112Q cells treated with R1881 (48 hr) together with either B2 or vehicle (72 hr) 
shows that cell survival is decreased by ligand and that this effect is attenuated by B2. 
Graph, mean ± sem, n = 3, *P = 0.05 (post hoc t-test). B: Caspase 3 assay of MN-1 cells 
stably expressing AR65Q and treated as indicated for 48 hr shows that B2 decreases 
caspase 3 activity but has no effect on the caspase 3 activation induced by staurosporin 
(inset). The caspase inhibitor z-VAD-FMK (10 M, 48 hr treatment) and the caspase 
activator staurosporin (1 M, 6 hr treatment) were used as controls. Graph, mean ±  sem, n 
= 3, *P = 0.004 (post hoc t-test). 
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Figure A1.4. B2 attenuates the toxicity of mutant AR in vivo. 
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Figure A1.4. B2 attenuates the toxicity of mutant AR in vivo. Upper panel: Transgenic 
flies expressing AR52Q in the eye were fed with dihydrotestosterone (DHT) and either 
vehicle or B2. Exposure of the flies to DHT resulted in the alteration of the eye 
phenotype, which was attenuated by B2. A magnification of the posterior side of the eye 
is shown on the right of each panel. Middle panel:  Quantification of disease severity is 
shown in the graph (see Materials and Methods). Graph, mean ± sem, n = 45 for the 
DHT-fed flies and 57 for the DHT/B2-fed flies, *P = 0.001 (two-sample t-test). Bottom 
panel: Western blotting analysis of AR transgene expression levels reveals that B2 does 
not change mutant AR expression in flies. Tubulin (Tub) is shown as loading control. 
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Supplemental Figure A1.1 
 
 
 
 
Supplemental Figure A1.1. B2 does not alter AR transcript levels in cultured cells. 
Real-time PCR analysis of (A) PC12-AR112Q cells and (B) HEK293T cells transiently 
expressing either normal (AR24Q) or mutant (AR65Q) AR and treated with the androgen 
analog R1881 together with either B2 or vehicle. The AR mRNA was normalized to 18S 
rRNA. Graph, mean ± s.e.m., n = 3. (B, bottom panel) AR protein was detected by 
western blotting. Tubulin is shown as loading control.
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Supplemental Figure A1.2 
 
 
Supplemental Figure A1.2. B21 alters AR function in cultured cells. Transcriptional 
assay was performed in HEK293T cells transiently transfected with vector expressing 
either AR24Q or AR65Q and the reporter vectors pARE-E1b-Luc and pCMVβ. The cells 
were treated with B21 for 48 hours and R1881 (10 nM) for 24 hours as indicated, and 
processed for luciferase and beta-galactosidase assays. Luciferase activity was 
normalized to beta-galactosidase activity. Graph, mean ± s.e.m., n = 3, p = 0.001, (post-
hoc t-test).
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Supplemental Figure A1.3 
 
 
 
 
Supplemental Figure A1.3. Acetylation-defective AR has increased transactivation 
function. Transcriptional assay of HEK293T cells transfected with the indicated AR 
constructs and the reporter vectors pARE-E1b-Luc and pCMVβ and treated with either 
vehicle or R1881 for 48 hours shows that lack of acetylation at the KXKK consensus site 
results in increased AR transactivation. Graph, mean ± s.e.m., n = 3. 
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Supplemental Figure A1.4 
 
  
Supplemental Figure A1.4. B2 decreases mutant AR toxicity in cultured cells. A) 
Propidium iodide incorporation followed by fluorescence-activated cell sorter analysis of 
PC12-AR112Q cells exposed to ligand and B2 for 48 and 72 hours, respectively, shows 
that B2 decreases ligand-induced cell death. Graph, mean ± SD, n = 2. B) Caspase 3 
assay of motor neuron-derived MN-1 cells treated with vehicle or B21 for 48 hours 
shows that B21 decreases caspase 3 activity. Z-VAD-FMK and staurosporin were used as 
negative and positive controls, respectively. Graph, mean ± s.e.m., n = 3, p = 0.01 (two-
sample t-test). 
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Abstract 
All cells are endowed with two catabolic pathways for degrading protein: the ubiquitin-
proteasome system (UPS) and autophagy. While these routes of protein degradation were 
long considered to be parallel and complementary systems, new evidence has revealed 
interaction between the UPS and autophagy, suggesting a coordinated relationship that 
becomes critical in times of cellular stress. Here we introduce the basics and parallels of 
the UPS and autophagy, review the evidence for cross-regulation of the two systems, and 
highlight their emerging coordinated relationship. Throughout, we review the evidence 
suggesting that impairment of autophagy could contribute to the initiation or progression 
of age-related neurodegeneration.  
 
Introduction 
In awarding the Nobel Prize in Chemistry to Aaron Ciechanover, Avram Hershko and 
Irwin Rose in 2004, the Royal Swedish Academy of Sciences praised these scientists as 
innovators. After decades of work focusing on how the cell produces proteins, these 
pioneers had broken with tradition and highlighted the equally important process of how 
the cell degrades proteins. Indeed, the idea that the proteome (a term yet to be invented) 
was dynamic, with proteins continually synthesized and degraded, was challenged well 
into the 1950s. What Ciechanover, Hershko, and Rose discovered in the mid-1980s was 
an exquisitely controlled and efficient system of selectively labeling and targeting 
proteins for degradation, now well known as the ubiquitin-proteasome system (UPS). 
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According to Ciechanover, the identification of the UPS marked the end of a long search 
for a non-lysosomal proteolytic system (Ciechanover, 2005). Although the lysosome had 
been characterized as a catabolic organelle some 30 years before, several lines of 
evidence indicated that some portion of intracellular protein degradation could not be 
explained based on the known mechanisms of lysosomal activity. If the lysosome non-
selectively degraded all proteins, one might predict that all proteins would be degraded at 
approximately the same rate. Yet, empirically, protein half-lives varied widely from a 
few minutes to as long as several days. Secondly, the discovery that the stability of only a 
subset of proteins was sensitive to physiological conditions (most notably nutrient 
availability) was difficult to reconcile with a single, bulk lysosome-based degradation 
system. A third line of evidence for a non-lysosomal proteolytic system was the 
differential sensitivity of particular proteins to lysosomal inhibitors, suggesting that 
distinct groups of proteins are degraded by distinct degradation pathways, only one of 
which is dependent on lysosomal proteases. Finally, the fact that degradation of some 
proteins was ATP-dependent suggested that lysosomal proteases (which degrade proteins 
in an exergonic manner) could not be the sole means of degradation. This delineation 
between lysosomal- and non-lysosomal-based degradation permitted these astute 
investigators to intuit an alternative degradation system, culminating in elucidation of the 
UPS as we understand it today. 
 
The manner in which the UPS was discovered and initially characterized underscored the 
differences between the UPS and lysosome-mediated degradation. Indeed, for many years 
these two catabolic pathways were viewed as distinct catabolic pathways with no point of 
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intersection. Recent years have seen renewed interest in that which the UPS specifically 
is not – that is, relatively non-selective bulk degradation of intracellular proteins that 
requires lysosomal proteases – a process broadly defined as autophagy. The recent 
heightened interest in autophagy, combined with the wealth of knowledge of the UPS, 
has highlighted the similar goals of the two catabolic pathways: first, their 
complementary role in recycling macromolecules, and second, their turnover of 
misfolded and/or damaged proteins. Further studies have begun to identify functional and 
physical interactions between the two systems, uncovering what may be a hierarchical 
relationship between the pathways. Thus the two systems that were identified based on 
their differences are presently being revealed to be surprisingly similar and intimately 
interrelated.  
 
The UPS and Autophagy: A Division of Labor 
The distinctions used by researchers in the 1980s to differentiate the UPS from autophagy 
remain the key characteristics of these systems as they are defined today. The UPS is a 
highly selective catabolic process which serves as the primary route of degradation for 
thousands of short-lived proteins, many of which serve regulatory functions in such key 
processes as cell cycle control, transcriptional regulation, and signal transduction. An 
important class of substrates for degradation by the UPS is misfolded and damaged 
proteins, since elimination of these proteins is important to prevent their accumulation in 
protein aggregates that are inherently toxic. UPS substrates are first marked for 
degradation by the covalent addition of a ubiquitin molecule to particular lysine(s) within 
139 
the target protein; these ubiquitin molecules are added in an ATP-dependent manner 
through the sequential action of ubiquitin-activating (E1), -conjugating (E2), and -ligating 
(E3) enzymes. An additional ubiquitin moiety is added to a specific lysine residue in the 
preceding ubiquitin molecule, and this process is repeated to form a polyubiquitin chain 
on the substrate, sometimes involving the activity of a polyubiquitin (E4) ligase. 
Ubiquitin molecules have a total of seven lysine residues (at positions 6, 11, 27, 29, 33, 
48, and 63), and the particular lysine residue used for conjugation of one ubiquitin 
monomer to another – defining distinct ubiquitin topologies –  appears to have important 
functional consequences for the substrate.  For example, K48-linked polyubiquitin chains 
are targeted to the proteasome, while K63-linked polyubiquitin chains are involved in 
other functions, as will be explored below (Chau et al., 1989; Arnason and Ellison, 1994). 
Those substrates targeted for UPS degradation are directed to the proteasome, where 
ubiquitin molecules are recycled and substrates are enzymatically degraded to 
oligopeptides. These oligopeptides are subsequently broken down into amino acids by 
non-specific peptidases, thereby regenerating molecules essential to metabolic 
homeostasis. 
 
In contrast, autophagy (literally “self-eating”) describes a process in which cellular 
components such as organelles and longer-lived proteins are delivered to the lysosome 
for degradation. While autophagy serves a diverse array of functions (reviewed in 
(Mizushima, 2005)), this chapter will focus on its evolutionarily conserved function as 
the critical mediator of metabolic homeostasis in the face of changing nutrient availability 
(Abeliovich and Klionsky, 2001) as well as its role in neuroprotection. Autophagy is 
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generally considered to be a less selective degradative system than the UPS, and is 
typically described as a process in which large portions of cytoplasm are engulfed within 
membranes and delivered to the lysosome in bulk. This characterization describes the 
best-studied subtype of autophagy, known as macroautophagy. However, more several 
specialized forms of autophagy exist, including microautophagy and chaperone-mediated 
autophagy (CMA). These subsystems are distinguished by the identity of the substrates 
and the route by which these substrates reach the lysosomal compartment. 
Microautophagy consists of direct engulfment of small volumes of cytosol by lysosomes, 
while CMA involves selective, receptor-mediated translocation of proteins into the 
lysosomal lumen. In contrast, macroautophagy involves the de novo formation of an 
isolation membrane which expands to engulf a portion of the cytosol, eventually fusing to 
form a new vacuole termed an autophagosome. Autophagosomes undergo a series of 
maturation steps before fusing with lysosomes to deliver their cargo for degradation by 
lysosomal proteases. Breakdown products from the lysosome are translocated across the 
lysosomal membrane to the cytosol, where they are reused in metabolic processes. There 
appears to be capacity for selectivity within the process of macroautophagy, as some 
processes have been observed that appear to be specific for mitochondria (mitophagy), 
portions of the nucleus (nucleophagy), peroxisomes (pexophagy), endoplasmic reticulum 
(reticulophagy), microorganisms (xenophagy), ribosomes (ribophagy) or protein 
aggregates (aggrephagy) (reviewed in (Kundu and Thompson, 2008)). Macroautophagy 
forms the basis of this chapter and will be referred to hereafter simply as “autophagy”. 
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The UPS and Autophagy: Functional Parallels 
Despite such gross differences between the UPS and autophagy at a mechanistic level, 
two key functional parallels have been well-established. First, both systems play 
important roles in maintaining cellular pool of free amino acids, particularly in the setting 
of limited nutrient availability. Protein catabolism mediated by the UPS and autophagy 
are crucial for recycling amino acids during acute and chronic starvation, respectively. 
Second, both systems play essential roles in protecting the integrity of the proteome 
which is continually threatened by non-native protein-protein interactions and can lead to 
the formation of insoluble aggregates. Even under normal conditions cells constitutively 
produce aberrant proteins, and the challenge to protein quality control can become even 
greater with proteotoxic insults such as protein oxidation, aberrant translation, or mutant 
gene products. To counteract protein aggregation and its consequences, cells are 
equipped with protective mechanisms that scrutinize the cell for non-native proteins and 
assist in their refolding or degradation. The UPS and autophagy are both important to this 
quality control system and deficiency of either system is associated with accumulation of 
defective proteins in insoluble aggregates with attendant cytotoxicity. 
 
The importance of eliminating misfolded or defective proteins is perhaps most evident in 
the context of the nervous system. As post-mitotic, highly metabolically active cells, 
neurons are particularly vulnerable to the long-term accumulation of proteins that engage 
in aberrant interactions or acquire other toxic properties. Indeed, a broad array of 
neurodegenerative diseases are characterized by the accumulation of misfolded proteins 
in affected brain regions. These deposits are frequently immuno-positive for ubiquitin 
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and other UPS components, suggesting a failure in the cell’s capacity to clear proteins 
marked for degradation. In addition, accumulations of autophagic vacuoles in affected 
brain regions of patients with Alzheimer’s disease, Parkinson’s disease, Creutzfeldt-
Jakob disease, and many of the polyglutamine diseases suggest that autophagy could play 
a role in the initiation or progression of disease (Anglade et al., 1997; Sapp et al., 1997; 
Sikorska et al., 2004; Nixon et al., 2005).   
 
The observation that these protein deposits in the setting of disease occur alongside (and 
despite) signs of both UPS and autophagic activity raises the question of which system 
has failed in its task of degrading these misfolded proteins. The answer may be both: the 
in vitro turnover of neurodegenerative disease-causing proteins such as polyglutamine-
expanded proteins, polyalanine-expanded proteins, and α-synuclein can be altered by 
manipulation of either the UPS or the autophagy-lysosomal system (Bennett et al., 1999; 
Cummings et al., 1999; Kegel et al., 2000; Martin-Aparicio et al., 2001; Ravikumar et al., 
2002; Taylor et al., 2003b; Webb et al., 2003; Davies et al., 2006). Such wide-ranging 
sensitivities indicate that more than one degradative route may be available to some 
proteins, and have led to the suggestion that the choice of route for a particular substrate 
may be influenced by which system is most capable of degrading it. For example, in the 
case of α-synuclein, it has been suggested that soluble forms of the protein can be 
efficiently degraded by the proteasome, while aggregated or oligomeric forms require the 
bulk degradation of the autophagic pathway (Webb et al., 2003). Such a model further 
suggests that autophagy could provide an alternate, compensatory route of degradation 
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when a particular substrate cannot be cleared efficiently by the proteasome, or when the 
UPS is more globally compromised. 
 
While the clearance of disease proteins is likely to be cytoprotective in and of itself, 
degradation of intracellular proteins in general – whether misfolded, damaged, or simply 
no longer useful – has the advantage of recycling amino acids for further use by the cell. 
As mentioned above, the best-characterized and evolutionarily conserved role for 
autophagy lies in its response to chronic starvation. As such, autophagy is negatively 
regulated by the nutrition-dependent insulin/PI3K and TOR signaling pathways; when 
nutrients are removed, active PI3K inhibits TOR, allowing autophagy to reallocate 
nutrients from nonessential cytoplasmic components to vital cellular processes. The UPS 
has also been implicated in response to starvation, though its major role appears to be 
mobilization of nutrients in the context of acute starvation.  
 
The UPS and Autophagy: Molecular Parallels 
Apart from functional parallels between the UPS and autophagy with respect to recycling 
amino acids and implications of impaired function in the setting of neurodegenerative 
disease, a number of molecular parallels between autophagy and the UPS have emerged 
as the details of each system have been delineated. Of particular note is the striking 
similarity between the processes of autophagy induction and ubiquitin conjugation. Both 
processes utilize molecules that have come to be defined as UBLs (ubiquitin-like 
proteins): while the UPS uses the eponymous ubiquitin molecule, autophagy induction is 
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regulated by post-translational modification by two UBL proteins, known as Atg8 and 
Atg12. Atg8 and Atg12 are also members of a family of evolutionarily conserved 
proteins known as the Atg (autophagy-related) proteins; these Atg proteins are the 
effectors and regulatory proteins that initiate and elongate the autophagosomal membrane 
(reviewed in (Xie and Klionsky, 2007)). UBLs share similar structural domains and are 
likely ancestrally related (Figure A2.1) (Love et al., 2007). Moreover, the UBL 
conjugation system is also highly conserved between the UPS and autophagy (Figure 
A2.2): in both cases, the carboxyl group of the C-terminal glycine of the UBL is activated 
and attacked by a thiol-group-containing E1-activating enzyme to generate an E1-UBL 
thiolester. The activated UBL is then transferred to an E2-conjugating enzyme, and 
finally ligated to the target. In the case of the UBL Atg8, this target is not a protein, but 
the membrane-bound phospholipid phosphotidylethanolamine (PE). As PE is a 
component of the autophagosomal membrane, this PE-Atg8 reaction results in the 
studding of the inner and outer membrane of the autophagosome with Atg8. A 
mammalian homolog of Atg8 known as MAP-LC3 (microtubule-associated protein light 
chain 3, typically abbreviated as LC3) associates with phagophores in an analogous 
manner, and is therefore used as a primary histological marker of autophagosomes. Pro-
LC3 is cleaved cotranslationally to yield a protein known as “LC3-I.” When LC3-I 
becomes conjugated to PE and covalently associates with the phagophore, it forms “LC3-
II.” Consequently, the generation and turnover of LC3-II is used as an index of autophagy 
induction and/or flux (Klionsky et al., 2008). Because LC3-II remains on the inner 
membrane of autophagosomes until lysosomal enzymes degrade it, increased steady-state 
levels of LC3-II may be due to induction of autophagosome formation, a blockade in 
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their maturation, or both. The striking similarities between the ubiquitination system that 
precedes proteasomal digestion and the autophagy induction system that culminates in 
lysosomal digestion have led to the suggestion that these two catabolic pathways may 
have evolved from a common, ancestral biological pathway. 
 
Points of Intersection Between the UPS and Autophagy: Cross-Regulation 
As the list of similarities between the UPS and autophagy continued to grow, several 
groups began to realize that these shared characteristics did not simply reflect two 
parallel systems, but that these pathways could intersect in meaningful ways. This 
intersection was not predicted by the early researchers working to characterize the UPS, 
because of the apparently strict rule that agents that disrupt lysosomal function have no 
effect on the ATP-dependent turnover of short-lived and abnormal proteins (Pickart, 
2004). 
 
The first solid evidence that the UPS intersected with autophagy emerged in the mid-
1990s, when ubiquitin modification was identified as an essential signal in the 
endosomal-lysosomal system that permits lysosomal degradation of certain integral 
membrane proteins. Specifically, several groups showed that a subset of endocytosed 
proteins requires ubiquitin conjugation in order to achieve internalization from the 
plasma membrane (Kolling and Hollenberg, 1994; Hicke and Riezman, 1996) and that 
monoubiquitination is sufficient as an endocytic internalization signal (Terrell et al., 
1998). In addition, K63-linked ubiquitin topologies were found to stimulate endocytosis 
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(Galan and Haguenauer-Tsapis, 1997). Ubiquitination was also found to serve as a 
sorting signal for endosomes, targeting endosomal cargo to multivesicular bodies 
(MVBs) in the lysosomal degradation pathway (Komada and Kitamura, 2005). This 
pathway is also used in lysosome biogenesis, indicating that ubiquitination can influence 
the autophagy-lysosomal pathway at its most fundamental level. This latter observation 
was also the first of several observations suggesting a hierarchical relationship between 
these catabolic pathways, with autophagy under the control of the ubiquitin-proteasome 
system, as discussed below. 
 
More recent evidence linking the UPS and autophagy comes from research into p53, a 
short-lived transcription factor whose steady-state levels are tightly controlled by the 
UPS. p53 plays multiple well-described roles in the regulation of the cell cycle and cell 
death, and several groups have now confirmed an additional function for p53 in the 
regulation of autophagy. Activation of p53 is believed to activate autophagy through both 
transcription-dependent and -independent mechanisms (Feng et al., 2005; Crighton et al., 
2006; Amaravadi et al., 2007; Zeng et al., 2007; Abida and Gu, 2008; Maclean et al., 
2008), while inhibition of p53 also appears to activate autophagy, though strictly in a 
transcription-independent manner (Tasdemir et al., 2008). The paradox in which 
autophagy may be induced by both activation and inhibition of p53 remains to be 
resolved, though it has been suggested that the different types of p53-dependent 
autophagy activation could potentially be dictated by the nature of the stress signal 
(Levine and Abrams, 2008). The notion that the UPS can dictate the steady-state levels of 
a key autophagy signaling molecule such as p53 suggests a model in which the UPS 
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holds the reins of autophagy induction, acting upstream of autophagy to control the 
signals that induce or inhibit this degradative pathway. 
 
Further intersection of the UPS and autophagy can be found in the specialized form of 
macroautophagy known as mitophagy (mitochondria-specific autophagy), a process vital 
to protecting cells from oxidative stress (Kim et al., 2007). Parkin, a protein best known 
as a gene deleted in juvenile Parkinson’s disease, is also an E3 ubiquitin ligase that was 
recently shown to be recruited to impaired mitochondria, where it mediates the 
engulfment of mitochondria by autophagosomes (Narendra et al., 2008). Though the 
ubiquitination activity of Parkin was not directly tested in this paper, it will be interesting 
to determine whether its ubiquitination signal involves mono- or poly-ubiquitination. Of 
particular interest is Parkin’s ability to assemble K63-linked polyubiquitin chains, which 
form a ubiquitin chain topology that has been linked to autophagy and will be discussed 
more below (Lim et al., 2005).  
 
Autophagy and the UPS: Coordinated Function 
While these points of intersection highlighted regulatory crosstalk between the UPS and 
autophagy, there was until recently little evidence to show functional overlap between the 
two systems beyond their shared abilities to degrade disease-associated proteins. 
However, two papers published back-to-back in Nature in 2006 revealed a level of 
interaction that few would have predicted (Hara et al., 2006; Komatsu et al., 2006). Both 
of these papers described conditional knockouts of individual Atg genes within the 
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nervous system, and both reported that these mice showed neurodegeneration with 
extensive ubiquitin-positive pathology despite evidence of an intact UPS (Figure A2.3). 
These papers were significant in two respects. First, they revealed an essential role for 
basal autophagy (as opposed to nutritionally-induced autophagy) in the development and 
maintenance of the central nervous system, even in the absence of any disease-related 
mutant proteins. Second, the accumulation of ubiquitin conjugates despite an intact, 
functioning UPS was the first evidence that autophagy might play a role the degradation 
of ubiquitin-tagged substrates. Subsequent to the determination that a deficiency of 
autophagy leads to neurodegeneration with accumulation of ubiquitin conjugates, it was 
determined that induction of autophagy was able to suppress degeneration associated 
with UPS impairment and accelerate the clearance of misfolded protein in Drosophila 
melanogaster. These results demonstrated for the first time that not only does 
autophagy functionally complement the UPS, but is able to compensate for an impaired 
UPS (Pandey et al., 2007b). In fact, impairment of the UPS is such a potent and 
consistent stimulus of autophagy that it has become a frequent method of experimentally 
inducing autophagy both in vitro and in vivo (Rideout et al., 2004; Iwata et al., 2005a). 
 
Molecular links between the UPS and autophagy 
The UPS and autophagy clearly share roles in maintaining metabolic homeostasis and 
degrading abnormal proteins, while ubiquitin modification evidently can lead substrates 
into the autophagic system. What signals might mediate this coordination between the 
UPS and autophagy? Several clues have come to light from in vitro studies in which cells 
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are challenged by either high-level expression of misfolded protein or direct impairment 
of the UPS. In such contexts, many cells actively transport ubiquitinated, misfolded 
proteins to juxtanuclear bodies termed aggresomes (Johnston et al., 1998). Aggresomes 
are thought to be cytoprotective, acting as a mechanism to sequestrate potentially toxic 
proteins and facilitate their clearance by autophagy (Taylor et al., 2003b). While 
controversy surrounds the question of whether aggresomes are formed in vivo, they have 
provided significant insight into the molecular machinery that protects cells from 
misfolded stress. In particular, several proteins involved in aggresome formation have 
subsequently been shown to play roles in managing toxic proteins in vivo, including 
Parkin, histone deacetylase 6 (HDAC6) and p62. The common threads linking HDAC6 
and p62 to aggresomes are K63-linked polyubiquitin chains, which are thought to target 
proteins to aggresomes, among other functions. The E3 ubiquitin ligase Parkin is capable 
of generating such K63 linkages (Lim et al., 2005), and overexpression of Parkin leads to 
aggresome formation (Junn et al., 2002). HDAC6 is a cytoplasmic deacetylase whose 
targets include α-tubulin, Hsp90, and cortactin. HDAC6 interacts with polyubiquitinated 
proteins through a Zn-finger ubiquitin-binding domain, and also interacts with dynein 
motors, suggesting that it may provide a link between ubiquitinated proteins and transport 
machinery (Kawaguchi et al., 2003; Kopito, 2003; Iwata et al., 2005a). Indeed, HDAC6 
was recently demonstrated to operate as an adaptor between Parkin-mediated K63-linked 
polyubiquitinated substrates and the dynein motor complex, effectively coordinating 
delivery of substrates to autophagic machinery (Olzmann et al., 2007; Olzmann and Chin, 
2008). In Drosophila, HDAC6 overexpression was found to suppress degeneration 
associated with UPS impairment as well as degeneration caused by toxic polyglutamine 
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expression; this suppression was autophagy-dependent, supporting a role for HDAC6 in 
linking the UPS with compensatory autophagy (Pandey et al., 2007b). p62 is a second 
aggresome-related cytosolic protein that is thought to operate as an adaptor between 
ubiquitinated proteins and autophagic machinery, as it harbors both a ubiquitin-associated 
domain and an LC3-interacting region (Geetha and Wooten, 2002; Seibenhener et al., 
2004; Pankiv et al., 2007). p62 has been observed in ubiquitin-positive inclusions in a 
variety of neurodegenerative disease brains (Kuusisto et al., 2001a, 2002; Zatloukal et al., 
2002), and converging evidence from experimental studies suggest that p62 protects 
against misfolded stress by facilitating a connection between ubiquitinated substrates and 
autophagic machinery (Bjorkoy et al., 2005; Komatsu et al., 2007; Pankiv et al., 2007; 
Ichimura et al., 2008; Nezis et al., 2008; Ramesh Babu et al., 2008). In a model similar to 
that described for HDAC6, p62 has been proposed to partner specifically with K63-
linked polyubiquitin to promote the clearance of protein inclusions by autophagy (Tan et 
al., 2007). 
 
Autophagy is Cytoprotective (Except When it Isn’t) 
Whereas the neurodegeneration with ubiquitin-pathology observed in autophagy-
deficient mice was unexpected, it was consistent with prior observations that genetic 
alteration of lysosomal activity has dramatic impact on the central nervous system. For 
example, knockout of cathepsin D, a lysosomal protease enriched in neuronal tissues, 
resulted in neurodegeneration and accumulation of autophagosomes and lysosomes in 
both mice and Drosophila  (Koike et al., 2000; Myllykangas et al., 2005; Shacka et al., 
151 
2007).  On the basis of these observations one might predict that impairment of 
autophagy could contribute to neurodegenerative disease in humans. Indeed, primary 
lysosomal dysfunction in inherited congenital “lysosomal storage disorders” has long 
been recognized to cause severe neurodegenerative phenotypes characterized 
pathologically by accumulations of lysosomes and autophagic vacuoles (Nixon et al., 
2008). For example, the neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous 
group of inherited, neurodegenerative disorders with onset ranging from infancy to late 
adulthood that are caused by a variety of defects in lysosomal function. Furthermore, a 
growing list of adult-onset, familial neurological diseases have been linked to mutations 
expected to have an impact on autophagy-lysosomal function (reviewed in (Nixon et al., 
2008)), including Parkinson’s disease (mutations in the lysosomal protein ATP13A2 are 
linked to early-onset PD) (Ning et al., 2008), Charcot- Marie-Tooth type 2B (a 
dominantly inherited form of peripheral neuropathy caused by mutations in the 
endosomal-lysosomal trafficking protein Rab7 ) (Verhoeven et al., 2003), and distal-
spinobulbar muscular atrophy (a form of motor neuron disease caused by mutations in the 
lysosomal trafficking protein dynactin) (Puls et al., 2005). These latter two diseases are 
caused by mutations in components of the vesicular transport machinery, implicating 
impaired trafficking of autophagic components as important to pathogenesis. Indeed, 
microtubule-based vesicular trafficking is essential to the delivery of autophagosomes to 
lysosomes (Kimura et al., 2008), and the relatively long axons of the sensory and motor 
neurons affected in these diseases may impart particular vulnerability. 
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How might autophagy be cytoprotective? One possibility, given the evidence that 
autophagy can degrade disease-causing proteins, is that autophagy’s protective action is 
mediated through accelerated turnover of misfolded proteins. This idea is supported by 
experimental evidence in models of neurodegenerative disease. In these studies, genetic 
inhibition of autophagy enhanced degeneration in spinobulbar muscular atrophy (SBMA) 
and Alzheimer’s disease models (Pandey et al., 2007b; Pickford et al., 2008) and was 
associated with higher levels of disease-related proteins, suggesting that augmenting 
autophagic clearance of these cytotoxic proteins could provide benefit. Indeed, 
pharmacological activation of TOR using rapamycin suppressed toxicity in in vitro and in 
vivo models of SBMA and Huntington’s disease (Ravikumar et al., 2002; Ravikumar et 
al., 2004; Berger et al., 2006; Pandey et al., 2007b). 
 
Such a model, however, may be too simplistic. Accelerated turnover of mutant disease-
causing proteins would be predicted to be cytoprotective, but such a mechanism does not 
explain how autophagy can suppress degeneration in models of proteasome impairment. 
It seems unlikely that autophagy upregulation can normalize the turnover of short-lived 
proteins that are normally degraded by the UPS, effectively replacing the UPS function 
with respect to regulatory networks. Instead, it seems reasonable to invoke another shared 
function of the UPS and autophagy – that of maintaining metabolic balance. Perhaps, 
through induction of autophagy, the metabolic balance that is disrupted with UPS 
impairment can be restored, replenishing the cellular pool of nutrients and allowing the 
cell to regain essential functions.  
 
153 
However, the role for autophagy in neurodegeneration may not always be so 
straightforward. In the case of Alzheimer’s disease, a complex picture is emerging in 
which impaired autophagosome-lysosome fusion, combined with decreasing efficiency of 
the lysosomal system, causes accumulation of autophagic vacuoles (Nixon, 2007). These 
vacuoles may contribute to pathology by interfering with normal cellular functions such 
as intracellular trafficking and metabolic turnover of nutrients. In addition, recent studies 
have suggested that the toxic amyloid-β species may be generated by autophagic 
degradation of the amyloid beta precursor protein (Yu et al., 2005). These findings 
support a model of Alzheimer’s disease pathogenesis in which autophagy induction 
produces toxic species, while defective clearance of autophagic vacuoles lead to 
exacerbation of disease (Nixon, 2007). 
 
Final thoughts 
The complex relationship between autophagy and neurodegeneration, as illustrated by the 
example of Alzheimer’s disease, highlights several unresolved questions. As mentioned 
above, many neurodegenerative diseases show accumulations of autophagic vacuoles; in 
addition, autophagosomes are frequently found in dying neurons. However, these 
morphological studies cannot determine whether the increased frequency of autophagic 
vacuoles in disease brain is due to induced autophagy or impaired autophagic flux. 
Furthermore, these studies cannot distinguish between the role of autophagy in 
cytoprotection or in cell death. Finally, if the increased autophagic vacuoles reflect 
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endogenous upregulation of autophagy, it is unclear why this induction is insufficient to 
protect against proteotoxicity. 
 
Further questions concern the details of the interrelatedness of the UPS and autophagy. 
Several questions in particular concern the compensatory function of autophagy in the 
context of UPS impairment. For example, it is not known whether this compensatory 
relationship is reciprocal – that is, whether induction of the UPS is able to compensate for 
impaired autophagy. Few reagents exist to upregulate the UPS, though one study found 
that upregulation of the UPS may afford neuroprotection from toxicity caused by disease 
proteins (Seo et al., 2007). However, the authors did not examine the effects of UPS 
upregulation in autophagy-deficient cells. In addition, the molecular players that might 
transduce signals to induce compensatory autophagy remain unknown. Also, how is the 
decision made between degradative pathways for any particular protein substrate when 
more than one route is available? HDAC6 and p62 have both been implicated in directing 
ubiquitinated proteins for autophagic degradation, but the mechanisms whereby these 
proteins identify their targets and influence their degradation are still unknown. Some 
evidence suggests that different ubiquitin topologies might identify different classes of 
substrates, with K48-linked chains being degraded by the UPS, while K63-linked chains 
are recognized by HDAC6 and p62 and possibly degraded by autophagy (Figure A2.4). 
However, experimental limitations in distinguishing the effects of K48- and K63-
ubiquitin chains must be overcome in order these questions, and in vivo evidence for a 
link between K63-linked chains and autophagy is still lacking.It is further evidence of the 
irony of nature that the molecule that Ciechanover, Hershko, and Rose discovered at the 
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heart of their search for a non-lysosomal proteolytic pathway appears to be intimately 
linked to lysosomal proteolysis. At the very least, their decision to name the molecule 
“ubiquitin” turns out to have been made with remarkable foresight. 
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Figures and Legends 
Figure A2.1. Ubiquitin-like (UBL) molecules share three-dimensional structures and 
common ancestry.  
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Figure A2.1. Ubiquitin-like (UBL) molecules share three-dimensional structures and 
common ancestry. (a) Ribbon diagrams of the UBL proteins Atg8, Atg12, and ubiquitin 
reveal a common ubiquitin fold. α-helices are shown in green, β-strands in purple, and 
unstructured loops in orange. Images were generated using PDB codes 1UBQ (ubiquitin), 
1UGM (Atg8), and 1WZ3 (Atg12) and PYMOL. (b) Cladogram of human UBL proteins 
demonstrate the evolutionary relationships between UBL molecules and illustrate the 
ancestral relationship between ubiquitin and autophagy-related genes. Cladogram 
generated by multiple sequence alignment of human UBL proteins using Clustal 
W2.0.10.  
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Figure A2.2. Autophagy, the UPS, and SUMOylation use parallel conjugation 
systems of UBL modification.  
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Figure A2.2. Autophagy, the UPS, and SUMOylation use parallel conjugation 
systems of UBL modification. (a) In the autophagy pathway, the UBL Atg12 is 
activated by the E1-like molecule Atg7, transferred to the E2-like Atg10, and is 
subsequently conjugated to Atg5. No E3-like protein has been identified in this pathway. 
(b) Also in the autophagy pathway, the UBL Atg8 is activated by the E1-like molecule 
Atg7, transferred to the E2-like Atg3, and is conjugated to phosphotidylethanolamine 
(PE) via the E3-like activity of the Atg5-Atg12 complex. (c) In the UPS, the UBL protein 
ubiquitin is activated by an E1-activating enzyme, transferred to an E2-conjugating 
enzyme, and linked to its target substrate through the action of an E3-ligating enzyme. (d) 
In the SUMOylation pathway, SUMO is first activated via the E1-like complex formed 
by AOS1 and UBA2, transferred to the E2-conjugating enzyme Ubc9, and finally ligated 
to its substrate through an E3-ligating enzyme. Though each conjugation pathway is 
similar, each has significantly different downstream effects.  
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Figure A2.3 
 
Figure A2.3. Conditional knockout of Atg5 in the mouse nervous system results in 
ubiquitin-positive inclusions and accumulation of polyubiquitinated proteins.  
(a) Immunohistochemistry of brain sections from control and Atg5 conditional knockout 
mice at six weeks of age. Ubiquitin staining (1B3) reveals ubiquitin-positive inclusion 
bodies in the cytoplasm of large neurons in the thalamus, pons, medulla, and dorsal root 
ganglion (DRG). Genotypes shown: control (Atg5flox/+; nestin-Cre) and Atg5 knockout 
(Atg5flox/flox; nestin-Cre). Scale bar 10µm. (b) Triton-X-100-soluble polyubiquitinated 
proteins accumulate in Atg5flox/flox; nestin-Cre brains. Brain homogenate was prepared 
at indicated times and separated into Triton-X-100-soluble (S) and –insoluble (P) 
fractions and immunoblotted with anti-ubiquitin antibodies. Arrowhead indicates the 
stacking gel. Reprinted from (Hara et al., 2006) with permission.  
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Figure A2.4 
 
 
 
 
Figure A2.4. Protein degradation can be accomplished by two major intracellular 
pathways: the UPS and autophagy. In the UPS pathway, misfolded protein substrates 
are tagged with K48-linked polyubiquitin chains and targeted to the proteasome for 
degradation. The signal for degradation by macroautophagy is not known, but in vitro 
evidence suggests that K63-linked polyubiquitination leads to aggresome formation and 
subsequent degradation of misfolded proteins by autophagy. The process of 
macroautophagy involves the expansion of a phagophore or isolation membrane that 
surrounds a portion of the cytoplasm. The phagophore seals and matures to form an 
autophagosome, which in mammals joins with late endosomes and multivesicular bodies 
(MVBs) to form a new structure termed an amphisome. Amphisomes then fuse with 
lysosomes to deliver their cargo for lysosomal degradation. 
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Abstract 
Protein degradation is an essential cellular function that, when dysregulated or impaired, 
can lead to a wide variety of disease states. The two major intracellular protein 
degradation systems are the ubiquitin-proteasome system (UPS) and autophagy, a 
catabolic process that involves delivery of cellular components to the lysosome for 
degradation. While the UPS has garnered much attention as it relates to 
neurodegenerative disease, important links between autophagy and neurodegeneration 
have also become evident. Furthermore, recent studies have revealed interaction between 
the UPS and autophagy, suggesting a coordinated and complementary relationship 
between these degradation systems that becomes critical in times of cellular stress. Here 
we describe autophagy and review evidence implicating this system as an important 
player in the pathogenesis of neurodegenerative disease. We discuss the role of 
autophagy in neurodegeneration and review its neuroprotective functions as revealed by 
experimental manipulation in disease models. Finally, we explore potential parallels and 
connections between autophagy and the UPS, highlighting their collaborative roles in 
protecting against neurodegenerative disease.  
 
A precarious balance 
The energy expenditure needed to produce protein is substantial; thus, the degradation of 
these macromolecules comes at a high cost. Nevertheless, protein turnover is essential for 
removing defective proteins and for contributing to the pool of amino acids required for 
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continued protein synthesis, particularly in times of limited nutrient availability. 
Furthermore, many essential cellular functions – including cell division, transcription, 
and signal transduction – are regulated by fluctuation in protein levels accomplished by 
altering the balance of protein synthesis and degradation. The role of protein catabolism 
in protecting cells from defective, misfolded proteins has been the subject of increased 
attention as its relevance to human disease has become apparent. A substantial fraction of 
newly synthesized proteins are translated incorrectly or fold incorrectly due to errors in 
synthesis or genetic mutations (Wheatley and Inglis, 1980; Schubert et al., 2000; Vabulas 
and Hartl, 2005; Yewdell, 2005). Oxidative or nitrosylative damage adds to the burden of 
defective proteins. Efficient degradation of these proteins is essential, as cells cannot risk 
the long-term accumulation of proteins that engage in aberrant protein-protein 
interactions, form insoluble aggregates, or acquire other toxic properties. Considering the 
importance of protein catabolism in maintaining cell homeostasis, it is not surprising that 
dysregulation of protein turnover is associated with myriad disease states such as cancer 
and neurodegeneration (Kundu and Thompson, 2008). 
 
Two major pathways accomplish regulated protein catabolism: the ubiquitin-proteasome 
system (UPS) and the autophagy-lysosomal system. The UPS serves as the primary route 
for degradation for thousands of short-lived proteins and provides the exquisite 
specificity and temporal control needed for fine-tuning the steady-state levels of many 
regulatory proteins (Ciechanover et al., 2000). UPS-mediated catabolism is also essential 
to maintain amino acid pools in acute starvation and contributes significantly to the 
degradation of defective proteins (Wheatley and Inglis, 1980; Ciechanover and Brundin, 
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2003; Vabulas and Hartl, 2005). Autophagy, by contrast, is primarily responsible for 
degrading long-lived proteins and maintaining amino acid pools in the setting of chronic 
starvation, although its contribution to the degradation of defective proteins may equal 
that of the UPS. Though it has received less attention than the UPS historically, 
breakthroughs in the molecular genetics of autophagy have led to a renaissance of interest 
in this catabolic pathway and has revealed many surprising insights about its regulation, 
function, and contribution to protein degradation, in both normal and disease states. This 
review will (1) highlight the parallels between the UPS and autophagy in their roles and 
regulation, (2) explore the role of autophagy in neurodegeneration, noting parallels with 
the UPS, and (3) discuss emerging evidence of a functional relationship between the UPS 
and autophagy and its relevance to neurodegeneration.  
 
The basics: roles and regulation  
“Autophagy”, literally “self-eating”, describes a catabolic process in which cell 
constituents such as organelles and proteins are delivered to the lysosomal compartment 
for degradation. Autophagy is an evolutionarily conserved process whose primary task in 
lower organisms is the maintenance of metabolic homeostasis in the face of changing 
nutrient availability (Abeliovich and Klionsky, 2001). This role in recycling is 
complementary to that of the UPS, which degrades proteins to generate oligopeptides that 
are subsequently degraded into amino acids while replenishing the cell’s supply of free 
ubiquitin. Recent advances have demonstrated that autophagy also serves a surprisingly 
diverse array of additional functions, including organelle clearance, antigen presentation, 
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elimination of microbes, as well as regulation of development and cell death (Mizushima, 
2005). Traditionally, autophagy has been considered a less selective degradative pathway 
than the UPS and is frequently illustrated as the engulfment of large portions of 
cytoplasm (including nearby cytosolic bystanders) and delivery of the contents to the 
lysosome in bulk. This view of autophagy as a crude, nonselective form of catabolism has 
been challenged by the appreciation of specialized forms of autophagy that are 
distinguished by the identity of the substrates and the route by which these substrates 
reach the lysosomal compartment (Figure A3.1). Microautophagy consists of direct 
engulfment of small volumes of cytosol by lysosomes (Ahlberg et al., 1982), whereas 
chaperone-mediated autophagy (CMA) involves selective, receptor-mediated 
translocation of proteins into the lysosomal lumen (Dice, 1990). These processes are 
distinguished from macroautophagy, in which an isolation membrane expands to engulf a 
portion of the cell, eventually fusing to form a new autophagic vacuole that subsequently 
fuses with a lysosome (Arstila and Trump, 1968). Even within the category of 
macroautophagy, there appears to be capability for selectivity, as autophagic processes 
have been observed that appear to be specific for mitochondria (mitophagy), portions of 
the nucleus (nucleophagy), peroxisomes (pexophagy), endoplasmic reticulum 
(reticulophagy), microorganisms (xenophagy), ribosomes (ribophagy) or protein 
aggregates (aggrephagy) (reviewed in (Kundu and Thompson, 2008)). 
While the molecular regulation of microautophagy remains obscure, there has been 
substantial insight into the regulation of CMA and macroautophagy. CMA is a process in 
which proteins harboring a pentapeptide motif related to the sequence KFERQ are 
specifically recognized by a cytosolic chaperone, the heat shock cognate protein of 70 
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kDa (hsc70). The substrate-chaperone complex is then targeted to the lysosome by 
binding to lysosome-associated membrane protein 2A (LAMP-2A) which carries out 
receptor-mediated translocation of the substrate into the lysosome for degradation (Dice, 
1990; Cuervo and Dice, 1996). Up to 30% of all cytosolic proteins harbor the CMA 
recognition motif and are potentially subject to degradation by this catabolic pathway 
during long-term nutrient deprivation (Dice, 1990, 2007). 
 
While it remains unclear how substrates are specifically marked for degradation by 
macroautophagy (hereafter referred to as autophagy), the identification of a family of 
autophagy-related (Atg) genes in yeast and their homologues in higher organisms has 
permitted minute dissection of the general process by which autophagy engulfs and 
degrades its targets. The initial step in autophagy involves expansion of a membranous 
structure called the “isolation membrane” or “phagophore” that engulfs a portion of the 
cell; the membrane eventually fuses to form a new double-membraned structure known 
as an autophagosome (Figure A3.1). The process of autophagy is controlled by parallel 
activation cascades that involve ubiquitin-like (UBL) protein modification, strikingly 
similar to the activation cascade that regulates the UPS (Figure A3.2a). In the first arm of 
the Atg conjugation system, phagophore membrane elongation is triggered through the 
sequential action of an E1-like protein (Atg7) and an E2-like protein (Atg10) leading to 
an isopeptide linkage between the C-terminal glycine in the UBL protein Atg12 and a 
lysine residue of Atg5 (Figure A3.2b). These Atg12-Atg5 conjugates are further cross-
linked to Atg16 to form a large (~350 kDa) multimeric complex, which has been thought 
to act as a structural support for membrane expansion (Reggiori and Klionsky, 2005). 
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More recent work has demonstrated that the Atg12-Atg5 conjugate can function as an 
E3-like enzyme in the second arm of the Atg conjugation cascade to promote lipidation 
of Atg8 (Hanada et al., 2007). In a second arm of the Atg conjugation system, Atg4 
cleaves the UBL protein Atg8 to promote interaction with Atg7. Atg8 is then conjugated 
with the phospholipid phosphotidylethanolamine (PE) by the concerted action of the E2-
like Atg3 and the E3-like Atg12-Atg5 conjugate. Of note, this E3-like activity results in a 
protein-lipid conjugation, in contrast to the classical E3 protein-protein conjugation of the 
UPS. As PE is a component of the autophagosomal membrane, the lipidation reaction 
results in studding of the inner and outer membranes of autophagosomes with Atg8 
(Figure A3.2c).  
 
Once formed, new autophagosomes move through a stepwise maturation process that 
culminates with fusion to a lysosome permitting degradation of the lumenal contents. In 
mammals, autophagosomes first fuse with endosomes and multivesicular bodies to form 
amphisomes, which subsequently fuse with lysosomes to create degradative vacuoles 
termed autolysosomes (Berg et al., 1998). Autophagosomes and autolysosomes can be 
distinguished morphologically, as autophagosomes contain contents with densities 
similar to cytosol, while autolysosomes appear as electron-dense material with a hollow 
rim beneath the limiting membrane. However, because of occasional ambiguity in 
distinguishing autophagosomes, amphisomes, and autolysosomes morphologically, the 
term “autophagic vacuole” frequently appears in the literature to refer to all three 
structures.  
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Four metazoan homologs of Atg8 have been identified: MAP-LC3 (microtubule-
associated protein light chain 3), GABARAP (γ-aminobutyric-acid-type-A-receptor-
associated protein), GATE-16 (Golgi-associated ATPase enhancer of 16 kDa), and 
Atg8L, although GABARAP, GATE-16, and Atg8L have not been extensively 
characterized. While GABARAP and GATE-16 may also be conjugated to PE in 
experimental systems, at present MAP-LC3 (typically abbreviated LC3) is the only 
protein that is known to remain associated with the autophagosome in higher eukaryotes. 
Pro-LC3 is cleaved co-translationally to create a form of LC3 denoted “LC3-I”. LC3-I 
becomes conjugated to PE to form “LC3-II” and thereby covalently associates with the 
phagophore. Consequently, the generation and turnover of LC3-II is used as an index of 
autophagy induction and/or flux (Klionsky et al., 2008). LC3-II staining is also used as a 
primary histological marker of autophagosomes. Because LC3-II remains on the inner 
membrane of autophagosomes until lysosomal enzymes degrade it, increased steady-state 
levels of LC3-II may be due to induction of autophagosome formation, a blockade in 
their maturation, or both. Distinguishing between these possibilities for experimental 
purposes is readily accomplished with the use of chemical inhibitors of maturation 
(Klionsky et al., 2008). 
 
A role for autophagy in neurodegeneration 
Many neurodegenerative diseases are characterized by accumulation of misfolded protein 
deposits in affected brain regions, suggesting a failure in the cell’s degradative capacity 
(Taylor et al., 2002). Neurons, as highly metabolically active, post-mitotic cells, are 
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especially vulnerable to the accumulation of defective proteins, and this may account for 
the frequency with which conformational diseases affect the nervous system. In most 
cases, these proteinaceous deposits are composed of ubiquitin conjugates, suggesting a 
failure in the clearance of proteins targeted for proteasomal degradation. Indeed, 
experimental evidence indicates that neurodegeneration is frequently associated with 
impaired UPS function, although whether this is a cause or consequence of 
neurodegeneration is a contested issue, as is reviewed elsewhere in this special issue. It 
has also been suggested that autophagy plays a role in the initiation or progression of 
some neurodegenerative diseases (McCray and Taylor, 2008). This suggestion originates 
from the observed accumulation of autophagic vacuoles in neurons from affected brain 
regions in a number of neurodegenerative diseases, including Alzheimer’s disease, 
Parkinson’s disease, Creutzfeldt-Jakob disease, and many of the polyglutamine diseases 
(Anglade et al., 1997; Sapp et al., 1997; Sikorska et al., 2004; Nixon et al., 2005). This 
notion has since been validated by experimental evidence and insights provided by 
human genetics, as described below. 
 
Neurodegeneration is frequently characterized by increased frequency of 
autophagic vacuoles 
Huntington’s and Alzheimer’s diseases are among the best-studied examples where 
histopathology implicates autophagy as playing a role in disease pathogenesis. 
Alzheimer’s disease pathology features massive accumulation of autophagic vacuoles 
within large swellings along dystrophic and degenerating neurites in neocortical and 
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hippocampal pyramidal neurons (Nixon et al., 2005). In Huntington’s disease, affected 
neurons show accumulation of huntingtin in cathepsin D-positive vacuoles (Sapp et al., 
1997). Cathepsin D is a lysosomal protease enriched in neuronal tissues, suggesting that 
these are autolysosomes. However, the observed increased frequency of autophagic 
vacuoles in disease brain is ambiguous with respect to whether autophagy is induced or 
whether autophagy flux is impaired. Furthermore, autophagosomes are frequently 
observed in dying neurons, where it is unclear whether autophagy is operating as a futile 
cytoprotective response, whether autophagy mediates cell death, or whether it is induced 
secondarily in a cell already otherwise committed to dying. Insight into the role of 
autophagy in neurodegeneration has been provided by studies indicating that: 1) some 
neurodegenerative disease-related proteins are degraded by autophagy, 2) impairment of 
autophagy promotes neurodegeneration in animal models and several human 
neurodegenerative diseases, and 3) manipulation of autophagy modifies phenotypes in 
animal models of neurodegeneration. 
 
Neurodegenerative disease-related proteins are degraded by autophagy 
That neurodegenerative disease-causing proteins are frequently degraded by autophagy 
was demonstrated by a series of in vitro studies which showed that pharmacological 
induction or inhibition of macroautophagy alters the rate of turnover of a number of 
disease-related proteins including polyglutamine-expanded proteins, polyalanine-
expanded proteins, as well as wild type and mutant forms of α-synuclein (Ravikumar et 
al., 2002; Webb et al., 2003). Moreover, ultrastructural analysis by immuno-electron 
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microscopy showed that in cell culture models, disease-related proteins are delivered to 
autophagic vacuoles (Kegel et al., 2000; Taylor et al., 2003b). CMA has also been found 
to contribute to the degradation of α-synuclein (Cuervo et al., 2004). Collectively, these 
studies suggested that autophagy contributes to the degradation of multiple disease 
proteins and the efficiency of this pathway could relate to the onset or progression of 
disease. Of note, there is evidence that many of these same disease-causing proteins are 
also degraded by the UPS (Bennett et al., 1999; Cummings et al., 1999; Martin-Aparicio 
et al., 2001), suggesting that more than one degradative route may be available to them. 
In the case of α-synuclein, for example, Webb et al. concluded that soluble forms of the 
disease protein are efficiently degraded by the UPS, while aggregated or oligomeric α-
synuclein require autophagy for clearance (Webb et al., 2003). These observations have 
led to the suggestion that autophagy provides an alternate, compensatory route of 
degradation when clearance by the UPS and CMA are compromised. The relative 
contribution of autophagy and the UPS to degrading disease-related substrates, and the 
relationship of this to the onset and progression of various diseases, remains to be 
elucidated – and this may differ amongst different diseases. 
   
Impairment of autophagy promotes neurodegeneration 
It is becoming increasingly evident that the autophagy-lysosomal system is essential to 
neuronal homeostasis, and may in some settings be neuroprotective. The consequences of 
impaired lysosome function, for example, may be observed in cathepsin D knockout mice 
and Drosophila melanogaster cathepsin D mutants which show neurodegeneration and 
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associated accumulation of autophagosomes and lysosomes (Koike et al., 2000; 
Myllykangas et al., 2005; Shacka et al., 2007). The importance of autophagy to neuronal 
homeostasis is further illustrated by characterization of mice with conditional knockout 
of Atg genes. These mice die prematurely with extensive neurodegeneration and 
ubiquitin-positive pathology (Hara et al., 2006; Komatsu et al., 2006). On the basis of 
these observations one might predict that impairment of autophagy could contribute to 
neurodegenerative disease in humans. Indeed, primary lysosomal dysfunction in inherited 
congenital "lysosomal storage disorders” has long been recognized to cause severe 
neurodegenerative phenotypes characterized pathologically by accumulations of 
lysosomes and autophagic vacuoles (Nixon et al., 2008). For example, the neuronal 
ceroid lipofuscinoses (NCLs) are a heterogeneous group of inherited, neurodegenerative 
disorders with onset ranging from infancy to late adulthood that are caused by a variety 
of defects in lysosomal function. Furthermore, a growing list of adult-onset, familial 
neurological diseases have been linked to mutations expected to have an impact on 
autophagy-lysosomal function (reviewed in (Nixon et al., 2008)), including Kufor-Rakeb 
syndrome (a form of early-onset parkinsonism with dementia) (Ning et al., 2008), 
Charcot-Marie-Tooth type 2B (CMT2B) (Verhoeven et al., 2003), and distal-spinobulbar 
muscular atrophy (distal-SBMA) (Puls et al., 2005). Mutations in CLN3, a 
transmembrane protein that localizes to the late endosomal/lysosomal membrane, cause a 
form of NCL. CLN3-related neurodegeneration appears to be a consequence of reduced 
autophagosome-lysosome fusion (Cao et al., 2006). Mutations in ATP13A2, which 
encodes a primarily neuronal lysosomal ATPase, were recently found to cause Kufor-
Rakeb syndrome (previously designated PARK9). Disease-causing mutations in 
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ATP13A2 result in protein retention in the endoplasmic reticulum and enhanced 
proteasomal degradation, suggesting that neurodegeneration could be caused by 
overwhelming the UPS and/or loss of function in lysosomal protein degradation (Ning et 
al., 2008). Mutations in Rab7 cause the dominantly inherited axonal neuropathy CMT2B. 
Rab7 participates in trafficking autophagosomes and fusion with lysosomes and disease-
causing mutations are predicted to impair this process (Gutierrez et al., 2004; Jager et al., 
2004; Kimura et al., 2007). Mutations in p150/dynactin are responsible for the motor 
neuron disease distal-SBMA. Microtubule-based vesicular trafficking is essential for 
delivery of autophagosomes to lysosomes and subsequent fusion (Kimura et al., 2008), 
and impaired dynein-mediated trafficking is associated with impaired 
autophagosome/lysosome fusion and reduced protein turnover (Ravikumar et al., 2004; 
Fader et al., 2008). Thus, motor neuron loss in distal-SBMA may result from impaired 
autophagosome trafficking and/or fusion with lysosomes. Indeed, a mouse model of 
distal-SBMA that expresses mutant p150/dynactin is characterized by accumulation of 
ubiquitin-positive aggregates and autophagic vacuoles in affected neurons (Laird et al., 
2008).  
 
Manipulation of autophagy modifies neurodegenerative phenotypes in animal 
models 
While deficiency in autophagy results in neurodegeneration, a separate question concerns 
the role of autophagy in the context of diseases initiated by mutations in genes unrelated 
to autophagic function. To investigate this perspective, researchers have turned to animal 
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models of common neurodegenerative diseases that are amenable to genetic and 
pharmacological manipulation of autophagy. These studies have largely shown that 
reduced autophagy worsens disease phenotypes whereas augmented autophagy provides 
benefit, leading to the conclusion that autophagy is cytoprotective. For example, in a 
Drosophila model of X-linked spinobulbar muscular atrophy (SBMA), a polyglutamine 
disease, degeneration was strongly enhanced by genetic inhibition of autophagy (Pandey 
et al., 2007b). Similarly, in transgenic mice expressing amyloid precursor protein, a 
model of Alzheimer’s disease, genetic inhibition of autophagy by heterozygous depletion 
of beclin-1 results in enhancement of neurodegeneration (Pickford et al., 2008). In both 
of these studies it was determined that autophagy deficiency resulted in greater 
accumulation of the offending, disease-related protein (Pandey et al., 2007b; Pickford et 
al., 2008), suggesting that autophagy was needed to degrade cytotoxic proteins. This 
provided the rationale for investigating whether increasing autophagic activity might 
provide benefit. Pharmacological upregulation of autophagy can be accomplished using 
the drug rapamycin, which works by inhibiting TOR (target of rapamycin), a pleiotropic 
molecule that negatively regulates autophagy, among other functions. Indeed, treatment 
with rapamycin ameliorates the degenerative phenotype in a Drosophila model of 
SBMA, as well as in Drosophila and mouse models of Huntington’s disease (Ravikumar 
et al., 2004; Berger et al., 2006; Pandey et al., 2007b). In addition, inducing autophagy in 
an TOR-independent manner using lithium (Sarkar et al., 2008b) or trehalose (Tanaka et 
al., 2004; Davies et al., 2006; Sarkar et al., 2007) has been shown to accelerate clearance 
of disease proteins in vitro (Sarkar et al., 2007) and protect against neurodegeneration in 
mouse and Drosophila models of Huntington’s disease (Tanaka et al., 2004; Sarkar et al., 
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2008b). These exciting results have opened the door to the possibility that 
pharmacological upregulation of autophagy by rapamycin, lithium, trehalose, or a newer 
generation of small molecules might be of therapeutic benefit for patients with 
neurodegenerative disease. Recently, high throughput screening efforts have identified 
small molecule activators of autophagy. Some of these compounds inhibit TOR and 
activate autophagy in a manner analogous to rapamycin, but other compounds are TOR-
independent and reflect multiple points of potential therapeutic intervention (Sarkar et al., 
2008a). There have been fewer efforts to manipulate UPS function for therapeutic benefit 
in neurodegenerative disease, but it was recently shown that use of a proteasome activator 
enhanced survival in an in vitro model of Huntington’s disease (Seo et al., 2007), 
suggesting that augmenting other routes of protein degradation may also provide 
neuroprotection.  
 
However, it should be pointed out that the relationship of autophagy to the accumulation 
of disease protein may not always be straightforward. There is evidence that in some 
cases cellular attempts to degrade cytotoxic protein aggregates interfere with normal 
autophagy function leading to lysosomal “indigestion” that ultimately compromises cell 
function or viability. For example, α-synuclein is degraded at least in part by CMA 
(Cuervo et al., 2004). Mutations in α-synuclein that are causative of familial Parkinson’s 
disease are poorly transferred to the lysosomal lumen and accumulate on the lysosomal 
surface, resulting in blockade of receptor-mediated translocation. This results in 
disrupting degradation of other CMA substrates (Cuervo et al., 2004; Massey et al., 
2006).  With respect to Alzheimer’s disease, an even more complex story is emerging. 
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Several lines of evidence suggest that there is an impairment of autophagy resulting from 
impaired autophagosome-lysosome fusion combined with decreasing efficiency of the 
lysosomal system (Nixon, 2007). These vacuoles may further contribute to pathogenesis 
by interfering with normal intracellular trafficking and/or by leaking undigested toxic 
contents into the cytosol, or more generally by disrupting normal metabolic turnover 
required for neuronal homeostasis. Recent evidence suggests that the autophagic turnover 
of amyloid beta precursor protein (APP) may underlie the generation of toxic amyloid-β 
species (Yu et al., 2005).Thus, the relationship of autophagy to Alzheimer’s disease 
progression is complex, with autophagy-related production of toxic amyloid-β that 
culminates in impaired autophagy and exacerbation of disease.  
 
Links between UPS and autophagy 
The UPS and autophagy were long viewed as independent, parallel degradation systems 
with no point of intersection. This view was initially challenged by the observation that 
monoubiquitination operates as a key signal in endocytosis, a process important for 
numerous cell functions including lysosomal biogenesis (Ross and Pickart, 2004). 
Subsequently, several lines of evidence have developed suggesting that the UPS and 
autophagy are functionally interrelated catabolic processes (Rideout et al., 2004; Iwata et 
al., 2005a; Pandey et al., 2007b). Specifically, these degradation systems share certain 
substrates and regulatory molecules, and show coordinated and, in some contexts, 
compensatory function. Thus, in contrast to the traditional notion of the UPS and 
autophagy providing discrete routes of degradation for short-lived and long-lived 
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proteins, respectively, it is increasingly clear that a substantial subset of proteins may be 
degraded by either pathway. Short-lived proteins normally degraded by the UPS can be 
selectively degraded by autophagy under certain conditions (Fuertes et al., 2003a; Li, 
2006), while longer-lived proteins can also be degraded by the UPS (Fuertes et al., 
2003b). The neuronal protein α-synuclein, for example, can be degraded by the UPS, 
macroautophagy and chaperone-mediated autophagy (Webb et al., 2003; Cuervo et al., 
2004). Under conditions in which one degradation system is compromised, enhanced 
degradation by an alternate pathway may become critical to maintaining pools of amino 
acids for protein synthesis and may protect against the accumulation of a toxic species. 
As mentioned above, dramatic illustration of the interrelatedness of the UPS and 
autophagy was provided by characterizations of mice with conditional knockout of the 
essential autophagy genes Atg5 or Atg7 in the central nervous system, which resulted in 
neurodegeneration with accumulation of ubiquitin-positive pathology (Hara et al., 2006; 
Komatsu et al., 2006). Given that these mice showed no observable defect in UPS 
function, these results suggest that some ubiquitin-tagged proteins may in fact normally 
be degraded by autophagy. This model is consistent with an older study showing that 
inactivation of the ubiquitin-activating enzyme E1 leads to a defect in autolysosomal 
degradation and to an absence of ubiquitin-positive proteins within lysosomes (Lenk et 
al., 1992).  
Further illustration of the relationship between the UPS and autophagy can be found in a 
series of in vitro studies that examined the behavior of cells following challenge to the 
UPS. When cultured cells are challenged with excess misfolded protein that overwhelms 
the UPS, or treated with proteasome inhibitors, ubiquitinated misfolded proteins are 
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actively transported to a cytoplasmic, juxtanuclear structure that has been termed an 
“aggresome” (Johnston et al., 1998). It has been inferred that aggresome formation in 
vitro is a cytoprotective response in cultured cells since their formation correlates 
inversely with cell death, whereas interventions that block aggresome formation enhance 
cytotoxicity and slow the rate of turnover of misfolded proteins (Kawaguchi et al., 2003; 
Taylor et al., 2003b; Arrasate et al., 2004; Iwata et al., 2005a; Yamamoto et al., 2006). 
While aggresomes superficially resemble the cytoplasmic inclusions present in some 
neurodegenerative diseases, evidence of aggresome formation in vivo is lacking, and 
most pathological inclusions found in neurodegenerative disease are clearly not 
aggresomes. Nevertheless, studying the phenomenon of aggresome formation in vitro has 
provided insight into the cellular management of misfolded proteins; for example, 
helping to identify molecular machinery that protects cells from misfolded protein stress. 
It has now been established that clearance of misfolded proteins from aggresomes is 
mediated at least in part by autophagy, implicating this pathway as a compensatory 
mechanism for degrading misfolded proteins when the proteasome is impaired (Taylor et 
al., 2003b; Iwata et al., 2005b; Iwata et al., 2005a; Yamamoto et al., 2006). 
 
In addition to aggresome formation, impairment of the UPS in vitro has been found to 
induce autophagy (Rideout et al., 2004; Iwata et al., 2005a). This is observed, for 
example, in HeLa cells after prolonged proteasomal inhibition as evidenced by 
redistribution of LC3 into numerous puncta (Figure A3.3a-c) and the accumulation of 
autophagic vacuoles based upon ultrastructural evaluation (Figure A3.3d-g). Similar 
induction of autophagy is observed in response to genetic impairment of the proteasome 
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in Drosophila (Pandey et al., 2007b). The role of autophagy induction in the setting of 
UPS impairment appears to be cytoprotective since degenerative phenotypes associated 
with proteasome impairment are enhanced in an autophagy-deficient background (Figure 
A3.4a-c), whereas this degeneration is suppressed when autophagy is induced with the 
TOR-inhibitor rapamycin (Figure A3.3d). Similar results have recently been observed in 
vitro using the proteasome inhibitor lactacystin, as pre-treatment with rapamycin 
attenuates lactacystin-induced apoptosis and reduces lactacystin- induced ubiquitinated 
protein aggregation (Pan et al., 2008). 
 
Although the mechanism whereby autophagy and UPS function are coordinated is little 
understood, several regulators have emerged as important players in mediating this 
crosstalk, including histone deacetylase 6 (HDAC6) (Iwata et al., 2005a; Pandey et al., 
2007a; Pandey et al., 2007b), p62/sequestosome 1 (p62) (Bjorkoy et al., 2005), and the 
FYVE-domain containing protein Alfy (Simonsen et al., 2004); notably, these proteins 
have all been found to regulate or be essential for aggresome formation. HDAC6 is a 
cytoplasmic microtubule-associated deacetylase whose targets include α-tubulin, Hsp90, 
and cortactin. HDAC6 interacts with polyubiquitinated proteins through a highly 
conserved Zn-finger ubiquitin-binding domain, and also interacts with dynein motors, 
suggesting that the molecule may provide a physical link between ubiquitinated cargo 
and transport machinery (Kawaguchi et al., 2003). HDAC6 activity appears to be 
important for trafficking ubiquitinated proteins and lysosomes in vitro and this has led to 
the suggestion that HDAC6 coordinates delivery of substrates to autophagic machinery 
(Kawaguchi et al., 2003; Kopito, 2003; Iwata et al., 2005a). In Drosophila, HDAC6 
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overexpression was found to suppress degeneration associated with impaired UPS 
activity and also suppressed degeneration caused by toxic polyglutamine expression. In 
both cases, this rescue by HDAC6 was found to be autophagy dependent, consistent with 
a role for HDAC6 in linking the UPS and compensatory autophagy (Pandey et al., 
2007b). HDAC6 activity was also reported to regulate chaperone expression in response 
to heat shock by deacetylating Hsp90 leading to release and activation of the transcription 
factor HSF-1 (Boyault et al., 2007). 
 
p62 is another cytosolic protein whose structure suggests a function as an adaptor 
molecule linking ubiquitinated proteins to autophagic machinery. The C-terminal portion 
of p62 harbors both a ubiquitin-associated (UBA) domain which interacts non-covalently 
with ubiquitinated proteins (Geetha and Wooten, 2002; Seibenhener et al., 2004) as well 
as an LC3- interacting region (LIR) (Pankiv et al., 2007). Cellular stresses such as 
polyglutamine expression, proteasome impairment, oxidative stress, and increased 
misfolded protein burden activate transcription and translation of p62, suggesting that it 
functions broadly in stress situations (Kuusisto et al., 2001b; Nagaoka et al., 2004). p62 
localizes to a variety of ubiquitin-positive neuropathological inclusions including Lewy 
bodies in Parkinson’s disease, neurofibrillary tangles in tauopathies, polyglutamine-
expanded huntingtin aggregates in Huntington’s disease, and aggregates of mutant SOD1 
in familial amyotrophic lateral sclerosis (Kuusisto et al., 2001a, 2002; Zatloukal et al., 
2002). A role for p62 in protecting against misfolded protein stress is supported by the 
observation that RNAi-mediated knockdown of p62 exacerbates polyglutamine toxicity 
in vitro and diminishes the formation of ubiquitin-positive inclusions in response to 
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misfolded protein stress (Bjorkoy et al., 2005) while reducing the ability of LC3 to co-
precipitate ubiquitinated proteins (Pankiv et al., 2007). Very recently, p62 was found to 
contain an LC3 recognition sequence that, when mutated, resulted in ubiquitin- and p62- 
positive inclusion formation (Ichimura et al., 2008). Thus, it has been suggested that p62 
provides a key link between autophagy and the UPS by facilitating autophagic 
degradation of ubiquitinated proteins. As predicted by this model, p62 null mice fail to 
form ubiquitin-positive protein aggregates in response to misfolded protein stress 
(Komatsu et al., 2007) and show age-related neurodegeneration (Ramesh Babu et al., 
2008). Consistent results were obtained in studies of Drosophila deficient in Ref(2)p, the 
Drosophila homologue of p62 (Nezis et al., 2008). Recent models propose that p62 and 
HDAC6 function analogously to facilitate autophagic degradation of proteins that display 
specific polyubiquitin topology. Specifically, it is suggested that K63-linked 
polyubiquitin chains recruit p62 and HDAC6 providing a signal for autophagic 
degradation (Olzmann et al., 2007; Tan et al., 2007). 
 
Alfy (autophagy-linked FYVE protein) is a third possible molecular link between 
autophagy and the UPS. Alfy is a member of the FYVE-domain family of proteins. In 
cells that are exposed to stressors such as starvation or UPS inhibition, Alfy relocalizes 
from the nuclear envelope to filamentous cytoplasmic structures that are near autophagic 
membranes and ubiquitinated protein inclusions, as well as within autophagosomes 
(Simonsen et al., 2004). Mutations in blue cheese, the Drosophila homology of human 
Alfy, lead to reduced longevity and the accumulation of ubiquitinated neural aggregates, 
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suggesting that its role in autophagic degradation may be involved in the clearance of 
ubiquitin aggregates (Finley et al., 2003; Simonsen et al., 2004).  
 
Summary and unresolved questions 
The last few years have led to substantial insight into the relationship between autophagy 
and the UPS. It has become apparent that there is significant similarity, and in some cases 
overlap, in the regulation of these catabolic pathways by UBL modification,  leading to 
the suggestion that they evolved from  a common biological origin (Hughes and Rusten, 
2007). Further, it has become evident that the function of autophagy and the UPS are 
coordinated. For example, impairment of the UPS results in upregulation of autophagy 
((Iwata et al., 2005a; Pandey et al., 2007b) and Figure A3.3), and in some contexts this 
upregulation of autophagy can compensate for impaired UPS function (Pandey et al., 
2007b). However, it is not known whether this compensatory relationship is reciprocal, as 
few reagents exist to upregulate the UPS. One study found that upregulation of UPS may 
afford neuroprotection from toxicity caused by disease proteins, though the authors did 
not examine the effects of UPS upregulation in autophagy-deficient cells (Seo et al., 
2007). The mechanism and the molecular players that regulate the relationship between 
autophagy and the UPS are beginning to be elucidated and, perhaps not surprisingly, 
recognition of UBL modification is emerging as a consistent theme.   
 
CMA is also clearly involved in the coordinated functioning of proteolytic pathways. 
CMA can selectively degrade some subunits of the proteasome, highlighting a 
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relationship between CMA and the UPS (Cuervo et al., 1995). In addition, acute blockage 
of CMA results in short-term impairment of both the UPS and macroautophagy, followed 
by a recovery of these catabolic systems as CMA blockade persists (Massey et al., 2008). 
Chronic blockage of CMA results in constitutive activation of macroautophagy, which 
appears to be compensatory (Massey et al., 2006). These interrelationships suggest a 
model in which the preferred route of degradation for a particular substrate may be linked 
to which system is most capable of efficiently degrading it.  
 
While much has been revealed in recent years, substantial questions remain. Most 
notable, it is largely unknown how the decision is made between degradative routes for 
any particular protein substrate when more than one pathway is available. HDAC6, p62, 
and Alfy have been implicated in directing ubiquitinated proteins for autophagic 
degradation, but the mechanisms whereby these proteins identify their targets and 
influence their degradation are still unknown. Tantalizing recent evidence suggests that 
different classes of substrates may be identified by polyubiquitin chains of differing 
topology, providing the signal for degradation by one proteolytic system or the other 
(Lim et al., 2005; Olzmann et al., 2007). More specifically, it has been suggested that 
polyubiquitin chains with K48-linked chains are primarily degraded by the UPS, whereas 
those with K63-linked chains are directed to autophagy. Indeed, one might envision a 
“ubiquitin code” that translates into interaction with specific ubiquitin binding proteins, 
including HDAC6, Alfy, p62 or other members of the UBA family (Elsasser and Finley, 
2005), which may in turn determine the fate of the substrate. However, experimental 
limitations in distinguishing between K48-, K63- and mixed-linkage ubiquitin chains 
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must be overcome in order to answer this question effectively, and many of these 
relationships remain largely unexplored.  This concept of different classes of 
substrates that are destined for degradation by differing pathways is consistent with one 
recent report in which disease-associated proteins were found to partition into two 
distinct intracellular compartments, with soluble ubiquitinated proteins accumulating in a 
proteasome-rich juxtanuclear region, and insoluble aggregated proteins accumulating in 
perivacuolar inclusions that colocalize with Atg8 (Kaganovich et al., 2008). It would be 
interesting to determine whether these proteins could be distinguished by differing UBL 
modifications. 
 
The mechanism by which upregulation of autophagy mitigates neurotoxicity associated 
with UPS impairment is also unresolved. It is unlikely that autophagy is able to 
compensate for the role of the UPS in fine-tuning the steady-state levels of short-lived 
regulatory proteins. More likely, augmentation of autophagy is neuroprotective by 1) 
maintaining the overall rate of catabolism, “freeing” amino acids that would otherwise lie 
useless in aggregated, nonfunctioning proteins, 2) eliminating specific protein substrates 
that would otherwise accumulate, aggregate and acquire toxic properties, or 3) a 
combination of these. 
 
Further illumination of the relationship between the UPS, autophagy and the relationship 
to human disease is vitally important and could lead to harnessing intrinsic catabolic 
pathways for therapeutic benefit. 
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Figures and Legends 
Figure A3.1. The UPS and the autophagy-lysosomal systems are the two main 
protein degradation systems in the cell. 
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Figure A3.1.  The UPS and the autophagy-lysosomal systems are the two main 
protein degradation systems in the cell. Proteins that are tagged with polyubiquitin 
chains are generally considered to be substrates for the UPS, which feeds unfolded 
proteins through the barrel of the 26S proteasome and generates small digested peptides. 
Recent evidence suggests that some ubiquitinated substrates can also be degraded via the 
autophagy-lysosomal system. This system is comprised of (1) macroautophagy, in which 
cytosolic components are engulfed and delivered to the lysosome in bulk, (2) 
microautophagy, in which small volumes of cytosol are directly engulfed by lysosomes, 
and (3) chaperone-mediated autophagy (CMA), in which soluble substrates associated 
with a specific chaperone complex are translocated into the lysosome through the LAMP-
2A lysosomal receptor. Macroautophagy involves a series of maturation steps: first, a 
portion of cytoplasm is surrounded by an expanding isolation membrane or phagophore. 
The phagophore seals to form an autophagosome, which in mammals fuses with late 
endosomes and multivesicular bodies to form an amphisome. The amphisome then fuses 
with a lysosome to form an autolysosome, in which cytosolic cargo is degraded by 
lysosomal hydrolases. LC3-II is a protein that associates with the inner and outer surfaces 
of autophagic membranes and provides a histological marker of autophagic vacuoles. 
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Figure A3.2. Assembly and elongation of autophagic membranes are accomplished 
via sequential action of UPS-like E1-E2-E3 cascades.  
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Figure A3.2. Assembly and elongation of autophagic membranes are accomplished 
via sequential action of UPS-like E1-E2-E3 cascades. In each case, an E1 enzyme 
activates a ubiquitin-like protein (UBL) such as ubiquitin, Atg12, or Atg8. The UBL is 
then transferred to an E2 conjugating enzyme, followed by an association with an E3 
ligase that promotes association of the UBL and its target. (a) In the UPS, ubiquitination 
of substrates is accomplished by an E1-activating enzyme, E2-conjugating enzyme, and 
an E3-ligase. (b) In the first arm of the Atg conjugation pathway, Atg12 associates with 
the E1-like Atg7, is transferred to the E2-like Atg10, and is subsequently conjugated to 
Atg5. No E3-like protein has been identified in this pathway. (c) In the second arm of the 
Atg conjugation pathway, Atg8 associates with the E1-like Atg7, is transferred to the E2-
like Atg3, and is conjugated to PE via the E3-like action of the Atg12-Atg5 complex. 
Adapted from (Geng and Klionsky, 2008) with permission. 
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Figure A3.3. Proteasome impairment leads to upregulation of autophagic activity. 
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Figure A3.3. Proteasome impairment leads to upregulation of autophagic activity.  
(a) HeLa cells that stably express the UPS reporter UbG76V-GFP were treated with the 
irreversible proteasome inhibitor epoximicin for 72 hours and monitored for cell death. 
Increasing levels of the GFP substrate indicate impaired UPS function. Note the 24 hours 
time point used in (b)-(g) is within the window during which proteasome function is 
impaired, but the cells remain viable. (b-c) Images of LC3 staining (red) and DAPI (blue) 
show accumulation of LC3 puncta in epoximicin-treated cells. (d-e) Transmission 
electron microscopy images of cells reveal autophagic structures and prominent 
vacuolization in epoximicin-treated cells. (f-g) Increased magnification of structures in 
(e) reveal multi-membraned structures consistent with autophagic activity.  
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Figure A3.4 
 
 
Figure A3.4.  A Drosophila model of proteasome impairment is modified by 
manipulation of autophagic activity. (a-b) The temperature-sensitive DTS7 mutant 
shows a normal eye phenotype at the permissive temperature of 22°C and a significant 
degenerative phenotype at the restrictive temperature of 28°C. (c) RNAi knockdown of 
the autophagy gene atg12 results in an enhancement of the DTS7 degenerative 
phenotype, suggesting that the autophagic activity that is induced in response to 
proteasome impairment is compensatory. (d) Treatment of DTS7 flies with rapamycin 
suppresses the degenerative phenotype, demonstrating that induction of autophagy can 
compensate for impaired proteasome function. Adapted from (Pandey et al., 2007b). 
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Abstract 
 
A prominent feature of late-onset neurodegenerative diseases is accumulation of misfolded 
protein in vulnerable neurons (Taylor et al., 2002). When levels of misfolded protein overwhelm 
degradative pathways, the result is cellular toxicity and neurodegeneration (Trojanowski and 
Lee, 2000). Cellular mechanisms for degrading misfolded protein include the ubiquitin-
proteasome system (UPS), the major non-lysosomal degradative pathway for ubiquitinated 
proteins, and autophagy, a lysosome-mediated degradative pathway (Rubinsztein, 2006). The 
UPS and autophagy have long been viewed as complementary degradation systems with no point 
of intersection (Ciechanover et al., 1984; Pickart, 2004). This view was challenged by two 
observations suggesting an apparent interaction: impairment of the UPS induces autophagy in 
vitro, and conditional knockout of autophagy in the mouse brain leads to neurodegeneration with 
ubiquitin-positive pathology (Rideout et al., 2004; Iwata et al., 2005a; Hara et al., 2006; Komatsu 
et al., 2006). It is not known whether autophagy is strictly a parallel degradation system, or 
whether it is a compensatory degradation system when the UPS is impaired; furthermore, if there 
is a compensatory interaction between these systems, the molecular link is not known. Here we 
show that autophagy acts as a compensatory degradation system when the UPS is impaired, and 
that histone deacetylase 6 (HDAC6), a microtubule-associated deacetylase that interacts with 
polyubiquitinated proteins (Kawaguchi et al., 2003), is an essential mechanistic link in this 
compensatory interaction. We found that compensatory autophagy was induced in response to 
mutations affecting the proteasome and in response to UPS impairment in a fly model of the 
neurodegenerative disease spinobulbar muscular atrophy (SBMA). Autophagy compensated for 
impaired UPS function in an HDAC6-dependent manner. Furthermore, expression of HDAC6 
was sufficient to rescue degeneration associated with UPS dysfunction in vivo in an autophagy-
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dependent manner. These findings have implications regarding the pathogenesis of 
neurodegenerative proteopathies as well as potential interventions for these devastating diseases. 
 
Results and Discussion 
DTS7 is a temperature sensitive, dominant negative mutant of the β2 subunit of the 
proteasome (Smyth and Belote, 1999). Using the UAS/GAL4 system (Brand and 
Perrimon, 1993), we targeted DTS7 expression to the eye to cause tissue-restricted 
proteasome impairment. At 22oC, proteasome function is intact and eye morphology was 
normal (Figure A4.1a). However, at 28oC substantial degeneration of the retina occurred 
due to proteasome impairment (Figure A4.1b). To investigate the role of HDAC6 in the 
setting of misfolded protein stress, we generated transgenic flies expressing wild type 
Drosophila HDAC6 (dHDAC6) as well as wild type and mutant versions of human 
HDAC6 (hHDAC6). Expression of either dHDAC6 or hHDAC6 strongly suppressed the 
degenerative phenotype associated with proteasome impairment (Figure A4.1c-d). 
However, expression of a catalytically dead mutant of hHDAC6 (H216A;H611A) failed 
to modify the degenerative phenotype, indicating that the deacetylase function of HDAC6 
is required for suppression. To assess the role of endogenous HDAC6, we used RNAi 
knockdown (Supplemental Figure A4.3). Targeted knockdown of dHDAC6 did not 
noticeably alter eye morphology on its own (Supplemental Figure A4.4), but strongly 
enhanced degeneration when the proteasome was impaired (Supplemental Figure A4.5). 
HDAC6 did not modify the rough eye phenotype caused by ectopic expression of the 
positive regulator of cell death reaper, indicating that HDAC6 is not a general suppressor 
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of cell death pathways (Supplemental Figure A4.6). Ectopic expression of dHDAC3 and 
dHDAC11 did not suppress degeneration caused by proteasome impairment indicating 
that this is not a general response of HDACs (not shown). 
 
Impaired UPS function has been implicated in a broad array of neurodegenerative 
disorders, but in vivo evidence is lacking (Ciechanover and Brundin, 2003). SBMA is an 
inherited neurodegenerative disease that is caused by polyglutamine (polyQ) repeat 
expansion in the androgen receptor (AR) gene (La Spada et al., 1991). Like most adult-
onset neurodegenerative diseases, SBMA pathology features accumulation of ubiquitin-
positive protein aggregates in vulnerable neurons (Li et al., 1998). To develop a 
Drosophila model of SBMA, we generated transgenic flies expressing full-length human 
AR with 12-121 glutamine repeats using the UAS/GAL4 system. Flies expressing polyQ-
expanded AR recapitulate key features of human SBMA, including ligand-dependent, 
polyQ length-dependent degeneration (Figure A4.1f, g and Supplemental Figure A4.7), 
as previously reported (Takeyama et al., 2002). 
 
To evaluate UPS function in this fly model of SBMA, we generated transgenic flies 
expressing a fluorescent reporter of UPS function. CL1-GFP is a fusion protein created 
by introducing a degradation signal to otherwise stable green fluorescent protein (GFP) 
(Bence et al., 2001). This protein is rapidly degraded by the UPS and its steady state 
levels reflect the functional status of this pathway (Neefjes and Dantuma, 2004). When 
stable GFP was expressed in eye imaginal discs from third instar larvae, a robust 
fluorescent signal was detected by confocal microscopy (Figure A4.1k). In contrast, eye 
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imaginal discs from control flies expressing the CL1-GFP reporter emitted a low 
fluorescent signal reflecting an active UPS (Figure A4.1l). To test the ability of the UPS 
reporter flies to detect proteasome impairment in vivo, we co-expressed CL1-GFP in the 
eye with DTS7. At 22oC, CL1-GFP reporter levels remained low in eye imaginal discs 
co-expressing DTS7, consistent with normal proteasome function (Figure A4.1m). In 
contrast, at 28oC, there was a significant increase in the CL1-GFP signal, demonstrating 
the ability of the reporter to detect proteasome impairment associated with a degenerative 
phenotype in vivo (Figure A4.1n and Supplemental Figure A4.8). UPS reporter RNA 
levels were not altered by the conditions used in our experiments (Supplemental Figure 
A4.9).  
 
We next expressed the CL1-GFP reporter in SBMA flies. In AR121 flies not exposed to 
ligand, fluorescent signal from the UPS reporter remained low indicating that proteasome 
function was normal despite high expression of polyQ-expanded AR (Figure A4.1o). 
However, flies reared on DHT exhibited a significant increase in reporter signal, 
indicating proteasome impairment in association with induction of toxicity (Figure A4.1p 
and Supplemental Figure A4.8). The ligand-dependent nature of this finding indicates 
that UPS impairment is not merely a consequence of over-expressed AR121. Proteasome 
impairment by AR expression is a polyQ length-dependent phenomenon because no 
impairment was observed in flies expressing AR12 (Supplemental Figure A4.8).  The 
finding of proteasome impairment in SBMA flies is consistent with a prior report that 
polyQ toxicity in vivo is enhanced by proteasome mutations (Chan et al., 2002).  
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The determination that there is impairment of the UPS in SBMA flies led us to examine 
the ability of HDAC6 to modify the degenerative phenotype in this model of human 
neurodegenerative disease. Consistent with the results using proteasome mutant flies, 
ectopic expression of either dHDAC6 or hHDAC6 suppressed the ligand-dependent 
degenerative phenotype in flies expressing polyQ-expanded AR (Figure A4.1h, i). 
Expression of the catalytically dead mutant of hHDAC6 (H216A; H611A) failed to 
modify the degenerative phenotype, indicating that the deacetylase function of HDAC6 is 
also required for suppression of polyQ toxicity (Figure A4.1j). Knockdown of 
endogenous HDAC6 with RNAi enhanced ligand-dependent degeneration in AR52 flies 
(Supplemental Figure A4.5). Thus, endogenous HDAC6 also plays a role in protecting 
cells from polyQ toxicity. 
 
We previously reported induction of autophagy and sequestration of polyQ-expanded AR 
in autophagic vacuoles in vitro (Taylor et al., 2003b). Induction of autophagy in vitro in 
response to proteasome impairment has also been described (Rideout et al., 2004; Iwata 
et al., 2005a). To determine whether autophagy is induced in vivo when the UPS is 
impaired, we performed ultrastructural evaluation by transmission electron microscopy 
(TEM) in the DTS7 and SBMA flies. In both cases, we found a significant increase in 
morphological features of autophagy (Figure A4.2f). These included autophagic vacuoles 
(AVs) such as early autophagosomes in which membranes surrounded cytoplasmic 
components (Figure A4.2a, b), more mature AVs (Figure A4.2c), multilamellar bodies 
(MLBs, Figure A4.2d) and multivesicular bodies (MVBs, Figure A4.2e). 
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To assess the role of autophagy when the UPS is impaired, we inhibited autophagy by 
RNAi knockdown of the autophagy genes atg6 and atg12. Knockdown of either atg6 or 
atg12 did not affect eye morphology (Supplemental Figure A4.10), indicating that the 
Drosophila eye can tolerate reduced autophagy when UPS function is intact, at least in 1-
day-old flies. In contrast, knocking down either atg6 or atg12 strongly enhanced the 
rough eye phenotype associated with UPS impairment in DTS7 flies reared at 28oC 
(Figure A4.2g-i) and in AR52 flies reared on DHT (Figure A4.2j-l). From these data, we 
can infer that the autophagy induced by UPS impairment is compensatory. 
 
We hypothesized that ectopic expression of HDAC6 suppressed degeneration by 
promoting autophagic degradation of aberrant protein. Thus, we examined AR levels in 
vivo and determined that expression of HDAC6 led to lower steady state levels of polyQ-
expanded AR in vivo, whereas inhibition of autophagy by knockdown of atg6 or atg12 
resulted in higher steady state levels (Figure A4.3a). These altered steady state levels 
occurred despite no significant change in RNA levels (Supplemental Figure A4.11), 
suggesting that HDAC6 accelerates the rate of AR degradation. To investigate this 
further, we adapted the inducible Geneswitch expression system (McGuire et al., 2004) to 
monitor protein turnover. In elav-GS;UAS-AR52 flies, no expression was detected prior 
to exposure to the inducing agent RU486 (data not shown). To induce expression, starved 
flies were fed sucrose media containing RU486 for one hour, which resulted in a pulse of 
expression that became detectable within 2 hours, peaked after approximately 10 hours, 
and then gradually decayed with a half-life of ~100 minutes (Figure A4.3b-c and 
Supplemental Figure A4.12). In elav-GS;UAS-AR52;UAS-dHDAC6 flies, there was a 
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parallel induction of AR52 expression, but an accelerated rate of decay, with a half-life of 
~50 minutes (Figure A4.3c-d and Supplemental Figure A4.12). Importantly, co-
expression of dHDAC6 not only accelerated the turnover of AR52 monomers ~2-fold, 
but also high molecular weight aggregates that were trapped in the stacking gel (Figure 
A4.3d). 
 
We determined that treatment with rapamycin suppressed degeneration caused by either 
proteasome impairment or polyQ toxicity (Figure A4.4a-d). This finding is consistent 
with a prior report in which rapamycin suppressed degeneration in fly and mouse models 
of Huntington’s disease (Ravikumar et al., 2004). Rescue by rapamycin has been 
attributed to inhibition of TOR and induction of autophagy, although a role for other 
TOR-regulated pathways could not be excluded (Harris and Lawrence, 2003; Ravikumar 
et al., 2004). We found that knockdown of atg12 blocked the ability of rapamycin to 
suppress degeneration when the proteasome was impaired, verifying that rapamycin 
rescue is autophagy-dependent (Figure A4.4e, f). Importantly, we also determined that 
knockdown of dHDAC6 blocked the ability of rapamycin to suppress degeneration, 
indicating that dHDAC6 is essential in order for induction of autophagy to compensate 
for proteasome impairment (Figure A4.4g, h). Furthermore, we determined that the 
ability of dHDAC6 to suppress degeneration was autophagy-dependent since rescue was 
blocked by knockdown of atg12 (Figure A4.4i-l). Thus, HDAC6 is integral to rescue of 
degeneration by autophagy and essential for autophagy to compensate for impaired UPS 
function. 
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Our findings extend previous studies in three important ways. First, we determined that 
induction of autophagy is sufficient to rescue degeneration associated with UPS 
impairment, dramatically illustrating the compensatory relationship between autophagy 
and the UPS. Second, we determined that HDAC6 activity is essential for autophagy to 
compensate for impaired UPS function. Finally, we determined that ectopic expression of 
HDAC6 alone is sufficient to rescue degeneration caused by proteasome mutations and 
polyQ toxicity, and does so in an autophagy-dependent manner. These observations are 
consistent with a mechanism in which HDAC6 facilitates turnover of aberrant protein by 
autophagy, lowering their steady state levels and mitigating toxicity. We recently 
determined that over-expression of HDAC6 also suppressed degenerative phenotypes in 
additional models of neurodegenerative disease including flies expressing pathologic Aβ 
fragments and other polyQ-expanded proteins (Pandey and Taylor, unpublished results). 
Thus, the HDAC6-mediated pathway of protein clearance may have broad relevance to 
degenerative proteopathies.  
 
While the current study indicates that the mechanism of HDAC6 rescue involves 
accelerated turnover of misfolded protein by autophagy, further study is required to 
determine the precise details of how this occurs. The mechanism could involve 
modulation of HSP90 activity, since this chaperone is a substrate of HDAC6 deacetylase 
activity (Kovacs et al., 2005).  Alternatively, HDAC6 may be involved in shuttling 
polyubiquitinated substrates to a location conducive to engulfment by autophagosomes, 
consistent with a known role for HDAC6 in the formation of aggresomes in vitro 
(Kawaguchi et al., 2003). A third possibility is that HDAC6 may contribute to the 
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transport of lysosomes to the site of autophagy, as suggested by the observation that 
HDAC6 knockdown results in dispersal of lysosomes away from the microtubule 
organizing center (Iwata et al., 2005a). Elucidating the precise role of HDAC6 in linking 
autophagy and the UPS promises to reveal tremendous insight to cellular management of 
misfolded protein. 
 
Acknowledgments  
We thank the Laboratory for Biological Ultrastructure at the University of Maryland for 
assistance with SEM, the Biomedical Imaging Core at the University of Pennsylvania for 
assistance with TEM, J. Belote and K. Takeyama for flies, and R. Kopito for the CL1-GFP 
construct. Financial support was provided by NIH grants to T.P.Y., E.H.B. and J.P.T., as 
well as support from the Morton Reich Research Fund, Kennedy’s Disease Association, 
and Muscular Dystrophy Association to J.P.T. 
 
Author Contributions  
Experimental work was performed by U.B.P., Z.N., Y.B., B.A.M., G.P.R., S.L.S., B.L.B. 
and J.P.T. Vital Reagents were provided by N.D., M.K., O.S., R.P., M.H., D.G., and 
T.P.Y. The manuscript was written by N.B.N., E.H.B. and J.P.T. All authors discussed of 
results and commented on the manuscript. 
 
Author Information Reprints and permissions information is available at 
npg.nature.com/reprintsandpermissions. The authors declare no competing financial 
interests. Correspondence and requests for materials should be addressed to J.P.T. 
206 
Methods 
Fly stocks 
All Drosophila stocks were maintained on standard media in 25oC incubators unless 
otherwise noted. DHT (Steraloids) was mixed with freshly made food once it had cooled 
to <50oC to a final concentration of 1 mM. Rapamycin (Sigma) was mixed with freshly 
made food once it had cooled to <50oC to a final concentration of 1 µM. To generate AR 
transgenic flies, cDNA encoding full length human AR with 12, 77, or 121 CAG repeats 
was subcloned into pUAST12. The cDNA for dHDAC6 was generated from EST 
LD43531 which encodes 1128 amino acids corresponding to HDAC6-RA on Flybase. 
KpnI and XbaI restriction sites were included in the 5’ and 3’ primers, respectively, for 
subcloning into the vector pAc5.1/V5 (Invitrogen). The cDNA for human HDAC6 and 
mutant human HDAC6 were previously described (Grozinger et al., 1999). The dHDAC6 
cDNA plus in-frame V5 tag was subsequently subcloned into pUAST. Transgenic 
Drosophila were generated using standard techniques (Rubin and Spradling, 1982). The 
GMR-GAL4 line was obtained from the Bloomington Stock Center (Bloomington, IN). 
UAS-DTS7 flies were provided by John Belote. AR20 and AR52 flies were provided by 
Ken-ichi Takeyama. Plasmid containing the cDNA for UPS reporter CL1-GFP was 
provided by Ron Kopito. To generate UPS reporter flies, cDNA encoding CL1-GFP was 
subcloned into pUAST and transgenics were generated as above. UAS-atg6KD flies were 
generated as described previously (Scott et al., 2004). Inverted repeats for UAS-atg12KD 
flies were generated with primers 5’-GGCGCGCCTATCC TTCTGAACGCCACTG-3’ 
and 5’-GCGGAATTCCTTAGCAAAGTCATGTGCG TATCG-3’ as described 
previously (Scott et al., 2004). For dHDAC6 knockdown, amplicon sequences were 
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obtained from the Heidelberg Fly Array Database (Hild et al., 2003) and a 500bp 
fragment was amplified by PCR and inserted into the AvrII and NheI sites of the pWIZ 
vector as described previously (Lee and Carthew, 2003). Quantitation of the degree of 
knockdown in the RNAi knockdown lines is shown in Supplemental Figure A4.3. Eye 
phenotypes of 1-day-old anesthetized flies were evaluated with a Leica MZ APO 
stereomicroscope and photographed with a Leica DFC320 digital camera. For each 
genotype and condition, at least 200 to >1000 flies were evaluated. Quantitation of eye 
phenotypes is shown in Supplemental Figure A4.2.  
 
TEM and confocal microscopy 
For TEM evaluation, fly heads were fixed with 2.5% glutaraldehyde/2% formaldehyde 
with 0.1 M sodium cacodylate and stored at 4oC until embedding. Heads were post-fixed 
with 2% osmium tetroxide followed by an increasing gradient dehydration step using 
ethanol and propylene oxide. Heads were then embedded in LX-112 medium (Ladd) and 
sections were cut ultrathin (90 nm), placed on uncoated copper grids, and stained with 
0.2% lead citrate and 1% uranyl acetate. Images were examined with a JEOL1010 
electron microscope at 80 kV. To quantitate morphologic features by TEM, we used 
longitudinal sections through the retina and identified photoreceptor neurons by the 
presence of rhabdomeres. 59-82 neurons from 5 flies per condition were scored for the 
presence of AVs, MVBs, and MLBs, and comparisons between conditions were made 
with a paired t-test. To evaluate GFP fluorescence in UPS reporter flies, imaginal eye 
discs were dissected from wandering third-instar larvae in a buffer containing 128 mM 
NaCl, 4 mM MgCl2, 2 mM KCl, 0.4 mM CaCl2, 70 mM sucrose and 5 mM HEPES. 
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After dissection, the discs were fixed in 4% paraformaldehyde for 30 minutes on ice, 
washed with standard saline three times, and mounted in Glycergel Mounting Medium 
(DAKO). Imaging was performed on a Bio-Rad MRC1024ES confocal laser scanning 
module on a Nikon Eclipse E600 and analyzed by using LaserSharp software.  
 
SEM 
SEM samples were collected and fixed in 2.5% gluteraldehyde (EMS) in PBS and post-
fixed for 15-30 minutes in 1.5% osmium tetroxide (Stevens Metallurgical) in PBS. 
Samples were then dehydrated in ethanol, immersed in hexamethyldisilazane 
(Polysciences Inc.) and dried in a desiccator for three days. Specimens were then coated 
with gold:palladium using a Denton DV-503 vacuum evaporator, and analyzed using an 
AMRAY 1820D scanning electron microscope.    
 
Biochemistry 
Immunoblots were performed as described previously (Taylor et al., 2003b) using 
antibodies against GFP (ab6556, Novus Biologicals), AR (N20, Santa Cruz Biotech), 119 
β-actin (119, Santa Cruz Biotech), tubulin (Sigma), V5 epitope (Invitrogen), and affinity-
purified antibody against dHDAC6. Protein signals were detected by chemiluminescence 
(Millipore Immobilon). To monitor protein turnover in vivo, 1-day-old adult flies of the 
appropriate genotype were collected and starved for 12 hours in a vial that contained only 
a Kimwipe soaked with 3 ml of water. After starvation, flies were placed in a vial that 
contained a Kimwipe soaked with 3 ml of 500 µM RU486 (Steraloids) dissolved in a 2% 
sucrose solution (minus DHT condition) or 500 µM RU486 and 1 mM DHT in a 2% 
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sucrose solution (plus DHT condition) for 1 hour, and then transferred to a vial 
containing normal food (minus DHT condition) or food containing 1 mM DHT (plus 
DHT condition) until collected for extract preparation. Five flies were collected every 2.5 
hours up to 20 hours, heads were removed, crushed in RIPA buffer, sonicated, and 
analyzed by Western blot. AR and β-actin protein levels were assessed by immunoblot. 
Quantitation of luminescence was performed with a Kodak IS2000RT instrument and 
Kodak Molecular Imaging software. The mean AR/actin ratios and standard error of the 
mean from ≥3 replicates were plotted on a logarithmic scale and used to determine the 
line of best fit by regression analysis (y = Ae-Kx). The slope of the best fit line was used to 
estimate half-life with the equation t1/2 = 0.693/K. 
 
 
Objective criteria for scoring retinal phenotypes 
All of the genotypes presented here exhibit highly uniform retinal phenotypes. We 
examined the eye phenotypes of at least 200 flies per genotype (>1000 in most cases) and 
the phenotypes represented in the SEM images are present in 100% of the animals. 
Among genetically identical flies, there was no appreciable variability in the phenotypes. 
In cases where enhancement or suppression is reported, it was present in 100% of the 
animals. In most cases, changes in the relative severity of the retinal phenotypes were 
qualitatively obvious. Nevertheless, to apply quantitative analysis, we randomly selected 
50-100 1-day-old flies per genotype and scored phenotypic severity using objective 
features. Eyes were examined for the presence or absence of the following features and 
given 1 point for each if present: 
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Feature Absent Present 
Supernumerary IOB 0 1 
Abnormal bristle orientation 0 1 
Ommatidial fusion 0 1 
Ommatidial pitting 0 1 
Disorganization of ommatidial array 0 1 
Retinal collapse 0 1 
 IOB, interommatidial bristles 
Two points were added if the affected area involved more than 5% of the eye and 4 
points were added if the affected area involved more than 50% of the eye. Comparisons 
between genotypes were made using Student’s t-test assuming equal variances. 
  
Real Time Quantitative PCR 
Total RNA was isolated from 5-10 animals of the appropriate genotype with TRIzol 
reagent (Invitrogen) and cDNA was generated using the SuperScript III First Strand 
Synthesis System (Invitrogen) following the manufacturer’s protocol. Concentrations for 
each primer probe set were individually optimized. Quantitative real-time PCR reactions 
were carried out in a total reaction volume of 50 µl of TaqMan Universal Master Mix 
(ABI) using an Applied Biosystems Fast 7500 machine for 40 cycles. Quantitation of 
each transcript was determined using the ∆∆CT method. Transcript levels relative to 
dGAPDH2 are shown in Supplemental Figure A4.3 for (a) two UAS-dHDAC6 KD lines, 
(b) two UAS-atg6KD lines, and (c) one UAS-atg12KD line. 
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The primer/probe set for Drosophila GAPDH2 (product number CT25538) were 
purchased from Applied Biosystems. Primer probe sets for other genes were as follows: 
 
dHDAC6: 
Forward primer: 5’-CGCTGTCGCGAACTAAATCTG-3’ 
Reverse primer: 5’-TCCTTGGTCGCCGATCTC-3’ 
Probe: 5’-6FAM-CCTGGAGTTGCCC-TAMRA -3’ 
 
Atg6: 
Forward primer: 5’-GCCTCTCCTCCAACTCTGAGATT-3’ 
Reverse primer: 5’-GCATGGAGTCGGCACACTCT-3’ 
Probe:  5’-6FAM-ACCATCCGCTGTGCG-TAMRA -3’ 
 
Atg12:  
Forward primer: 5’-TGTGCCCATCATCAAAAAGC-3’ 
Reverse primer: 5’-TCCAGCCGACTGTCTTGTTG-3’ 
Probe: 5’-6FAM-AACCTGGACCGTAGATC-TAMRA -3’ 
 
GFP:  
Forward primer 5'-CTGCTGCCCGACAACCA-3' 
Reverse  5'-GAACTCCAGCAGGACCATGTG-3' 
Probe  5'-6FAM-AAAGACCCCAACGAGAAGCGCGA-TAMRA-3' 
 
AR: 
Forward primer:  5'-GCAGGCAAGAGCACTGAAGATA-3' 
Reverse primer:  5'-CCTTTGGTGTAACCTCCCTTGA-3' 
Probe:   5'-6FAM-TGCTGAGTATTCCCC-TAMRA-3' 
 
 
212 
Figures and Legends 
Figure A4.1. HDAC6 rescues degeneration in flies with proteasome impairment and 
in a fly model of SBMA that exhibits impaired UPS function. 
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Figure A4.1. HDAC6 rescues degeneration in flies with proteasome impairment and 
in a fly model of SBMA that exhibits impaired UPS function. (a-e) Scanning electron 
microscopy (SEM) images of fly eyes expressing DTS7 with or without the indicated 
HDAC6 transgenes. (a) Normal eyes in DTS7 flies reared at 22oC. (b) Rough eyes in 
DTS7 flies reared at 28oC. Degeneration was suppressed by expression of dHDAC6 (c) 
or hHDAC6 (d), but not a catalytically dead mutant of hHDAC6 (e). (f-j) SEM images of 
fly eyes expressing AR52 with or without the indicated HDAC6 transgenes. (f) Normal 
eyes in AR52 flies reared without DHT. (g) Rough eyes in AR52 flies reared with DHT. 
Degeneration was suppressed by expression of dHDAC6 (h) or hHDAC6 (i), but not a 
catalytically dead mutant of hHDAC6 (j). (k-p) Detection of UPS reporter in imaginal 
eye discs from third instar larvae by confocal microscopy. High level fluorescence was 
found in flies expressing GFP (k, positive control), but fluorescence was barely 
detectable in control flies expressing CL1-GFP (l, negative control). CL1-GFP 
accumulates in DTS7 flies with temperature-dependent proteasome impairment (compare 
m to n) and in AR52 flies with ligand-dependent degeneration (compare o to p). The 
retinal phenotypes of 200 to >1000 flies of each genotype were examined. Quantitative 
analyses of eye phenotypes and proteasome impairment are presented in Supplemental 
Figure A4.2 and Supplemental Figure A4.3, respectively. (DHT, dihydrotestosterone).  
214 
Figure A4.2. Induction of compensatory autophagy in flies with proteasome 
mutations and in SBMA flies.  
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Figure A4.2. Induction of compensatory autophagy in flies with proteasome 
mutations and in SBMA flies. (a-e) Representative examples of autophagic vacuoles 
detected by TEM in retinal sections used to generate the quantitative data shown in (f). 
(a) An autophagosome (red arrow) containing cytoplasmic contents in a photoreceptor 
neuron from an AR52 fly reared on DHT. (b) Higher magnification of the 
autophagosome in a. (c) Multiple autophagolysosomes (red arrows) containing dense, 
amorphous material from an AR52 fly reared on DHT. (d) A juxtanuclear multilamellar 
body (red arrow) from a DTS7 fly reared at 28oC. (e) A multivesicular body (red arrow) 
from a DTS7 fly reared at 28oC. (f) A significant increase in the frequency of neurons 
with autophagic figures in DTS7 flies reared at 28oC compared to those reared at 22oC 
and in AR52 flies reared on DHT compared to those reared off DHT. Data show mean 
±s.d., n = 59-82 neurons in 5 sections/condition. No accumulation of autophagic figures 
was found in AR12 flies. (g-l) SEM images of fly eyes expressing the indicated 
transgenes. RNAi knockdown of atg6 and atg12 enhances degeneration in DTS7 flies 
reared at 28oC (compare h, i to g) and AR52 flies reared on DHT (compare k, l to j). 200 
to >1000 fly eyes of each genotype were examined. Quantitative analyses of eye 
phenotypes are presented in Supplemental Figure A4.2. (N, nucleus; Rh, rhabdomere).  
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Figure A4.3. HDAC6 accelerates the turnover of polyQ-expanded AR. 
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Figure A4.3. HDAC6 accelerates the turnover of polyQ-expanded AR. (a, b, d) 
Western blots from flies expressing the indicated transgenes. (a) Steady state levels of 
AR52 protein are reduced in flies over-expressing dHDAC6, but are elevated in flies in 
which atg6 or atg12 has been knocked down. (b) Western blots showing the temporal 
profile of AR52 protein monomer and high molecular weight aggregate levels after a 
brief pulse of expression. AR52 protein became detectable by 2.5 hours after treatment 
with RU486, reached a peak at 10 hours, and then slowly decayed. (c) A logarithmic plot 
of AR52/actin ratios was used to determine the line of best fit by regression analysis (y = 
Ae-Kx). R2 = 0.9117 (AR52-DHT), R2 = 0.7808 (AR52+DHT), R2 = 0.9719 (HDAC6 + 
AR52-DHT), R2 = 0.9644 (HDAC6 + AR52+DHT). Half-life was determined by the slope of 
the best fit line with the equation t1/2 = 0.693/K. Half-life of AR52 in vivo was reduced 
~2-fold in flies co-expressing dHDAC6 and did not differ significantly depending on the 
presence (broken lines) or absence (solid lines) of DHT. Plots of the mean AR52/actin 
ratios are shown in Supplemental Figure A4.12. (d) Flies co-expressing dHDAC6 showed 
a nearly identical profile of induced expression as in b, but AR protein decayed at an 
accelerated rate. Exogenous dHDAC6 was detected by immunoblot against the V5 
epitope.  
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Figure A4.4 
 
 
 
Figure A4.4. Rescue of degeneration by HDAC6 is autophagy-dependent.  
(a-l) SEM images of fly eyes expressing the indicated transgenes. The rough eye 
phenotypes caused by (a) proteasome mutation or by (b) expression of polyQ-expanded 
AR were both suppressed by rearing flies on the TOR inhibitor rapamycin (c, d). (e,f) 
Rapamycin failed to suppress degeneration in an autophagy-deficient background created 
by knockdown of atg12, confirming that rescue by rapamycin is autophagy-dependent. 
(g, h) Rapamycin also failed to suppress degeneration when HDAC6 levels were knocked 
down, demonstrating that autophagy induction via the TOR pathway is HDAC6-
dependent. (k-j) HDAC6 failed to suppress degeneration in an autophagy-deficient 
background, confirming that rescue by HDAC6 is dependent on autophagy (compare k, l 
to i, j). 200 to >1000 fly eyes of each genotype were examined. Quantitative analyses of 
eye phenotypes are presented in Supplemental Figure A4.2.  
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Supplemental Figure A4.1. It was long held that the UPS and autophagy were distinct 
degradation systems with no point of intersection. This view was challenged by the 
finding of prominent ubiquitin-positive pathology that accumulates in autophagy-
deficient mice despite normal UPS function. Those studies strongly suggest that 
autophagy participates in the degradation of ubiquitinated substrates under basal 
conditions and, by so doing, plays a vital neuroprotective role complementary to that of 
the UPS (a). The data here indicates that when the UPS is overwhelmed, for example by 
proteasome mutations or excess misfolded protein, autophagy also provides 
compensatory degradation of misfolded proteins (b). Furthermore, we find that the 
microtubule-associated deacetylase HDAC6 is essential for autophagy to compensate for 
impaired UPS function. Most important with respect to therapeutic implications, we find 
that over-expression of HDAC6 is sufficient to rescue degeneration in Drosophila models 
of neurodegenerative disease and does so in an autophagy-dependent manner, a finding 
that has important therapeutic implications. 
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Supplemental Figure A4.2. Quantitative analyses of eye phenotypes.  
 
 
 
 
221 
 
Supplemental Figure A4.2. Quantitative analyses of eye phenotypes. We examined 
the eye phenotypes of at least 200 flies per genotype (>1000 in most cases) and the 
phenotypes represented in the SEM images are present in 100% of the animals. Among 
genetically identical flies, we did not observe significant variability in the phenotypes. In 
cases where enhancement or suppression is reported, it was present in 100% of the 
animals. In most cases, changes in the relative severity of the retinal phenotypes were 
qualitatively obvious. Nevertheless, to apply quantitative analysis, 50-100 flies per 
genotype were randomly selected for objective scoring according to the criteria described 
in Supplemental Methods. Comparisons were made using Student’s t-test. Data show 
mean phenotype score ± s.d. * =p<0.01. ** =p<0.001. 
  
Supplemental Figure A4.3 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure A4.3. Quantitation of RNAi knockdown. UAS-dHDAC6KD, 
UAS-atg6KD, and UAS-atg12KD lines were generated as described in Supplemental 
Methods. To determine the degree of knockdown of each relevant transcript, these lines 
were crossed with the driver line Actin5c-GAL4 and total RNA was isolated from 5-10 
larvae. Quantitation was performed as described in Supplemental Methods. Data show 
mean transcript levels relative to GAPDH2 and standard error. Transcript levels relative 
to dGAPDH2 are shown for (a) two UAS-dHDAC6 KD lines, (b) two UAS-atg6KDlines, 
and (c) one UAS-atg12KD line. Knockdown of dHDAC6 was also examined at the protein 
level by immunoblot as shown in Supplemental Figure A4.4. Consistent with the results 
shown here, the UAS-atg12KD knockdown line used here was previously shown to reduce 
autophagy induction by approximately 75% in the Drosophila fat body based on a 
Lysotracker assay (Scott et al., 2004). 
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Supplemental Figure A4.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure A4.4. Knockdown of endogenous dHDAC6 in the eye causes 
no overt phenotype in 1-day-old adult flies. (a) Western blot with affinity-purified anti-
dHDAC6 validating knockdown of dHDAC6 when the dsRNA is ubiquitously expressed 
in larvae using the driver Tub-GAL4. Western blot for tubulin serves as a loading control. 
(b) Targeted RNAi knockdown of dHDAC6 in the eye using the driver GMR-GAL4 has 
no overt effect on the external morphology of the eye of a 1-day-old fly. UAS-HDAC6KD 
line 13A3 is shown. ~200 fly eyes of each genotype have been examined. Quantitative 
analyses of eye phenotypes are presented in Supplemental Figure A4.2.  
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Supplemental Figure A4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure A4.5. Targeted knockdown of dHDAC6 enhances the 
degenerative phenotype in flies with mutations in the proteasome and in SBMA flies 
that have impaired UPS function. (a) GMR-GAL4; UAS-DTS7 flies develop a rough 
eye phenotype when reared at 28oC. (b) In GMR-GAL4; UAS-DTS7; UAS-dHDAC6KD 
flies the rough eye phenotype is enhanced. (c) GMR-GAL4; UAS-AR52 flies develop a 
rough eye phenotype when reared on food containing DHT. (d) In GMR-GAL4; UAS-
AR52; UAS-dHDAC6KD flies the rough eye phenotype is enhanced. ~200 fly eyes of 
each genotype have been examined. Quantitative analyses of eye phenotypes are 
presented in Supplemental Figure A4.2. 
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Supplemental Figure A4.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure A4.6. Ectopic expression of dHDAC6 does not suppress the 
phenotype associated with mis-expression of the positive cell death regulator reaper.  
(a) GMR-GAL4; UAS-reaper flies develop a rough eye phenotype. (b) In GMR-GAL4; 
UAS-reaper; UAS-dHDAC6 flies the rough eye phenotype is unchanged. ~200 fly eyes 
of each genotype have been examined. Quantitative analyses of eye phenotypes are 
presented in Supplemental Figure A4.2. 
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Supplemental Figure A4.7. A Drosophila model of SBMA.  
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Supplemental Figure A4.7. A Drosophila model of SBMA. Expression of human AR 
resulted in ligand-dependent, polyQ length-dependent degeneration. Flies not treated with 
DHT had normal eyes (top row). Flies reared on food containing DHT showed polyQ 
length-dependent degeneration (bottom row). Degeneration was most severe at the 
posterior eye margin. There was disorganization of the ommatidial array, fusion of 
ommatidia, and abnormal bristles. Longer repeat length caused a more severe 
degenerative phenotype that extended further anteriorly. Ligand-dependent, polyQ 
length-dependent degeneration recapitulates two key features of human SBMA. >1000 
fly eyes of each genotype have been examined. Quantitative analyses of eye phenotypes 
are presented in Supplemental Figure A4.2. 
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Supplemental Figure A4.8  
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure A4.8. Monitoring UPS function in vivo. (a) Quantitation of 
fluorescent signal from 8-10 imaginal eye discs from each genotype and condition reveals 
significant UPS impairment in DTS7 flies reared at 28oC and in AR52 flies reared on 
DHT, but not in AR12 flies reared on DHT. (b) Quantitation of Western blots for GFP in 
adult flies expressing the indicated transgenes under the indicated conditions reveals 
significant UPS impairment in DTS7 flies reared at 28oC and in AR52 flies reared on 
DHT. Protein levels were normalized to actin. Comparisons were made using Student’s t-
test assuming equal variances. Data shows mean and standard deviation. *= p<0.01.(c-d) 
Detection of CL1-GFP reporter in imaginal eye discs from third instar larvae by confocal 
microscopy reveals no evidence of ligand-dependent UPS impairment in AR12 flies. (c) 
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GMR-GAL4; UAS-CL1-GFP; UAS-AR12Q (-DHT). (d) GMR-GAL4; UAS-CL1-GFP; 
UAS-AR12Q (+DHT). 
Supplemental Figure A4.9 
 
 
 
Supplemental Figure A4.9. Accumulation of CL1-GFP reporter protein with UPS 
impairment occurs without significant change in transcript levels as determined by 
real-time quantitative PCR. Total RNA was isolated from 5-10 flies and real time 
quantitative PCR was performed as described in Supplemental Methods. (a) RNA 
quantitation from larvae, corresponding to Figure A4.1 and Supplemental Figure A4.8a. 
(b) RNA quantitation from adult flies, corresponding to Supplemental Figure A4.8b. Data 
show mean GFP/GAPDH2 ratios and standard error. 
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Supplemental Figure A4.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure A4.10. Knockdown of atg6 and atg12 does not affect eye 
morphology. One-day-old (a) GMR-GAL4;UAS-atg6KD and (b)GMR-GAL4;UAS-
atg12KD flies reared at 28oC were examined by SEM.  
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Supplemental Figure A4.11  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure A4.11. Reduced levels of AR52 protein with ectopic expression 
of dHDAC6 occurs without significant change in AR transcript levels. This was 
determined by real-time quantitative PCR as described in Supplemental Methods. 
AR/GAPDH2 ratios and standard error for each condition are shown. 
 
 232
Supplemental Figure A4.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure A4.12. HDAC6 accelerates the turnover of polyQ-expanded 
AR. A logarithmic plot of the AR52/actin ratio in 3-4 consecutive experiments showed 
accelerated turnover of AR52 with co-expression of dHDAC6. The experiment was 
performed with or without exposure to DHT, as indicated. Exposure to DHT did not 
significantly influence the rate of AR52 turnover. This data was used to determine the 
line of best fit by regression analysis (y = Ae-Kx) as presented in Figure A4.3. The slope 
of the best fit line was used to estimate half-life with the equation t1/2 = 0.693/K. Half-life 
of AR52 in vivo was reduced approximately 2-fold in flies co-expressing dHDAC6 
independent of exposure to DHT. 
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